"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,S,US D0737912 S,059-064-410-794-282,2015-09-01,2015,US 201429494678 F,2014-06-23,US 201429494678 F,2014-06-23,Iron club head,,TAYLOR MADE GOLF CO,TAYLOR SCOTT;;NUNEZ ROBERT;;FARLEY CHAD ALLEN,TAYLOR MADE GOLF COMPANY INC (2014-07-24),https://lens.org/059-064-410-794-282,Design Right,no,0,1,1,1,0,,,2102;;D21/747,0,0,,,,ACTIVE
2,US,B1,US 6190649 B1,027-485-447-204-009,2001-02-20,2001,US 29835099 A,1999-04-23,US 29835099 A,1999-04-23,Polyether-based bile acid sequestrants,"The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The invention further relates to a method for reducing blood cholesterol, treating atherosclerosis, treating hypercholesterolemia and/or reducing plasma lipid content of a mammal. The methods of the invention comprise orally administering to the patient a therapeutically effective amount of a polymer characterized by a polyether backbone and amino or ammonium groups pendant therefrom. The amino nitrogen atoms can be substituted by one or more substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the polymer comprises pendant ammonium or quaternary ammonium groups, the polymer will be associated with a pharmaceutically acceptable anion.",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI,WASTE MANAGEMENT HOLDINGS INC (2003-02-18);;GELTEX PHARMACEUTICALS INC (1999-09-22);;GENZYME CORPORATION (2003-03-27),https://lens.org/027-485-447-204-009,Granted Patent,yes,18,7,5,5,0,A61K31/785;;A61K31/785,A61K31/785,424/78.08,0,0,,,,EXPIRED
3,AU,A,AU 2000/046546 A,000-412-875-928-014,2000-11-10,2000,AU 2000/046546 A,2000-04-20,US 29835099 A;;US 0010808 W,1999-04-23,Polyether-based bile acid sequestrants,,GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI,,https://lens.org/000-412-875-928-014,Patent Application,no,0,0,5,5,0,A61K31/785;;A61K31/785,A61K31/785,,0,0,,,,DISCONTINUED
4,WO,A2,WO 2000/064428 A2,166-049-418-085-222,2000-11-02,2000,US 0010808 W,2000-04-20,US 29835099 A,1999-04-23,POLYETHER-BASED BILE ACID SEQUESTRANTS,"The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The invention further relates to a method for reducing blood cholesterol, treating atherosclerosis, treating hypercholesterolemia and/or reducing plasma lipid content of a mammal. The methods of the invention comprise orally administering to the patient a therapeutically effective amount of a polymer characterized by a polyether backbone and amino or ammonium groups pendant therefrom. The amino nitrogen atoms can be substituted by one or more substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the polymer comprises pendant ammonium or quaternary ammonium groups, the polymer will be associated with a pharmaceutically acceptable anion.",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI,,https://lens.org/166-049-418-085-222,Patent Application,yes,0,2,5,5,0,A61K31/785;;A61K31/785,A61K31/785,,0,0,,,,PENDING
5,US,S,US D0735284 S,001-375-987-072-130,2015-07-28,2015,US 201429494677 F,2014-06-23,US 201429494677 F,2014-06-23,Iron club head,,TAYLOR MADE GOLF CO,TAYLOR SCOTT;;NUNEZ ROBERT;;FARLEY CHAD ALLEN,TAYLOR MADE GOLF COMPANY INC (2014-07-24),https://lens.org/001-375-987-072-130,Design Right,no,0,1,1,1,0,,,2102;;D21/747,0,0,,,,ACTIVE
6,US,S,US D0731606 S,119-014-903-500-245,2015-06-09,2015,US 201429494679 F,2014-06-23,US 201429494679 F,2014-06-23,Iron club head,,TAYLOR MADE GOLF CO,TAYLOR SCOTT;;NUNEZ ROBERT;;FARLEY CHAD ALLEN,TAYLOR MADE GOLF COMPANY INC (2014-07-24),https://lens.org/119-014-903-500-245,Design Right,no,0,0,1,1,0,,,2102;;D21/747,0,0,,,,ACTIVE
7,US,B1,US 6517825 B1,020-181-760-058-733,2003-02-11,2003,US 71378400 A,2000-11-15,US 71378400 A;;US 29835099 A,1999-04-23,Polyether-based bile acid sequestrants,"
    The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The invention further relates to a method for reducing blood cholesterol, treating atherosclerosis, treating hypercholesterolemia and/or reducing plasma lipid content of a mammal. The methods of the invention comprise orally administering to the patient a therapeutically effective amount of a polymer characterized by a polyether backbone and amino or ammonium groups pendant therefrom. The amino nitrogen atoms can be substituted by one or more substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the polymer comprises pendant ammonium or quaternary ammonium groups, the polymer will be associated with a pharmaceutically acceptable anion. 
",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI,GENZYME CORPORATION (2003-03-27),https://lens.org/020-181-760-058-733,Granted Patent,yes,23,4,5,5,0,A61K31/785;;A61K31/785,A61K31/785,424/78.08;;424/400;;424/484;;424/486;;424/487,1,0,,,"Patent Abstracts of Japan, vol. 1998, No. 09, Jul. 31, 1998 for JP 10 101531 A (KAO Corp.), Arp. 21, 1998.",EXPIRED
8,US,S,US D0737913 S,066-160-310-119-443,2015-09-01,2015,US 201429494680 F,2014-06-23,US 201429494680 F,2014-06-23,Iron club head,,TAYLOR MADE GOLF CO,TAYLOR SCOTT;;NUNEZ ROBERT;;FARLEY CHAD ALLEN,TAYLOR MADE GOLF COMPANY INC (2014-07-24),https://lens.org/066-160-310-119-443,Design Right,no,0,2,1,1,0,,,2102;;D21/747,0,0,,,,ACTIVE
9,WO,A3,WO 2000/064428 A3,187-073-439-571-774,2001-02-08,2001,US 0010808 W,2000-04-20,US 29835099 A,1999-04-23,POLYETHER-BASED BILE ACID SEQUESTRANTS,"The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The invention further relates to a method for reducing blood cholesterol, treating atherosclerosis, treating hypercholesterolemia and/or reducing plasma lipid content of a mammal. The methods of the invention comprise orally administering to the patient a therapeutically effective amount of a polymer characterized by a polyether backbone and amino or ammonium groups pendant therefrom. The amino nitrogen atoms can be substituted by one or more substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the polymer comprises pendant ammonium or quaternary ammonium groups, the polymer will be associated with a pharmaceutically acceptable anion.",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI,,https://lens.org/187-073-439-571-774,Search Report,yes,5,0,5,5,0,A61K31/785;;A61K31/785,A61K31/785,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1998, no. 09 31 July 1998 (1998-07-31)",PENDING
10,US,A1,US 2013/0243720 A1,159-449-864-256-385,2013-09-19,2013,US 201213534672 A,2012-06-27,US 201213534672 A;;US 30742009 A;;US 2007/0014688 W;;US 81872706 P,2006-07-05,Iron(II)-Containing A Treatments for Hyperphosphatemia,"A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.",HUVAL CHAD;;DHAL PRADEEP;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD;;DHAL PRADEEP;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/159-449-864-256-385,Patent Application,yes,5,0,6,6,0,A61K33/26;;A61K33/26;;A61K9/145;;A61K9/145;;A61K9/146;;A61K9/146;;A61K31/295;;A61K31/295;;A61K31/785;;A61K31/785;;A61K45/06;;A61K45/06;;A61P1/00;;A61P3/00;;A61P7/00;;A61P39/04,A61K33/26;;A61K31/295;;A61K31/785;;A61K45/06,424/78.27;;514/502;;424/646;;424/78.35;;424/648;;424/643,1,0,,,"Kuroda et al. (Jpn. J. Nephrol 3:468-473, 1995, IDS)",DISCONTINUED
11,US,A1,US 2010/0135950 A1,193-584-040-185-734,2010-06-03,2010,US 30742007 A,2007-06-25,US 30742007 A;;US 81872706 P;;US 2007/0014688 W,2006-07-05,Iron(II)-Containing Treatments for Hyperphosphatemia,"A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.",GENZYME CORP,HUVAL CHAD;;DHAL PRADEEP;;HOLMES-FARLEY STEPHEN RANDALL,GENZYME CORPORATION (2008-01-29),https://lens.org/193-584-040-185-734,Patent Application,yes,64,11,6,6,0,A61K33/26;;A61K33/26;;A61K9/145;;A61K9/145;;A61K9/146;;A61K9/146;;A61K31/295;;A61K31/295;;A61K31/785;;A61K31/785;;A61K45/06;;A61K45/06;;A61P1/00;;A61P3/00;;A61P7/00;;A61P39/04,A61K31/785;;A61K31/295;;A61K33/26;;A61K33/30;;A61P1/00;;A61P39/04,424/78.35;;424/648;;514/502;;424/643,0,0,,,,DISCONTINUED
12,US,S,US D0772996 S,153-772-574-810-562,2016-11-29,2016,US 201529533409 F,2015-07-16,US 201529533409 F,2015-07-16,Golf club head,,TAYLOR MADE GOLF CO,TAYLOR SCOTT;;NUNEZ ROBERT;;FARLEY CHAD ALLEN;;JAMES ANDREW,TAYLOR MADE GOLF COMPANY INC (2015-08-08),https://lens.org/153-772-574-810-562,Design Right,no,0,10,1,1,0,,,2102;;D21/759,0,0,,,,ACTIVE
13,US,A1,US 2014/0044671 A1,088-749-874-484-091,2014-02-13,2014,US 201314056365 A,2013-10-17,US 201314056365 A;;US 201113286489 A;;US 65694510 A;;US 79973907 A;;US 79796606 P,2006-05-05,AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS,"Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH 2 CH 2 — group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.",GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP;;HOLMES-FARLEY S RANDALL,,https://lens.org/088-749-874-484-091,Patent Application,yes,0,0,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,A61K31/785;;C08G73/02,424/78.38;;528/405;;424/78.08,0,0,,,,DISCONTINUED
14,BR,A2,BR PI0720234 A2,168-675-634-296-914,2013-12-24,2013,BR PI0720234 A,2007-12-10,US 87471506 P;;US 2007/0025216 W,2006-12-14,COMPOSIÇÃO FARMACÊUTICA,,GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,,https://lens.org/168-675-634-296-914,Patent Application,no,0,0,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/785,,0,0,,,,DISCONTINUED
15,EP,A2,EP 2049014 A2,171-597-973-951-992,2009-04-22,2009,EP 07810553 A,2007-07-16,US 2007/0016240 W;;US 83146106 P;;US 83732206 P;;US 84764106 P,2006-07-18,AMINE DENDRIMERS,,GENZYME CORP,HOLMES-FARLEY S RANDALL;;DHAL PRADEEP K;;HUVAL CHAD C,,https://lens.org/171-597-973-951-992,Patent Application,yes,0,0,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61B5/055,,0,0,,,,DISCONTINUED
16,WO,A3,WO 2008/005217 A3,025-891-038-941-180,2008-02-21,2008,US 2007/0014688 W,2007-06-25,US 81872706 P,2006-07-05,IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA,"A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selecte from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.",GENZYME CORP;;HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/025-891-038-941-180,Search Report,yes,5,0,6,6,0,A61K33/26;;A61K33/26;;A61K9/145;;A61K9/145;;A61K9/146;;A61K9/146;;A61K31/295;;A61K31/295;;A61K31/785;;A61K31/785;;A61K45/06;;A61K45/06;;A61P1/00;;A61P3/00;;A61P7/00;;A61P39/04,A61K31/295;;A61K9/14;;A61K33/26,,1,1,079-101-703-099-553,7563956,"KURODA S ET AL: ""EFFECT OF IRON AS A NEW TYPE OF PHOSPHATE BINDER IN HEMODIALYSIS PATIENTS"", JAPANESE JOURNAL OF NEPHROLOGY - NIHON JINZO GAKKAISHI, NIHON JINZO GAKKAI, TOKYO, JP, vol. 8, no. 37, August 1995 (1995-08-01), pages 468 - 473, XP008002871, ISSN: 0385-2385",PENDING
17,WO,A2,WO 2000/038664 A2,131-274-924-648-009,2000-07-06,2000,US 9930469 W,1999-12-20,US 21955898 A,1998-12-23,AMINE CONDENSATION POLYMER BILE ACID SEQUESTRANTS,"A method for binding bile salts in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of one or more amine polymers prepared by the process comprising the step of reacting a substituted or unsubstituted aliphatic, aromatic or aralkyl bifunctional electrophile with at least one monomer comprising a substituted or unsubstituted hydrophobic moiety and a single nucleophilic substituent which is multireactive.",GELTEX PHARMA INC,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;WHITESIDES GEORGE M,,https://lens.org/131-274-924-648-009,Patent Application,yes,0,10,3,3,0,A61K31/785;;A61P3/06,A61K31/785,,0,0,,,,PENDING
18,WO,A2,WO 2007/130463 A2,138-070-330-615-55X,2007-11-15,2007,US 2007/0010650 W,2007-05-02,US 79796606 P,2006-05-05,AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS,"Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a -CH 2 CH 2 - group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.",GENZYME CORP;;HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/138-070-330-615-55X,Patent Application,yes,0,2,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,C08G73/02,,0,0,,,,PENDING
19,AR,A1,AR 060751 A1,170-312-325-259-959,2008-07-10,2008,AR P070101925 A,2007-05-04,US 79796606 P,2006-05-05,POLIMEROS DE CONDENSACION DE AMINAS COMO SECUESTRANTES DE FOSFATOS,"Se describe un polímero o una sal fisiologicamente aceptable del mismo. El polímero comprende, un monomero amina multifuncional polimerizado. El monomero amina comprende al menos dos grupos amina y al menos dos átomos de nitrogeno acíclicos que están conectados a través de un grupo -CH2CH2-, siempre que el monomero amina no sea etilendiamina o dietilentriamina. Los polímeros descritos se pueden utilizar para unirse a aniones en un sujeto que necesita tal tratamiento.",GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/170-312-325-259-959,Patent Application,no,0,0,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,,,0,0,,,,DISCONTINUED
20,US,A1,US 2010/0093857 A1,044-712-252-281-884,2010-04-15,2010,US 44822207 A,2007-12-10,US 44822207 A;;US 87471506 P;;US 2007/0025216 W,2006-12-14,AMIDO-AMINE POLYMER COMPOSITIONS,"Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,GENZYME CORPORATION (2009-06-12),https://lens.org/044-712-252-281-884,Patent Application,yes,99,3,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/221;;A61K31/132;;A61P13/12,514/549;;514/740,0,0,,,,ACTIVE
21,EP,A1,EP 2120972 A1,052-914-704-534-375,2009-11-25,2009,EP 07867688 A,2007-12-10,US 2007/0025216 W;;US 87471506 P,2006-12-14,AMIDO-AMINE POLYMER COMPOSITIONS,,GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,,https://lens.org/052-914-704-534-375,Patent Application,yes,0,0,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/785,,1,0,,,See references of WO 2008076242A1,DISCONTINUED
22,WO,A3,WO 2007/130463 A3,000-069-635-878-198,2008-01-03,2008,US 2007/0010650 W,2007-05-02,US 79796606 P,2006-05-05,AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS,"Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a -CH 2 CH 2 - group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.",GENZYME CORP;;HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/000-069-635-878-198,Search Report,yes,4,0,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,C08G73/02,,1,1,081-472-928-361-748,14533165;;10.1002/anie.200351500,"MARKUS KLAPPER, CORNELIU HAMCIUC, RAINER DYLLICK-BRENZINGER, KLAUS MÜLLEN: ""Poly(methylene amine): A Polymer with the maximum possible number of Amino Groups on a Polymer Backbone"", ANGEW. CHEM. INT. ED., vol. 42, 2003, Weinheim, pages 4687 - 4690, XP002456407",PENDING
23,WO,A1,WO 2008/076242 A1,107-206-897-822-280,2008-06-26,2008,US 2007/0025216 W,2007-12-10,US 87471506 P,2006-12-14,AMIDO-AMINE POLYMER COMPOSITIONS,"Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",GENZYME CORP;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,,https://lens.org/107-206-897-822-280,Patent Application,yes,2,2,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/785,,0,0,,,,PENDING
24,WO,A2,WO 2008/005217 A2,113-406-137-464-55X,2008-01-10,2008,US 2007/0014688 W,2007-06-25,US 81872706 P,2006-07-05,IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA,"A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selecte from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.",GENZYME CORP;;HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/113-406-137-464-55X,Patent Application,yes,0,7,6,6,0,A61K33/26;;A61K33/26;;A61K9/145;;A61K9/145;;A61K9/146;;A61K9/146;;A61K31/295;;A61K31/295;;A61K31/785;;A61K31/785;;A61K45/06;;A61K45/06;;A61P1/00;;A61P3/00;;A61P7/00;;A61P39/04,A61K31/295;;A61K9/14;;A61K33/26,,0,0,,,,PENDING
25,US,A1,US 2015/0196586 A1,112-108-176-312-565,2015-07-16,2015,US 201514615954 A,2015-02-06,US 201514615954 A;;US 99120908 A;;US 2006/0033437 W;;US 73446205 P;;US 71399105 P,2005-09-02,POLYMERIC MOLECULAR RECEPTORS AS PHOSPHATE SEQUESTRANTS,"Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing functional groups which bind phosphate. Variations of such polymer and compositions are disclosed.",GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,GENZYME CORPORATION (2008-03-27),https://lens.org/112-108-176-312-565,Patent Application,yes,0,0,8,8,0,A61K31/785;;A61K31/785;;A61K31/77;;A61K31/77;;A61K31/787;;A61K31/787;;A61P3/00;;A61P5/18;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P39/00;;C08F226/02;;C08F226/02;;C08F226/04;;C08F226/04;;C08F226/06;;C08F226/06,A61K31/785;;A61K31/77,,0,0,,,,DISCONTINUED
26,US,B2,US 8986669 B2,177-882-914-788-540,2015-03-24,2015,US 99120906 A,2006-08-25,US 99120906 A;;US 71399105 P;;US 73446205 P;;US 2006/0033437 W,2005-09-02,Method for removing phosphate and polymer used therefore,"Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing functional groups which bind phosphate. Variations of such polymer and compositions are disclosed.",HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,GENZYME CORPORATION (2006-10-03),https://lens.org/177-882-914-788-540,Granted Patent,yes,100,10,8,8,0,A61K31/785;;A61K31/785;;A61K31/77;;A61K31/77;;A61K31/787;;A61K31/787;;A61P3/00;;A61P5/18;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P39/00;;C08F226/02;;C08F226/02;;C08F226/04;;C08F226/04;;C08F226/06;;C08F226/06,A61K31/74;;A61K31/785;;A61K31/787;;C08F226/02;;C08F226/04;;C08F226/06,424/78.17,44,36,014-421-542-498-637;;090-264-176-174-068;;073-074-746-492-276;;089-551-918-367-384;;016-205-437-942-376;;055-585-701-440-853;;019-501-367-052-495;;148-264-692-351-393;;036-961-131-011-471;;159-263-834-456-866;;042-991-943-849-821;;034-091-939-029-106;;137-110-048-545-719;;081-358-209-315-340;;029-651-022-420-201;;081-472-928-361-748;;006-836-959-903-102;;031-846-521-635-380;;071-216-935-223-604;;150-928-460-596-448;;015-930-525-310-569;;084-167-477-082-034;;061-217-689-441-682;;116-635-444-889-388;;045-357-296-258-363;;036-910-309-684-180;;099-738-580-867-973;;000-261-303-928-531;;110-841-784-249-474;;016-727-749-993-963;;037-984-672-901-82X;;053-660-488-479-381;;023-702-197-545-187;;095-708-959-753-29X;;128-292-318-129-648;;039-890-476-525-420,10.1016/j.tet.2006.07.094;;10.1021/ma060950q;;10.1021/cm048821g;;10.1021/jo0481304;;15760182;;10.1002/1521-3935(20011001)202:15<3035::aid-macp3035>3.0.co;2-l;;10.1002/1521-3935(20010801)202:12<2623::aid-macp2623>3.0.co;2-i;;10.1007/bf02879540;;10.1016/s0032-3861(01)00256-7;;10.1016/s0032-3861(00)00757-6;;10.1039/b006048h;;10.1021/ma001090v;;10.1021/ma000438j;;10.1016/s0032-3861(98)00268-7;;10.1093/ndt/12.5.961;;9175050;;10.1021/ma00035a017;;14533165;;10.1002/anie.200351500;;10.1021/ma00089a012;;10.1021/ja00120a032;;10.1002/ange.19931050916;;16297497;;10.1016/j.addr.2005.09.019;;10.1016/j.eurpolymj.2003.11.012;;10.1021/jo025625p;;12027725;;15588909;;10.1016/j.jconrel.2004.08.024;;10.1016/j.memsci.2004.03.034;;16787091;;10.1021/ja060875z;;10.1021/ie048837g;;15848007;;10.1016/j.ijpharm.2005.01.026;;10.1007/s00396-001-0625-4;;10.1159/000072822;;12915774;;10.1177/039139880502800806;;16211530;;10.3109/03639049109043813;;10.1016/0378-5173(92)90302-i;;10.1016/0378-5173(90)90404-r;;10.1016/0378-5173(93)90263-f;;10.1016/0378-5173(96)04489-4;;12210050;;10.1002/jps.10197,"Jayamurugan, Govindasamy, et al., ""Synthesis of Large Generation poly(propul ether imine) (PETIM) Dendrimers"" Tetrahedron, 62 (2006) 9582-9588.;;Xiuru Li, et al., ""Synthesis and Characterization of Hyperbranched Poly(ester amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines"" Macromolecules, 39 (2006) 7889-7899.;;Pérignon, Nelly et al., ""Formation and Stabilization in Water of Metal Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers"" Chem Mater., 16 (2004) 4856-4858.;;Koç, Fikret, et al. ""Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence"" J. Org. Chem., 70 (2005) 2021-2025.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers, 3a: comparison of copoly(sulfone-amine)s containing piperazine and 4,4'-trimethylenedipiperidine units"" Macromolecular Chemistry and Physics (2001), 202(15), 3035-3042.;;Gao, Chao, ""Hyperbranched polymers made from A2- and BB2'-type monomers; 3. Polyaddition of N-methyl 1,3-propanediamine to divinyl sulfone"" Macromolecular Chemistry and Physics (2001), 202(12), 2623-2629.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers (iv). Copolymerization of divinyl sulfone with 4,4'-trimethylenedipiperidine and N-ethylethylenediamine"" Science in China, Series B: Chemistry (2001), 44(2), 207-215.;;Gao, C., ""Preparation of Water Soluble hyperbranched poly(sulfoneamine)s by polyaddition of N-ethylethylenediamine to divinyl sulfone"" Polymer (2001), 42(18), 7603-7610.;;Gao, C., ""Hyperbranched polymers made from A2, B2 and BB'2 type monomers, 2. Preparation of hyperbranched copoly(sulfone-amine)s by polyaddition of N-ethylethylenediamine and piperazine to divinylsulfone"" Polymer (2001), 42(8), 3437-3443.;;Gao, Chao, ""Synthesis of hyperbranched polymers from commercially available A2 and BB'2 type monomers"" Chemical Communications (Cambridge), 1 (2001) 107-108.;;Gao, Chao, ""Polyaddition of B2 and BB'2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(sulfon-amine)s"" Macromolecules (2001), 34(2), 156-161.;;Yan, Deyue, ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)piperazine to Divinyl Sulfone"" Macromolecules (2000), 33(21), 7693-7699.;;Hobson, Lois J., et al. ""Poly(amidoamine) Hyperbranched Systems:Synthesis, Structure and Characterization"" Polymer, 40 (1999) 1279-1297.;;Rosenbaum, Holmes-Farley, Mandeville, Pitruzzello, Goldberg, ""Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats"" Nephrology Dialysis Transplantation, vol. 12 (1997) 961-964.;;Mourey, T. H., et al., ""Unique Behavior of Dendritic Molecules: Intrinsic Viscosity of Polyether Dendrimers"" Macromolecules, 25 (1992) 2401-2406.;;Janssen, H.M. et al, ""The Synthesis and Characterization of Dendritic Molecules"" Eindhoven University of Technology [No date available].;;Klapper, Marcus et al., ""Poly(methylene amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone"" Angew. Chem. Int. Ed., 42 (2003) 4687-4690 (XP002456407).;;Kremer, Michael, et al., ""Pore-Size Distributions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and Crosslnker/Monomer Ratio"" Macromolecules, 27 (1994) 2965-2973.;;Jansen, Johan F.G.A. et al. ""The Dendritic Box: Shape-Selective Liberation of Encapsulated Guests"" J. Am. Chem. Soc., 117 (1995) 4417-4418.;;de Brabander-van den Berg, Ellen M. M. et al., ""Poly(propylenimin)-Dendrimere: Synthese in gröbetaerem Mabetastab durch heterogen katalysierte Hydrierungen"" Angew. Chem. (1993) 1370-1372. [in German only].;;Duncan, Ruth et al., ""Dendrimer biocompatibility and toxicity"" Advanced Drug Delivery Reviews, 57 (2005) 2215-2237.;;Huval, Chad C. et al., ""Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants"" European Polymer Journal, 40 (2004) 693-701.;;Newkome, George R. et al., ""Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction"" J. Org. Chem., 67 (2002) 3957-3960.;;Schatzlein, Andreas G. et al., ""Preferential liver gene expression with polypropylenimine dendrimers"" Journal of Controlled Release, 101 (2005) 247-258.;;Shao, Lu et al., ""Transport properties of cross-linked polyimide membranes induced by different generations of diaminobutane (DAB) dendrimers"" Journal of Membrane Science, 238 (2004) 153-163.;;Stasko, Nathan A. et al., ""Dendrimers as a Scaffold for Nitric Oxide Release"" J. Am. Chem. Soc., 128 (2006) 8265-8271.;;Xiao, Youchang et al., ""Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Films"" Ind. Eng. Chem. Res., 44 (2005) 3059-3067.;;Bhadra, D. et al., ""Glycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting"" International Journal of Pharmaceutics, 295 (Mar. 2005) 221-233.;;Pavlov, G. M. et al. ""Molecular Characteristics of Poly(propylene imine) Dendrimers as Studied with Translational Diffusion and Viscometry"" Colloid. Polym. Sci., 280 (2002) 416-423.;;Chertow, Glenn M. et al. ""The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients"" Am. J. Nephrol., 23:5 (2003) 307-314.;;Katopodis, K. P. et al. ""Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphosphatemia in Dialysis Patients"" The International Journal of Artificial Organs, 28:8 (2005) 803-807.;;Selmeczi, B. et al. ""Investigations of the Influence of Some Novel Auxiliary Agents on the Physical Properties of Tablets"" Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary), [No date available].;;Mattsson, S. et al. ""Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties"" S.T.P. Pharma Sciences, 11:3 (2001) 211-220.;;Soltero, Richard et al. ""The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Gluconate Sustained Release Dosage Forms"" Drug Development and Industrial Pharmacy, 17:1 (1991) 113-140.;;Hammouda, Y. et al. ""The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets"" Pharm. Ind., 37:5 (1975) 361-363.;;Caramella, Carla et al. ""Experimental Evidence of Disintegration Mechanisms"" Acta Pharm. Technol., 35:1 (1989) 30-33.;;Tirkkonen, Sirpa et al. ""Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall"" International Journal of Pharmaceutics, 88 (1992) 39-51.;;Mitchell, Karen et al. ""The Influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydroxypropylmethylcellulose Gels and Matrix Tablets"" International Journal of Pharmaceutics, 66 (1990) 233-242.;;Tirkkonen, Sirpa et al. ""Release of Indomethacin from Tabletted Ethylcellulose Microcapsules"" International Journal of Pharmaceutics, 92 (1993) 55-62.;;Ferrari, F. et al. ""Investigation on Bonding and Distintegration Properties of Pharmaceutical Materials"" International Journal of Pharmaceutics, 136 (1996) 71-79.;;Lin, Shan-Yang et al. ""Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets"" Journal of Pharmaceutical Sciences, 91:9 (Sep. 2002) 2040-2046.;;Schulz, W. ""Brief Evaluation: Sevelamer Hydrochloride"" Drug, Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3 (2001) 621-626.;;Maroni, Bradley J. et al. ""Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial"" ERA-EDTA: Abstract #551794 (2006).;;""Renvela: sevelamer carbonate"" Prescribing Information, Genzyme Corporation, Nov. 2007.",INACTIVE
27,EP,A2,EP 1951266 A2,162-074-901-178-022,2008-08-06,2008,EP 06802428 A,2006-08-25,US 2006/0033437 W;;US 71399105 P;;US 73446205 P,2005-09-02,METHOD FOR REMOVING PHOSPHATE AND POLYMER USED THEREFORE,,GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/162-074-901-178-022,Patent Application,yes,0,0,8,8,0,A61K31/785;;A61K31/785;;A61K31/77;;A61K31/77;;A61K31/787;;A61K31/787;;A61P3/00;;A61P5/18;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P39/00;;C08F226/02;;C08F226/02;;C08F226/04;;C08F226/04;;C08F226/06;;C08F226/06,A61K31/785;;A61K31/787;;C08F226/02;;C08F226/04;;C08F226/06,,1,0,,,See references of WO 2007027566A2,DISCONTINUED
28,WO,A3,WO 2007/027566 A3,050-214-407-680-499,2007-12-13,2007,US 2006/0033437 W,2006-08-25,US 71399105 P;;US 73446205 P,2005-09-02,METHOD FOR REMOVING PHOSPHATE AND POLYMER USED THEREFORE,"Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing functional groups which bind phosphate. Variations of such polymer and compositions are disclosed.",GENZYME CORP;;HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/050-214-407-680-499,Search Report,yes,5,0,8,8,0,A61K31/785;;A61K31/785;;A61K31/77;;A61K31/77;;A61K31/787;;A61K31/787;;A61P3/00;;A61P5/18;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P39/00;;C08F226/02;;C08F226/02;;C08F226/04;;C08F226/04;;C08F226/06;;C08F226/06,A61K31/785;;A61K31/787;;C08F226/02;;C08F226/04;;C08F226/06,,0,0,,,,PENDING
29,WO,A3,WO 2007/056405 A3,077-309-605-995-75X,2007-11-08,2007,US 2006/0043402 W,2006-11-07,US 73459305 P,2005-11-08,MAGNESIUM-CONTAINING POLYMERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA,"A pharmaceutical composition comprising an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable magnesium compound comprising a magnesium ion is disclosed. A method of treating hyperphosphatemia in a patient is also disclosed. The method comprises the step of administering to the subject an effective amount of the disclosed pharmaceutical composition.",GENZYME CORP;;HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/077-309-605-995-75X,Search Report,yes,3,0,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,A61K31/132;;A61K33/06,,3,3,008-548-456-739-60X;;055-558-433-061-414;;110-841-784-249-474,12105237;;10.1093/ndt/17.7.1170;;10.1111/j.1523-1755.2004.09005.x;;15296504;;10.1159/000072822;;12915774,"MALLUCHE HARTMUT H ET AL: ""Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions."", NEPHROLOGY, DIALYSIS, TRANSPLANTATION : OFFICIAL PUBLICATION OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION - EUROPEAN RENAL ASSOCIATION JUL 2002, vol. 17, no. 7, July 2002 (2002-07-01), pages 1170 - 1175, XP002447724, ISSN: 0931-0509;;EMMETT MICHAEL: ""A comparison of clinically useful phosphorus binders for patients with chronic kidney failure"", KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 66, no. Suppl 90, September 2004 (2004-09-01), pages S25 - S32, XP002378636, ISSN: 0085-2538;;CHERTOW G M ET AL: ""The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients"", AMERICAN JOURNAL OF NEPHROLOGY, KARGER, BASEL, CH, vol. 23, no. 5, September 2003 (2003-09-01), pages 307 - 314, XP009030087, ISSN: 0250-8095",PENDING
30,AR,A1,AR 060690 A1,026-362-846-919-371,2008-07-10,2008,AR P060104871 A,2006-11-07,US 73459305 P,2005-11-08,POLIMEROS QUE CONTIENEN MAGNESIO PARA LA HIPERFOSFATEMIA,"Se describe una composicion farmacéutica consistente en un polímero de amina alifática o una sal farmacéuticamente aceptable del mismo y un compuesto de magnesio farmacéuticamente aceptable que contiene un ion magnesio. Se describe también un método de tratamiento de la hiperfosfatemia en un paciente. El método consiste en la etapa de administracion al sujeto de una cantidad efectiva de la composicion farmacéutica descrita. Reivindicacion 2: La composicion farmacéutica de la reivindicacion 1, donde el compuesto de magnesio es seleccionado entre el grupo consistente en oxido de magnesio, hidroxido de magnesio, carbonato de magnesio, formiato de magnesio y una combinacion de éstos. Reivindicacion 4: La composicion farmacéutica de la reivindicacion 1, donde el polímero de amina alifática contiene una o más unidades repetitivas representadas por una formula estructural seleccionada entre (1) a (6), o una sal de las mismas, donde: y y z son independientemente cero o un numero entero de uno a diez; R, R1, R2, y R3, independientemente, son H, un grupo alquilo substituido o no substituido o un grupo arilo y X es un contraion negativamente intercambiable.",GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/026-362-846-919-371,Patent Application,no,0,0,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,,,0,0,,,,PENDING
31,WO,A3,WO 2000/038664 A3,089-637-396-549-013,2001-07-26,2001,US 9930469 W,1999-12-20,US 21955898 A,1998-12-23,AMINE CONDENSATION POLYMER BILE ACID SEQUESTRANTS,"A method for binding bile salts in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of one or more amine polymers prepared by the process comprising the step of reacting a substituted or unsubstituted aliphatic, aromatic or aralkyl bifunctional electrophile with at least one monomer comprising a substituted or unsubstituted hydrophobic moiety and a single nucleophilic substituent which is multireactive.",GELTEX PHARMA INC,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;WHITESIDES GEORGE M,,https://lens.org/089-637-396-549-013,Search Report,yes,2,0,3,3,0,A61K31/785;;A61P3/06,A61K31/785,,2,2,011-410-074-650-569;;076-559-363-745-20X,5433090;;10.1016/0021-9150(70)90030-4;;10.1007/978-1-4684-2250-4_15,"PARKINSON, T.M. ET AL: ""Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man"", ATHEROSCLEROSIS, vol. 11, no. 3, 1970, pages 531 - 537, XP000974394;;CHARLES E. DAY: ""Control of low density lipoproteins and atherosclerosis with the bile acid sequestrants colestipol, cholestyramine and polidexide"", LOW DENSITY LIPOPROTEINS, 1976, pages 421 - 438, XP000971182",PENDING
32,BR,A2,BR PI0715053 A2,043-254-987-982-401,2013-03-19,2013,BR PI0715053 A,2007-07-16,US 83146106 P;;US 83732206 P;;US 84764106 P;;US 2007/0016240 W,2006-07-18,"composiÇço farmacÊutica, mÉtodo para tratar doenÇas, e, polÍmero","COMPOSIÇçO FARMACÊUTICA, MÉTODO PARA TRATAR DOENÇAS, E, POLÍMERO. Composições e compostos ligantes de lons podem incluir compostos, polímeros e composições que incluem grupos amina. Polímeros ligantes de lons podem ser polímeros aminados reticulados e podem ser usados para remover lons, tais como lons fosfato, do trato gastrointestinal de animais, tais como humanos. Tais compostos, polímeros e composições são usados terapeuticamente para tratar uma variedade de condições médicas, tal como hiperfosfatemia.",GENZYME CORP,HOLMES-FARLEY S RANDALL;;DHAL PRADEEP K;;HUVAL CHAD C,,https://lens.org/043-254-987-982-401,Patent Application,no,0,0,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61B5/055,,0,0,,,,DISCONTINUED
33,CA,A1,CA 2620406 A1,065-208-428-899-151,2007-03-08,2007,CA 2620406 A,2006-08-25,US 71399105 P;;US 73446205 P;;US 2006/0033437 W,2005-09-02,METHOD FOR REMOVING PHOSPHATE AND POLYMER USED THEREFORE,"Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phospha te levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing function al groups which bind phosphate. Variations of such polymer and compositions are disclosed.",GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/065-208-428-899-151,Patent Application,no,0,0,8,8,0,A61K31/785;;A61K31/785;;A61K31/77;;A61K31/77;;A61K31/787;;A61K31/787;;A61P3/00;;A61P5/18;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P39/00;;C08F226/02;;C08F226/02;;C08F226/04;;C08F226/04;;C08F226/06;;C08F226/06,A61K31/785;;A61K31/787;;C08F226/02;;C08F226/04;;C08F226/06,,0,0,,,,DISCONTINUED
34,WO,A2,WO 2008/011047 A2,114-535-307-710-870,2008-01-24,2008,US 2007/0016240 W,2007-07-16,US 83146106 P;;US 83732206 P;;US 84764106 P,2006-07-18,AMINE DENDRIMERS,"Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.",GENZYME CORP;;HOLMES-FARLEY S RANDALL;;DAHL PRADEEP K;;HUVAL CHAD C,HOLMES-FARLEY S RANDALL;;DAHL PRADEEP K;;HUVAL CHAD C,,https://lens.org/114-535-307-710-870,Patent Application,yes,0,20,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61K49/10,,0,0,,,,PENDING
35,WO,A3,WO 2008/011047 A3,145-304-860-271-638,2008-12-04,2008,US 2007/0016240 W,2007-07-16,US 83146106 P;;US 83732206 P;;US 84764106 P,2006-07-18,AMINE DENDRIMERS,"Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.",GENZYME CORP;;HOLMES-FARLEY S RANDALL;;DAHL PRADEEP K;;HUVAL CHAD C,HOLMES-FARLEY S RANDALL;;DAHL PRADEEP K;;HUVAL CHAD C,,https://lens.org/145-304-860-271-638,Search Report,yes,1,0,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61B5/055,,1,0,,,"JOHAN F.G., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, no. 15, April 1995 (1995-04-01), pages 4417 - 4418, XP008104118",PENDING
36,EP,A2,EP 2043627 A2,057-000-090-016-370,2009-04-08,2009,EP 07796408 A,2007-06-25,US 2007/0014688 W;;US 81872706 P,2006-07-05,IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA,,GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/057-000-090-016-370,Patent Application,yes,0,0,6,6,0,A61K33/26;;A61K33/26;;A61K9/145;;A61K9/145;;A61K9/146;;A61K9/146;;A61K31/295;;A61K31/295;;A61K31/785;;A61K31/785;;A61K45/06;;A61K45/06;;A61P1/00;;A61P3/00;;A61P7/00;;A61P39/04,A61K31/295;;A61K9/14;;A61K33/26,,1,0,,,See references of WO 2008005217A3,DISCONTINUED
37,US,A1,US 2009/0162314 A1,169-513-935-795-439,2009-06-25,2009,US 8375006 A,2006-11-07,US 8375006 A;;US 73459305 P;;US 2006/0043402 W,2005-11-08,Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia,"A pharmaceutical composition comprising an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable magnesium compound comprising a magnesium ion is disclosed. A method of treating hyperphosphatemia in a patient is also disclosed. The method comprises the step of administering to the subject an effective amount of the disclosed pharmaceutical composition.",HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,GENZYME CORPORATION (2008-05-21),https://lens.org/169-513-935-795-439,Patent Application,yes,62,12,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,A61K31/765;;A61P7/00,424/78.38,3,2,106-679-115-180-396;;057-471-914-266-024,10.1002/pdi.1900;;10.1111/j.1440-1797.2004.00338.x;;15663645,"Machine Translation of EP1046410; Accessed 12/2/11.;;Gunatillake, N. D. et al., Sevelamer, Practical Diabetes 31 [2014] pp. 349-351;;STURTEVANT (Sturtevant, et al., Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders, Nephrology 9 (2004), pp. 406-413).",DISCONTINUED
38,US,A1,US 2009/0047233 A1,083-184-524-676-109,2009-02-19,2009,US 99120906 A,2006-08-25,US 99120906 A;;US 71399105 P;;US 73446205 P;;US 2006/0033437 W,2005-09-02,Method for removing Phosphate and Polymer Used Therefore,"Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing functional groups which bind phosphate. Variations of such polymer and compositions are disclosed.",GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,GENZYME CORPORATION (2008-03-27),https://lens.org/083-184-524-676-109,Patent Application,yes,100,2,8,8,0,A61K31/785;;A61K31/785;;A61K31/77;;A61K31/77;;A61K31/787;;A61K31/787;;A61P3/00;;A61P5/18;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P39/00;;C08F226/02;;C08F226/02;;C08F226/04;;C08F226/04;;C08F226/06;;C08F226/06,A61K31/395;;A61K31/132;;A61P39/00;;C08F12/04;;C08F12/28,424/78.32;;526/310;;526/312;;526/263;;526/259;;424/78.35,0,0,,,,INACTIVE
39,EP,A2,EP 2016114 A2,137-569-082-132-36X,2009-01-21,2009,EP 07776627 A,2007-05-02,US 2007/0010650 W;;US 79796606 P,2006-05-05,AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS,,GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/137-569-082-132-36X,Patent Application,yes,0,0,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,C08G73/02,,0,0,,,,DISCONTINUED
40,US,A1,US 2015/0011645 A1,156-504-329-440-99X,2015-01-08,2015,US 201414496823 A,2014-09-25,US 201414496823 A;;US 30941409 A;;US 2007/0016240 W;;US 83146106 P;;US 83732206 P;;US 84764106 P,2006-07-18,AMINE DENDRIMERS,"Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;HUVAL CHAD C,,https://lens.org/156-504-329-440-99X,Patent Application,yes,0,0,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,C07C211/14,514/674;;564/512,0,0,,,,DISCONTINUED
41,US,B2,US 8889738 B2,013-045-312-074-238,2014-11-18,2014,US 201213417592 A,2012-03-12,US 201213417592 A;;US 44822209 A;;US 2007/0025216 W;;US 87471506 P,2006-12-14,Amido-amine polymer compositions,"Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,GENZYME CORPORATION (2007-02-22),https://lens.org/013-045-312-074-238,Granted Patent,yes,100,4,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/22;;A61K31/04;;A61K31/165;;A61K31/23;;A61K31/785,514/549;;514/740,46,37,014-421-542-498-637;;090-264-176-174-068;;073-074-746-492-276;;089-551-918-367-384;;016-205-437-942-376;;055-585-701-440-853;;019-501-367-052-495;;148-264-692-351-393;;036-961-131-011-471;;159-263-834-456-866;;042-991-943-849-821;;034-091-939-029-106;;137-110-048-545-719;;081-358-209-315-340;;029-651-022-420-201;;081-472-928-361-748;;000-719-232-475-767;;006-836-959-903-102;;031-846-521-635-380;;071-216-935-223-604;;150-928-460-596-448;;015-930-525-310-569;;084-167-477-082-034;;061-217-689-441-682;;116-635-444-889-388;;045-357-296-258-363;;036-910-309-684-180;;099-738-580-867-973;;000-261-303-928-531;;110-841-784-249-474;;016-727-749-993-963;;037-984-672-901-82X;;053-660-488-479-381;;023-702-197-545-187;;095-708-959-753-29X;;128-292-318-129-648;;039-890-476-525-420,10.1016/j.tet.2006.07.094;;10.1021/ma060950q;;10.1021/cm048821g;;10.1021/jo0481304;;15760182;;10.1002/1521-3935(20011001)202:15<3035::aid-macp3035>3.0.co;2-l;;10.1002/1521-3935(20010801)202:12<2623::aid-macp2623>3.0.co;2-i;;10.1007/bf02879540;;10.1016/s0032-3861(01)00256-7;;10.1016/s0032-3861(00)00757-6;;10.1039/b006048h;;10.1021/ma001090v;;10.1021/ma000438j;;10.1016/s0032-3861(98)00268-7;;10.1093/ndt/12.5.961;;9175050;;10.1021/ma00035a017;;14533165;;10.1002/anie.200351500;;10.1016/s0021-9673(00)88914-1;;10.1021/ma00089a012;;10.1021/ja00120a032;;10.1002/ange.19931050916;;16297497;;10.1016/j.addr.2005.09.019;;10.1016/j.eurpolymj.2003.11.012;;10.1021/jo025625p;;12027725;;15588909;;10.1016/j.jconrel.2004.08.024;;10.1016/j.memsci.2004.03.034;;16787091;;10.1021/ja060875z;;10.1021/ie048837g;;15848007;;10.1016/j.ijpharm.2005.01.026;;10.1007/s00396-001-0625-4;;10.1159/000072822;;12915774;;10.1177/039139880502800806;;16211530;;10.3109/03639049109043813;;10.1016/0378-5173(92)90302-i;;10.1016/0378-5173(90)90404-r;;10.1016/0378-5173(93)90263-f;;10.1016/0378-5173(96)04489-4;;12210050;;10.1002/jps.10197,"Jayamurugan, Govindasamy, et al., ""Synthesis of Large Generation poly(propul ether imine) (PETIM) Dendrimers"" Tetrahedron, 62 (2006) 9582-9588.;;Xiuru Li, et al., ""Synthesis and Characterization of Hyperbranched Poly(ester amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines"" Macromolecules, 39 (2006) 7889-7899.;;Pérignon, Nelly et al., ""Formation and Stabilization in Water of Metal Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers"" Chem Mater., 16 (2004) 4856-4858.;;Koç, Fikret, et al. ""Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence"" J. Org. Chem., 70 (2005) 2021-2025.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers, 3a: comparison of copoly(sulfone-amine)s containing piperazine and 4,4'-trimethylenedipiperidine units"" Macromolecular Chemistry and Physics (2001), 202(15), 3035-3042.;;Gao, Chao, ""Hyperbranched polymers made from A2- and BB2'-type monomers; 3. Polyaddition of N-methyl 1,3-propanediamine to divinyl sulfone"" Macromolecular Chemistry and Physics (2001), 202(12), 2623-2629.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers (iv). Copolymerization of divinyl sulfone with 4,4'-trimethylenedipiperidine and N-ethylethylenediamine"" Science in China, Series B: Chemistry (2001), 44(2), 207-215.;;Gao, C., ""Preparation of Water Soluble hyperbranched poly(sulfone-amine)s by polyaddition of N-ethylethylenediamine to divinyl sulfone"" Polymer (2001), 42(18), 7603-7610.;;Gao, C., ""Hyperbranched polymers made from A2, B2 and BB'2 type monomers, 2. Preparation of hyperbranched copoly(sulfone-amine)s by polyaddition of N-ethylethylenediamine and piperazine to divinylsulfone"" Polymer (2001), 42(8), 3437-3443.;;Gao, Chao, ""Synthesis of hyperbranched polymers from commercially available A2 and BB'2 type monomers"" Chemical Communications (Cambridge), 1 (2001) 107-108.;;Gao, Chao, ""Polyaddition of B2 and BB'2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(sulfon-amine)s"" Macromolecules (2001), 34(2), 156-161.;;Yan, Deyue, ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)piperazine to Divinyl Sulfone"" Macromolecules (2000), 33(21), 7693-7699.;;Hobson, Lois J., et al. ""Poly(amidoamine) Hyperbranched Systems:Synthesis, Structure and Characterization"" Polymer, 40 (1999) 1279-1297.;;Rosenbaum, Holmes-Farley, Mandeville, Pitruzzello, Goldberg, ""Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats"" Nephrology Dialysis Transplantation, vol. 12 (1997) 961-964.;;Mourey, T. H., et al., ""Unique Behavior of Dendritic Molecules: Intrinsic Viscosity of Polyether Dendrimers"" Macromolecules, 25 (1992) 2401-2406.;;Janssen, H.M. et al, ""The Synthesis and Characterization of Dendritic Molecules"" Eindhoven University of Technology [No date available].;;Klapper, Marcus et al., ""Poly(methylene amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone"" Angew. Chem. Int. Ed., 42 (2003) 4687-4690 (XP002456407).;;Kuga, Shigenori, ""Pore Size Ditribution Analysis of Gel Substances by Size Exclusion Chromatography"" J. Chromatography, 206 (1981) 449-461.;;Kremer, Michael, et al., ""Pore-Size Distributions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and Crosslnker/Monomer Ratio"" Macromolecules, 27 (1994) 2965-2973.;;Jansen, Johan F.G.A. et al. ""The Dendritic Box: Shape-Selective Liberation of Encapsulated Guests"" J. Am. Chem. Soc., 117 (1995) 4417-4418.;;de Brabander-van den Berg, Ellen M. M. et al., ""Poly(propylenimin)-Dendrimere: Synthese in gröbetaerem Mabetastab durch heterogen katalysierte Hydrierungen"" Angew. Chem. (1993) 1370-1372. [in German only].;;Duncan, Ruth et al., ""Dendrimer biocompatibility and toxicity"" Advanced Drug Delivery Reviews, 57 (2005) 2215-2237.;;Huval, Chad C. et al., ""Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants"" European Polymer Journal, 40 (2004) 693-701.;;Newkome, George R. et al., ""Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction"" J. Org. Chem., 67 (2002) 3957-3960.;;Schatzlein, Andreas G. et al., ""Preferential liver gene expression with polypropylenimine dendrimeis"" Journal of Controlled Release, 101 (2005) 247-258.;;Shao, Lu et al., ""Transport properties of cross-linked polyimide membranes induced by different generations of diaminobutane (DAB) dendrimers"" Journal of Membrane Science, 238 (2004) 153-163.;;Stasko, Nathan A. et al., ""Dendrimers as a Scaffold for Nitric Oxide Release"" J. Am. Chem. Soc., 128 (2006) 8265-8271.;;Xiao, Youchang et al., ""Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Films"" Ind. Eng. Chem. Res., 44 (2005) 3059-3067.;;Bhadra, D. et al., ""Glycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting"" International Journal of Pharmaceutics, 295 (Mar. 2005) 221-233.;;Pavlov, G. M. et al. ""Molecular Characteristics of Poly(propylene imine) Dendrimers as Studied with Translational Diffusion and Viscometry"" Colloid. Polym. Sci., 280 (2002) 416-423.;;Chertow, Glenn M. et al. ""The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients"" Am. J. Nephrol., 23:5 (2003) 307-314.;;Katopodis, K. P. et al. ""Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphosphatemia in Dialysis Patients"" The International Journal of Artificial Organs, 28:8 (2005) 803-807.;;Selmeczi, B. et al. ""Investigations of the Influence of Some Novel Auxiliary Agents on the Physical Properties of Tablets"" Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary), [No date available].;;Mattsson, S. et al. ""Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties"" S.T.P. Pharma Sciences, 11:3 (2001) 211-220.;;Soltero, Richard et al. ""The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Gluconate Sustained Release Dosage Forms"" Drug Development and Industrial Pharmacy, 17:1 (1991) 113-140.;;Hammouda, Y. et al. ""The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets"" Pharm. Ind., 37:5 (1975) 361-363.;;Caramella, Carla et al. ""Experimental Evidence of Disintegration Mechanisms"" Acta Pharm. Technol., 35:1 (1989) 30-33.;;Tirkkonen, Sirpa et al. ""Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall"" International Journal of Pharmaceutics, 88 (1992) 39-51.;;Mitchell, Karen et al. ""The Influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydroxypropylmethylcellulose Gels and Matrix Tablets"" International Journal of Pharmaceutics, 66 (1990) 233-242.;;Tirkkonen, Sirpa et al. ""Release of Indomethacin from Tabletted Ethylcellulose Microcapsules"" International Journal of Pharmaceutics, 92 (1993) 55-62.;;Ferrari, F. et al. ""Investigation on Bonding and Distintegration Properties of Pharmaceutical Materials"" International Journal of Pharmaceutics, 136 (1996) 71-79.;;Lin, Shan-Yang et al. ""Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets"" Journal of Pharmaceutical Sciences, 91:9 (Sep. 2002) 2040-2046.;;Schulz, W. ""Brief Evaluation: Sevelamer Hydrochloride"" Drug, Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3 (2001) 621-626.;;Maroni, Bradley J. et al. ""Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial"" ERA-EDTA: Abstract #551794 (2006).;;""Renvela: sevelamer carbonate"" Prescribing Information, Genzyme Corporation, Nov. 2007.;;International Search Report dated Apr. 4, 2008 for PCT/US2007/025216.",INACTIVE
42,US,A1,US 2012/0237470 A1,023-741-466-268-934,2012-09-20,2012,US 201213417592 A,2012-03-12,US 201213417592 A;;US 44822209 A;;US 2007/0025216 W;;US 87471506 P,2006-12-14,AMIDO-AMINE POLYMER COMPOSITIONS,"Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,GENZYME CORPORATION (2007-02-22),https://lens.org/023-741-466-268-934,Patent Application,yes,1,8,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/785;;A61P1/00;;A61P13/12,424/78.01,0,0,,,,INACTIVE
43,CA,A1,CA 2626734 A1,060-110-164-203-634,2007-05-18,2007,CA 2626734 A,2006-11-07,US 73459305 P;;US 2006/0043402 W,2005-11-08,MAGNESIUM-CONTAINING POLYMERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA,,GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;DHAL PRADEEP K,,https://lens.org/060-110-164-203-634,Patent Application,no,0,0,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,A61K31/132;;A61K33/06,,0,0,,,,DISCONTINUED
44,US,A1,US 2010/0254935 A1,012-025-403-672-423,2010-10-07,2010,US 65694510 A,2010-02-19,US 65694510 A;;US 79973907 A;;US 79796606 P,2006-05-05,Amine condensation polymers as phosphate sequestrants,"Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH 2 CH 2 — group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.",GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,GENZYME CORPORATION (2007-10-15),https://lens.org/012-025-403-672-423,Patent Application,yes,99,1,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,A61K31/785;;A61P39/00,424/78.38;;424/78.08,0,0,,,,DISCONTINUED
45,US,A1,US 2012/0288471 A1,026-969-146-312-73X,2012-11-15,2012,US 201113286489 A,2011-11-01,US 201113286489 A;;US 65694510 A;;US 79973907 A;;US 79796606 P,2006-05-05,Amine Condensation Polymers as Phosphate Sequestrants,"Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH 2 CH 2 — group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.",HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/026-969-146-312-73X,Patent Application,yes,1,11,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,C08G73/02;;A61K31/785;;A61P3/12;;C08G59/10,424/78.38;;424/78.08;;528/405;;528/397,0,0,,,,DISCONTINUED
46,BR,A2,BR PI0618352 A2,121-533-896-088-032,2011-08-23,2011,BR PI0618352 A,2006-11-07,US 73459305 P;;US 2006/0043402 W,2005-11-08,composições farmacêuticas e métodos de tratamento da hiperfosfatemia em um paciente,"COMPOSIçõES FARMACêUTICAS E MéTODOS DE TRATAMENTO DA HIPERFOSFATEMIA EM UM PACIENTE. é revelada uma composição farmacêutica que compreende um polímero de amina alifática ou um sal farmaceuticamente aceitável deste, e um composto de magnésio farmaceuticamente aceitável, que compreende um ion de magnésio. E também revelado um método de tratamento de hiperfosfatemia em um paciente. Este método compreende a etapa de administração ao indivíduo de uma quantidade eficaz da composição farmacêutica revelada.",GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/121-533-896-088-032,Patent Application,no,0,0,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,A61K31/132;;A61K33/06,,0,0,,,,DISCONTINUED
47,WO,A2,WO 2007/027566 A2,136-897-980-987-841,2007-03-08,2007,US 2006/0033437 W,2006-08-25,US 71399105 P;;US 73446205 P,2005-09-02,POLYMERIC MOLECULAR RECEPTORS AS PHOSPHATE SEQUESTRANTS,"Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer. Each pendent group comprises at least two nitrogen-bearing functional groups which bind phosphate. Variations of such polymer and compositions are disclosed.",GENZYME CORP;;HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/136-897-980-987-841,Patent Application,yes,0,5,8,8,0,A61K31/787;;C08F226/04;;C08F226/06;;A61K31/77;;A61K31/785;;C08F226/02;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P39/00;;A61P5/18;;A61K31/787;;C08F226/04;;C08F226/06;;A61K31/785;;C08F226/02;;A61K31/77,,,0,0,,,,PENDING
48,CN,A,CN 1278180 A,157-970-184-854-984,2000-12-27,2000,CN 98810752 A,1998-10-26,US 96453697 A,1997-11-05,Method for treating hypercholesterolemia by using unsubstituted polydiallylamine,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S,,https://lens.org/157-970-184-854-984,Patent Application,no,0,3,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,DISCONTINUED
49,AU,A1,AU 2007/275711 A1,069-629-564-558-299,2008-01-24,2008,AU 2007/275711 A,2007-07-16,US 83732206 P;;US 84764106 P;;US 83146106 P;;US 2007/0016240 W,2006-07-18,Amine dendrimers,,GENZYME CORP,HOLMES-FARLEY S RANDALL;;DAHL PRADEEP K;;HUVAL CHAD C,,https://lens.org/069-629-564-558-299,Patent Application,no,0,0,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61B5/055,,0,0,,,,DISCONTINUED
50,US,A1,US 2010/0124542 A1,037-784-728-474-788,2010-05-20,2010,US 30941407 A,2007-07-16,US 30941407 A;;US 83146106 P;;US 83732206 P;;US 84764106 P;;US 2007/0016240 W,2006-07-18,AMINE DENDRIMERS,"Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.",GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,GENZYME CORPORATION (2009-01-20),https://lens.org/037-784-728-474-788,Patent Application,yes,99,11,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61K31/765;;A61P1/00;;C08G65/26,424/78.37;;528/405,0,0,,,,DISCONTINUED
51,US,B2,US 8163799 B2,011-248-206-305-087,2012-04-24,2012,US 44822207 A,2007-12-10,US 44822207 A;;US 87471506 P;;US 2007/0025216 W,2006-12-14,Amido-amine polymer compositions,"Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C,GENZYME CORPORATION (2009-06-12),https://lens.org/011-248-206-305-087,Granted Patent,yes,99,16,8,8,0,A61K31/785;;A61K31/785;;A61K31/165;;A61K31/23;;A61P1/00;;A61P3/12;;A61P13/12,A61K31/221;;A61K31/132,514/549;;514/740,46,37,014-421-542-498-637;;090-264-176-174-068;;073-074-746-492-276;;089-551-918-367-384;;016-205-437-942-376;;055-585-701-440-853;;019-501-367-052-495;;148-264-692-351-393;;036-961-131-011-471;;159-263-834-456-866;;042-991-943-849-821;;034-091-939-029-106;;137-110-048-545-719;;081-358-209-315-340;;029-651-022-420-201;;081-472-928-361-748;;000-719-232-475-767;;006-836-959-903-102;;031-846-521-635-380;;071-216-935-223-604;;150-928-460-596-448;;015-930-525-310-569;;084-167-477-082-034;;061-217-689-441-682;;116-635-444-889-388;;045-357-296-258-363;;036-910-309-684-180;;099-738-580-867-973;;000-261-303-928-531;;110-841-784-249-474;;016-727-749-993-963;;037-984-672-901-82X;;053-660-488-479-381;;023-702-197-545-187;;095-708-959-753-29X;;128-292-318-129-648;;039-890-476-525-420,10.1016/j.tet.2006.07.094;;10.1021/ma060950q;;10.1021/cm048821g;;10.1021/jo0481304;;15760182;;10.1002/1521-3935(20011001)202:15<3035::aid-macp3035>3.0.co;2-l;;10.1002/1521-3935(20010801)202:12<2623::aid-macp2623>3.0.co;2-i;;10.1007/bf02879540;;10.1016/s0032-3861(01)00256-7;;10.1016/s0032-3861(00)00757-6;;10.1039/b006048h;;10.1021/ma001090v;;10.1021/ma000438j;;10.1016/s0032-3861(98)00268-7;;10.1093/ndt/12.5.961;;9175050;;10.1021/ma00035a017;;14533165;;10.1002/anie.200351500;;10.1016/s0021-9673(00)88914-1;;10.1021/ma00089a012;;10.1021/ja00120a032;;10.1002/ange.19931050916;;16297497;;10.1016/j.addr.2005.09.019;;10.1016/j.eurpolymj.2003.11.012;;10.1021/jo025625p;;12027725;;15588909;;10.1016/j.jconrel.2004.08.024;;10.1016/j.memsci.2004.03.034;;16787091;;10.1021/ja060875z;;10.1021/ie048837g;;15848007;;10.1016/j.ijpharm.2005.01.026;;10.1007/s00396-001-0625-4;;10.1159/000072822;;12915774;;10.1177/039139880502800806;;16211530;;10.3109/03639049109043813;;10.1016/0378-5173(92)90302-i;;10.1016/0378-5173(90)90404-r;;10.1016/0378-5173(93)90263-f;;10.1016/0378-5173(96)04489-4;;12210050;;10.1002/jps.10197,"Jayamurugan, Govindasamy, et al., ""Synthesis of Large Generation poly(propul ether imine) (PETIM) Dendrimers"" Tetrahedron, 62 (2006) 9582-9588.;;Xiuru Li, et al., ""Synthesis and Characterization of Hyperbranched Poly(ester amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines"" Macromolecules, 39 (2006) 7889-7899.;;Pérignon, Nelly et al., ""Formation and Stabilization in Water of Metal Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers"" Chem Mater., 16 (2004) 4856-4858.;;Koç, Fikret, et al. ""Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence"" J. Org. Chem., 70 (2005) 2021-2025.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers, 3a: comparison of copoly(sulfone-amine)s containing piperazine and 4,4'-trimethylenedipiperidine units"" Macromolecular Chemistry and Physics (2001), 202(15), 3035-3042.;;Gao, Chao, ""Hyperbranched polymers made from A2- and BB2'-type monomers; 3. Polyaddition of N-methyl 1,3-propanediamine to divinyl sulfone"" Macromolecular Chemistry and Physics (2001), 202(12), 2623-2629.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers (iv). Copolymerization of divinyl sulfone with 4,4'-trimethylenedipiperidine and N-ethylethylenediamine"" Science in China, Series B: Chemistry (2001), 44(2), 207-215.;;Gao, C., ""Preparation of Water Soluble hyperbranched poly(sulfone-amine)s by polyaddition of N-ethylethylenediamine to divinyl sulfone"" Polymer (2001), 42(18), 7603-7610.;;Gao, C., ""Hyperbranched polymers made from A2, B2 and BB'2 type monomers, 2. Preparation of hyperbranched copoly(sulfone-amine)s by polyaddition of N-ethylethylenediamine and piperazine to divinylsulfone"" Polymer (2001), 42(8), 3437-3443.;;Gao, Chao, ""Synthesis of hyperbranched polymers from commercially available A2 and BB'2 type monomers"" Chemical Communications (Cambridge), 1 (2001) 107-108.;;Gao, Chao, ""Polyaddition of B2 and BB'2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(sulfon-amine)s"" Macromolecules (2001), 34(2), 156-161.;;Yan, Deyue, ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)piperazine to Divinyl Sulfone"" Macromolecules (2000), 33(21), 7693-7699.;;Hobson, Lois J., et al. ""Poly(amidoamine) Hyperbranched Systems:Synthesis, Structure and Characterization"" Polymer, 40 (1999) 1279-1297.;;Rosenbaum, Holmes-Farley, Mandeville, Pitruzzello, Goldberg, ""Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats"" Nephrology Dialysis Transplantation, vol. 12 (1997) 961-964.;;Mourey, T. H., et al., ""Unique Behavior of Dendritic Molecules: Intrinsic Viscosity of Polyether Dendrimers"" Macromolecules, 25 (1992) 2401-2406.;;Janssen, H.M. et al, ""The Synthesis and Characterization of Dendritic Molecules"" Eindhoven University of Technology [No date available].;;Klapper, Marcus et al., ""Poly(methylene amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone"" Angew. Chem. Int. Ed., 42 (2003) 4687-4690 (XP002456407).;;Kuga, Shigenori, ""Pore Size Ditribution Analysis of Gel Substances by Size Exclusion Chromatography"" J. Chromatography, 206 (1981) 449-461.;;Kremer, Michael, et al., ""Pore-Size Distributions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and Crosslnker/Monomer Ratio"" Macromolecules, 27 (1994) 2965-2973.;;Jansen, Johan F.G.A. et al. ""The Dendritic Box: Shape-Selective Liberation of Encapsulated Guests"" J. Am. Chem. Soc., 117 (1995) 4417-4418.;;de Brabander-van den Berg, Ellen M. M. et al., ""Poly(propylenimin)-Dendrimere: Synthese in gröbetaerem Mabetastab durch heterogen katalysierte Hydrierungen"" Angew. Chem. (1993) 1370-1372. [in German only].;;Duncan, Ruth et al., ""Dendrimer biocompatibility and toxicity"" Advanced Drug Delivery Reviews, 57 (2005) 2215-2237.;;Huval, Chad C. et al., ""Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants"" European Polymer Journal, 40 (2004) 693-701.;;Newkome, George R. et al., ""Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction"" J. Org. Chem., 67 (2002) 3957-3960.;;Schatzlein, Andreas G. et al., ""Preferential liver gene expression with polypropylenimine dendrimers"" Journal of Controlled Release, 101 (2005) 247-258.;;Shao, Lu et al., ""Transport properties of cross-linked polyimide membranes induced by different generations of diaminobutane (DAB) dendrimers"" Journal of Membrane Science, 238 (2004) 153-163.;;Stasko, Nathan A. et al., ""Dendrimers as a Scaffold for Nitric Oxide Release"" J. Am. Chem. Soc., 128 (2006) 8265-8271.;;Xiao, Youchang et al., ""Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Films"" Ind. Eng. Chem. Res., 44 (2005) 3059-3067.;;Bhadra, D. et al., ""Glycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting"" International Journal of Pharmaceutics, 295 (Mar. 2005) 221-233.;;Pavlov, G. M. et al. ""Molecular Characteristics of Poly(propylene imine) Dendrimers as Studied with Translational Diffusion and Viscometry"" Colloid. Polym. Sci., 280 (2002) 416-423.;;Chertow, Glenn M. et al. ""The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients"" Am. J. Nephrol., 23:5 (2003) 307-314.;;Katopodis, K. P. et al. ""Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphosphatemia in Dialysis Patients"" The International Journal of Artificial Organs, 28:8 (2005) 803-807.;;Selmeczi, B. et al. ""Investigations of the Influence of Some Novel Auxiliary Agents on the Physical Properties of Tablets"" Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary), [No date available].;;Mattsson, S. et al. ""Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties"" S.T.P. Pharma Sciences, 11:3 (2001) 211-220.;;Soltero, Richard et al. ""The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Gluconate Sustained Release Dosage Forms"" Drug Development and Industrial Pharmacy, 17:1 (1991) 113-140.;;Hammouda, Y. et al. ""The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets"" Pharm. Ind., 37:5 (1975) 361-363.;;Caramella, Carla et al. ""Experimental Evidence of Disintegration Mechanisms"" Acta Pharm. Technol., 35:1 (1989) 30-33.;;Tirkkonen, Sirpa et al. ""Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall"" International Journal of Pharmaceutics, 88 (1992) 39-51.;;Mitchell, Karen et al. ""The Influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydroxypropylmethylcellulose Gels and Matrix Tablets"" International Journal of Pharmaceutics, 66 (1990) 233-242.;;Tirkkonen, Sirpa et al. ""Release of Indomethacin from Tabletted Ethylcellulose Microcapsules"" International Journal of Pharmaceutics, 92 (1993) 55-62.;;Ferrari, F. et al. ""Investigation on Bonding and Distintegration Properties of Pharmaceutical Materials"" International Journal of Pharmaceutics, 136 (1996) 71-79.;;Lin, Shan-Yang et al. ""Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets"" Journal of Pharmaceutical Sciences, 91:9 (Sep. 2002) 2040-2046.;;Schulz, W. ""Brief Evaluation: Sevelamer Hydrochloride"" Drug, Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3 (2001) 621-626.;;Maroni, Bradley J. et al. ""Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial"" ERA-EDTA: Abstract #551794 (2006).;;""Renvela: sevelamer carbonate"" Prescribing Information, Genzyme Corporation, Nov. 2007.;;International Search Report dated Apr. 4, 2008 for PCT/US2007/025216.",ACTIVE
52,WO,A8,WO 2007/056405 A8,168-911-168-039-655,2007-08-02,2007,US 2006/0043402 W,2006-11-07,US 73459305 P,2005-11-08,MAGNESIUM-CONTAINING POLYMERS FOR HYPERPHOSPHATEMIA,"A pharmaceutical composition comprising an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable magnesium compound comprising a magnesium ion is disclosed. A method of treating hyperphosphatemia in a patient is also disclosed. The method comprises the step of administering to the subject an effective amount of the disclosed pharmaceutical composition.",GENZYME CORP;;HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/168-911-168-039-655,Patent Application,no,0,0,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,,,0,0,,,,PENDING
53,CA,A1,CA 2658338 A1,068-212-469-800-34X,2008-01-24,2008,CA 2658338 A,2007-07-16,US 83146106 P;;US 83732206 P;;US 84764106 P;;US 2007/0016240 W,2006-07-18,AMINE DENDRIMERS,"Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.",GENZYME CORP,HUVAL CHAD C;;DAHL PRADEEP K;;HOLMES-FARLEY S RANDALL,,https://lens.org/068-212-469-800-34X,Patent Application,no,0,3,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61B5/055,,0,0,,,,DISCONTINUED
54,MX,A,MX 2009000611 A,089-308-824-801-143,2009-04-16,2009,MX 2009000611 A,2007-07-16,US 83146106 P;;US 83732206 P;;US 84764106 P;;US 2007/0016240 W,2006-07-18,AMINE DENDRIMERS.,"Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.",GENZYME CORP,HOLMES-FARLEY S RANDALL;;HUVAL CHAD C;;DHAL PRADEEP K,,https://lens.org/089-308-824-801-143,Patent Application,no,0,0,11,12,0,A61K31/785;;A61K47/59;;A61K47/595;;A61P1/00;;A61P11/00;;A61P13/12;;A61P19/02;;A61P27/02;;A61P3/00;;A61P3/14;;A61P5/18;;A61P7/00;;A61P9/10;;A61K31/785;;A61K47/595;;A61K47/59;;C07C211/14,A61K49/10,,0,0,,,,PENDING
55,AU,A,AU 2000/023748 A,158-522-845-096-736,2000-07-31,2000,AU 2000/023748 A,1999-12-20,US 21955898 A;;US 9930469 W,1998-12-23,Amine condensation polymer bile acid sequestrants,,GELTEX PHARMA INC,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;WHITESIDES GEORGE M,,https://lens.org/158-522-845-096-736,Patent Application,no,0,0,3,3,0,A61K31/785;;A61P3/06,A61K31/785,,0,0,,,,DISCONTINUED
56,US,A1,US 2008/0085259 A1,190-272-363-233-532,2008-04-10,2008,US 79973907 A,2007-05-02,US 79973907 A;;US 79796606 P,2006-05-05,Amine condensation polymers as phosphate sequestrants,"Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH 2 CH 2 — group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.",HUVAL CHAD C;;HOLMES-FARLEY STEPHEN R;;DHAL PRADEEP K,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN R;;DHAL PRADEEP K,GENZYME CORPORATION (2007-10-15),https://lens.org/190-272-363-233-532,Patent Application,yes,3,3,9,9,0,C08G73/0206;;A61P13/12;;A61P21/00;;A61P3/00;;A61P3/12;;A61P3/14;;A61P35/00;;A61P39/00;;A61P43/00;;A61P5/16;;C08G73/0206;;A61K31/785;;C08G73/02,A61K31/785;;A61P3/00;;C08G73/02,424/78.35;;525/540;;528/422,0,0,,,,DISCONTINUED
57,EP,A2,EP 1945196 A2,197-408-306-450-156,2008-07-23,2008,EP 06837106 A,2006-11-07,US 2006/0043402 W;;US 73459305 P,2005-11-08,MAGNESIUM-CONTAINING POLYMERS FOR HYPERPHOSPHATEMIA,,GENZYME CORP,HUVAL CHAD C;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/197-408-306-450-156,Patent Application,yes,0,0,10,10,0,A61K31/132;;A61K31/785;;A61K33/06;;A61P13/12;;A61P19/02;;A61P19/08;;A61P3/00;;A61P5/18;;A61P7/00;;A61P7/08;;A61P9/00;;A61K31/785;;A61K33/06;;A61K31/132,A61K31/132;;A61K33/06,,0,0,,,,DISCONTINUED
58,US,A1,US 2013/0266533 A1,041-201-736-105-859,2013-10-10,2013,US 201313751822 A,2013-01-28,US 201313751822 A;;US 2008/0002900 W;;US 44997408 A;;US 90559507 P,2007-03-08,SULFONE POLYMER COMPOSITIONS,"Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi-amine-monomer and a multifunctional sulfonyl-containing monomer comprising two or more amine-reactive groups.",GENZYME CORP,DHAL PRADEEP;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD;;POLOMOSCANIK STEVEN C,GENZYME CORPORATION (2009-10-28),https://lens.org/041-201-736-105-859,Patent Application,yes,3,9,5,5,0,C08G65/24;;C08G73/0253;;A61P13/12;;A61P3/00;;A61P3/12;;C08G73/0253;;C08G65/24;;C08G75/20,C08G75/20,424/78.17;;424/78.37;;424/78.36,3,3,034-091-939-029-106;;033-717-217-841-544;;038-001-005-847-192,10.1021/ma000438j;;10.3998/ark.5550190.0006.e03;;10.1016/j.progpolymsci.2003.12.002,"Yan et al., ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers"", Macromolecules, 2000, 33, 7693-7699.;;Mohapatra et al., ""Efficient and Selective cleavage of the tert-butooycarbonyl (Boc) group under basic condition"", ARKIVOC 2005, 20-28.;;Yan[b], ""Hyperbranched polymers: from synthesis to applications"", Prog. Polym. Sci. 2004, 29, 183-275.",DISCONTINUED
59,US,A1,US 2014/0219951 A1,131-054-708-285-210,2014-08-07,2014,US 201414248523 A,2014-04-09,US 201414248523 A;;US 45106010 A;;US 2008/0005308 W;;US 92404307 P,2007-04-27,AMIDO-AMINE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.",GENZYME CORP,DHAL PRADEEP;;HOLMES-FARLEY S RANDALL;;HUVAL CHAD;;POLOMOSCANIK STEVEN C,,https://lens.org/131-054-708-285-210,Patent Application,yes,1,0,5,5,0,A61K31/131;;A61K31/74;;A61K31/785;;A61P13/12;;A61P3/12;;A61P3/14;;A61P5/18;;A61P7/08;;A61K31/131;;A61K31/74;;A61K31/785,A61K31/785,424/78.37,0,0,,,,DISCONTINUED
60,EP,A1,EP 1578816 A1,099-964-441-092-974,2005-09-28,2005,EP 03768974 A,2003-11-19,US 0336861 W;;US 42751802 P,2002-11-19,POLYMERIC BORONIC ACID DERIVATIVES AS LIPASE INHIBITORS,,GENZYME CORP,HUVAL CHAD CORI;;LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/099-964-441-092-974,Patent Application,yes,0,0,5,5,0,A61K31/69;;A61K45/06;;C08F30/06;;C08F220/56;;C08F220/60;;C08F226/10;;C08F230/06;;C08F265/00;;C08F289/00;;C08F290/06;;C08F290/14;;C08F291/00;;C08F293/005;;C08F297/00;;C08F297/02;;C08F2438/02;;C08F230/06;;A61K45/06;;A61K31/69;;C08F265/00;;C08F291/00;;C08F297/00;;C08F290/14;;C08F290/06;;C08F289/00;;C08F293/005;;C08F220/56;;C08F2438/02;;C08F226/10;;C08F297/02;;C08F30/06;;C08F220/60,A61K31/69;;A61K45/06;;C08F30/06,,0,0,,,,DISCONTINUED
61,AU,A1,AU 2003/291567 A1,147-337-539-993-785,2004-06-15,2004,AU 2003/291567 A,2003-11-19,US 42751802 P;;US 0336861 W,2002-11-19,POLYMERIC BORONIC ACID DERIVATIVES AS LIPASE INHIBITORS,,GENZYME CORP,HUVAL CHAD CORI;;LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/147-337-539-993-785,Patent Application,no,0,0,5,5,0,A61K31/69;;A61K45/06;;C08F30/06;;C08F220/56;;C08F220/60;;C08F226/10;;C08F230/06;;C08F265/00;;C08F289/00;;C08F290/06;;C08F290/14;;C08F291/00;;C08F293/005;;C08F297/00;;C08F297/02;;C08F2438/02;;C08F230/06;;A61K45/06;;A61K31/69;;C08F265/00;;C08F291/00;;C08F297/00;;C08F290/14;;C08F290/06;;C08F289/00;;C08F293/005;;C08F220/56;;C08F2438/02;;C08F226/10;;C08F297/02;;C08F30/06;;C08F220/60,A61K31/69;;A61K45/06;;C08F30/06,,0,0,,,,DISCONTINUED
62,US,A1,US 2006/0134062 A1,025-742-780-186-90X,2006-06-22,2006,US 53563905 A,2005-12-21,US 53563905 A;;US 42751802 P;;US 0336861 W,2002-11-19,Polymeric boronic acid derivatives as lipase inhibitors,"Human obesity is a health problem affecting a significant proportion of the American population. Numerous methods of treating obesity have been developed, but all have serious drawbacks. The present invention discloses a novel class of polymers with either a sulfur atom or an electron withdrawing group between a polymer backbone and a pendant aryl boronic acid group. Polymers having such an electron withdrawing group have been found to be particularly effective in inhibiting lipase in vitro and in vivo. Methods of treating obesity and reducing absorption of fat are also disclosed.",HUVAL CHAD C;;LI XINHUA;;HOLMES-FARLEY STEPHEN R;;DHAL PRADEEP K,HUVAL CHAD C;;LI XINHUA;;HOLMES-FARLEY STEPHEN R;;DHAL PRADEEP K,GENZYME CORPORATION (2005-06-20),https://lens.org/025-742-780-186-90X,Patent Application,yes,10,23,5,5,0,A61K31/69;;A61K45/06;;C08F30/06;;C08F220/56;;C08F220/60;;C08F226/10;;C08F230/06;;C08F265/00;;C08F289/00;;C08F290/06;;C08F290/14;;C08F291/00;;C08F293/005;;C08F297/00;;C08F297/02;;C08F2438/02;;C08F230/06;;A61K45/06;;A61K31/69;;C08F265/00;;C08F291/00;;C08F297/00;;C08F290/14;;C08F290/06;;C08F289/00;;C08F293/005;;C08F220/56;;C08F2438/02;;C08F226/10;;C08F297/02;;C08F30/06;;C08F220/60,A61K31/69;;A61K31/785;;A61K45/06;;C08F30/06,424/78.27;;424/78.3,0,0,,,,DISCONTINUED
63,WO,A1,WO 2004/046211 A1,035-541-851-358-206,2004-06-03,2004,US 0336861 W,2003-11-19,US 42751802 P,2002-11-19,POLYMERIC BORONIC ACID DERIVATIVES AS LIPASE INHIBITORS,"Human obesity is a health problem affecting a significant proportion of the American population. Numerous methods of treating obesity have been developed, but all have serious drawbacks. The present invention discloses a novel class of polymers with either a sulfur atom or an electron withdrawing group between a polymer backbone and pendant aryl boronic acid group. Polymers having such an electron withdrawing group have been found to be particularly effective in inhibiting lipase in vitro and in vivo. Methods of treating obesity and reducing absorption of fat are also disclosed.",GENZYME CORP;;HUVAL CHAD CORI;;LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,HUVAL CHAD CORI;;LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K,,https://lens.org/035-541-851-358-206,Patent Application,yes,1,8,5,5,0,A61K31/69;;A61K45/06;;C08F30/06;;C08F220/56;;C08F220/60;;C08F226/10;;C08F230/06;;C08F265/00;;C08F289/00;;C08F290/06;;C08F290/14;;C08F291/00;;C08F293/005;;C08F297/00;;C08F297/02;;C08F2438/02;;C08F230/06;;A61K45/06;;A61K31/69;;C08F265/00;;C08F291/00;;C08F297/00;;C08F290/14;;C08F290/06;;C08F289/00;;C08F293/005;;C08F220/56;;C08F2438/02;;C08F226/10;;C08F297/02;;C08F30/06;;C08F220/60,A61K31/69;;A61K45/06;;C08F30/06,,1,0,,,"DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 10 June 1980 (1980-06-10), GARNER C W: ""Boronic acid inhibitors of porcine pancreatic lipase."", XP002273320, Database accession no. NLM7372625",PENDING
64,CA,A1,CA 2546696 A1,159-776-603-835-176,2004-06-03,2004,CA 2546696 A,2003-11-19,US 42751802 P;;US 0336861 W,2002-11-19,POLYMERIC BORONIC ACID DERIVATIVES AS LIPASE INHIBITORS,,GENZYME CORP,LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;HUVAL CHAD CORI,,https://lens.org/159-776-603-835-176,Patent Application,no,0,0,5,5,0,A61K31/69;;A61K45/06;;C08F30/06;;C08F220/56;;C08F220/60;;C08F226/10;;C08F230/06;;C08F265/00;;C08F289/00;;C08F290/06;;C08F290/14;;C08F291/00;;C08F293/005;;C08F297/00;;C08F297/02;;C08F2438/02;;C08F230/06;;A61K45/06;;A61K31/69;;C08F265/00;;C08F291/00;;C08F297/00;;C08F290/14;;C08F290/06;;C08F289/00;;C08F293/005;;C08F220/56;;C08F2438/02;;C08F226/10;;C08F297/02;;C08F30/06;;C08F220/60,C08F20/00;;A61K31/69;;A61K45/06;;C08F30/06,,0,0,,,,DISCONTINUED
65,WO,A3,WO 1999/022721 A3,014-013-877-916-48X,1999-05-14,1999,US US9822605,1998-10-26,"US 08/9/064,536",1997-11-05,UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA,A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.,"GELTEX PHARMACEUTICALS, INC.","HUVAL, Chad, Cori;;HOLMES-FARLEY, Stephen, Randall;;PETERSEN, John, S.;;DHAL, Pradeep, K.",,https://lens.org/014-013-877-916-48X,Search Report,yes,0,0,1,1,0,,A61K31/785,,0,0,,,,UNKNOWN
66,WO,A1,WO 2006/072054 A1,142-619-818-783-805,2006-07-06,2006,US 2005/0047582 W,2005-12-29,US 64064304 P,2004-12-30,ZINC-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA,"A method of treating hyperphosphatemia in a subject comprises the step of administering to the subject an effective amount of a pharmaceutically acceptable zinc salt. A pharmaceutical composition comprises a pharmaceutically acceptable carrier, a pharmaceutically acceptable zinc salt; and a phosphate sequestrant. In one embodiment, the phosphate sequestrant is selected from a pharmaceutically acceptable lanthanum, calcium, magnesium and iron salt. In another embodiment, the phosphate sequestrant is an amine polymer, wherein the molar ratio of a zinc ion of the ion salt to amine nitrogen atoms in the amine polymer is 0.1-3.0. The invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and an agent selected from the group consisting of a phosphate transport inhibitor, and HMG-CoA reductase inhibitor and an alkaline phosphatase inhibitor.",GENZYME CORP;;HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;SYBERTZ EDMUND J,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;SYBERTZ EDMUND J,,https://lens.org/142-619-818-783-805,Patent Application,yes,7,13,4,4,0,A61K31/315;;A61K31/315;;A61K33/30;;A61K33/30;;A61K45/06;;A61K45/06;;A61P3/00;;A61P3/12;;A61P5/18;;A61P7/00;;A61P13/12;;A61P43/00,A61K31/315;;A61P3/12,,1,1,055-558-433-061-414,10.1111/j.1523-1755.2004.09005.x;;15296504,"EMMETT MICHAEL: ""A comparison of clinically useful phosphorus binders for patients with chronic kidney failure"", KIDNEY INTERNATIONAL, vol. 66, no. Suppl. 90, September 2004 (2004-09-01), pages S25 - S32, XP002378636, ISSN: 0085-2538",PENDING
67,CA,A1,CA 2309027 A1,054-515-306-464-628,1999-05-14,1999,CA 2309027 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,METHOD FOR TREATING HYPERCHOLESTEROLEMIA WITH UNSUBSTITUTED POLYDIALLYLAMINE,A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.,GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;DHAL PRADEEP K;;PETERSEN JOHN S,,https://lens.org/054-515-306-464-628,Patent Application,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
68,CA,C,CA 2309027 C,060-534-444-482-50X,2007-10-02,2007,CA 2309027 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,METHOD FOR TREATING HYPERCHOLESTEROLEMIA WITH UNSUBSTITUTED POLYDIALLYLAMINE,A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.,GELTEX PHARMA INC,PETERSEN JOHN S;;DHAL PRADEEP K;;HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/060-534-444-482-50X,Granted Patent,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/787;;A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
69,WO,A1,WO 2000/069445 A1,091-892-634-398-186,2000-11-23,2000,US 9910568 W,1999-05-13,US 9910568 W,1999-05-13,COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA,"The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/091-892-634-398-186,Patent Application,yes,2,5,3,3,0,A61K45/06;;A61K31/785;;A61P9/10,A61K31/785;;A61K45/06;;A61P9/10,,0,0,,,,PENDING
70,AU,A,AU 1999/013646 A,187-630-596-298-731,1999-05-24,1999,AU 1999/013646 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,Method for treating hypercholesterolemia with unsubstituted polydiallylamine,,GENZYME CORP,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GENZYME CORPORATION (2003-07-10),https://lens.org/187-630-596-298-731,Patent Application,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
71,TW,B,TW 453878 B,028-827-352-732-750,2001-09-11,2001,TW 87118239 A,1998-11-03,US 96453697 A,1997-11-05,Pharmaceutical composition for removing bile salts,"A pharmaceutical composition for removing bile salts comprising a therapeutically effective amount of a polydiallylamine polymer, wherein said polymer is substantially free of alkylated amine monomers.",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/028-827-352-732-750,Granted Patent,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
72,US,S,US D0970668 S,042-855-883-465-300,2022-11-22,2022,US 202029758034 F,2020-11-11,US 202029758034 F,2020-11-11,Golf club head,,TAYLOR MADE GOLF CO,GREENSMITH MATTHEW;;BEACH TODD P;;JOHNSON MATTHEW DAVID;;NUNEZ ROBERT;;FARLEY CHAD ALLEN,,https://lens.org/042-855-883-465-300,Design Right,no,19,0,1,3,0,,,2102;;D21/759,4,0,,,"“Nike SasQuatch Tour Driver Review,” TheSandTrap.com, retrieved from https://thesandtrap.com/b/clubs/nike_sasquatch_tour_driver_review (6 pages).;;“Cobra BiO Cell and BiO Cell+,” EighteenUnderPar.com, retrieved from http://www.eighteenunderpar.com/blog/2013/11/13/cobra-bio-cell/ (3 pages).;;“Nike SQ Sumo 4950 Driver 2007,” Golf Online, retrieved from https://www.golfonline.co.uk/nike-sq-sumo-4950-driver-2007-p-2209.html (2 pages).;;“Titleist 907D1 and 907D2 Driver Review,” TheSandTrap.com, retrieved from https://thesandtrap.com/b/clubs/titleist_907d1_and_907d2_driver_review (9 pages).",ACTIVE
73,HU,A2,HU P0004279 A2,107-317-029-050-489,2002-03-28,2002,HU P0004279 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA,"A találmány olyan új ioncserélő gyantákra vonatkozik, amelyek javítottepesavmegkötő tulajdonságokkal rendelkeznek és aszérumkoleszterinszint csökkentésére használhatók. A polimerek vagygyanták, amelyeket a találmányban alkalmaznak, adott esetbentérhálósított poli(diallil-amin)-ok, amelyek nem szívódnak fel,ezáltal csökkentik a mellékhatásokat. A találmány szerintipoli(diallil-amin)-okra jellemző, hogy alkilezett aminmonomerektőllényegében mentesek. Ó",GELTEX PHARMA INC,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;PETERSEN JOHN S,,https://lens.org/107-317-029-050-489,Patent Application,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,PENDING
74,AT,T1,AT E235236 T1,158-482-206-538-370,2003-04-15,2003,AT 98957370 T,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,UNSUBSTITUIERTE POLYDIALLYLAMINEN ZUR BEHANDLUNG VON HYPERCHOLESTEROLEMIA,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/158-482-206-538-370,Granted Patent,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,PENDING
75,NZ,A,NZ 504216 A,064-467-254-452-340,2002-11-26,2002,NZ 50421698 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,Use of unsubstituted polydiallylamines as bile sequestering agents to treat hypercholesterolemia,"Pharmaceutical composition comprising a polydiallylamine polymer or salts thereof, said polymer characterized in that the polymer is substantially free of alkylated amine monomers.",GELTEX PHARMA INC,PETERSEN JOHN S;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI,"GENZYME CORPORATION, US (2003-06-27)",https://lens.org/064-467-254-452-340,Patent Application,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,DISCONTINUED
76,WO,A8,WO 2000/069445 A8,069-005-747-827-820,2001-07-26,2001,US 9910568 W,1999-05-13,US 9910568 W,1999-05-13,COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA,"The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/069-005-747-827-820,Patent Application,no,0,0,3,3,0,A61K45/06;;A61K31/785;;A61P9/10,A61K31/785;;A61K45/06;;A61P9/10,,0,0,,,,PENDING
77,EP,A2,EP 1028717 A2,114-864-295-026-162,2000-08-23,2000,EP 98957370 A,1998-10-26,US 9822605 W;;US 96453697 A,1997-11-05,UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,"*GENZYME CORP.ONE KENDALL SQUARE, CAMBRIDGE, MASSA (2003-03-26);;*GENZYME CORP. (2003-03-26);;GELTEX PHARMACEUTICALS, INC. (2003-01-08);;GENZYME CORPORATION (2003-11-03)",https://lens.org/114-864-295-026-162,Patent Application,yes,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
78,US,B1,US 6248318 B1,173-257-593-941-938,2001-06-19,2001,US 52197500 A,2000-03-09,US 52197500 A;;US 96453697 A,1997-11-05,Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers,A method for treating hypercholesterolemia in a patient that includes administering to the patient a therapeutically effective amount of a polydiallylamine polymer.,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GENZYME CORPORATION (2003-03-27),https://lens.org/173-257-593-941-938,Granted Patent,yes,27,27,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,424/78.35;;514/824,7,5,001-845-021-830-136;;000-111-675-082-916;;014-643-407-527-54X;;104-688-531-120-765;;014-044-113-436-437,10.1002/pol.1967.150050812;;7193034;;10.1016/0021-9150(80)90139-2;;8445955;;10.1002/med.2610130203;;13139319;;10.1111/j.1749-6632.1953.tb36398.x;;10.1002/macp.1967.021070106,"Negi, Youji et al., ""Cyclopolymerization of Diallylamine Derivatives in Dimethyl Sulfoxide,"" Journal of Polymer Science: Part A-I, 5:1951-1965 (1967).;;Kuron, G.W. et al., ""The Bile Acid Binding and Hypocholesterolemic Action of Two Water-Soluble Polymers,"" Atherosclerosis 37:353-360 (1980).;;Hodgkin, J.H. et al., ""Use of 13C-NMR in the Study of Reactions on Crosslinked Resins,"" Journal of Polymer Science 19(5):1239-1249 (1981).;;United States Serial No. 08/777,408, filed on Dec. 30, 1996, ""Poly (diallylamine)-Based Bile Acid Sequestrant"" by Stephen Randall Holmes-Farley, Pradeep K. Dhal and John S. Petersen.;;McCarthy, Peter A., ""New Approaches to Atherosclerosis: An Overview."" Medicinal Research Reviews, 13(2):139-159 (1993).;;Heming, Arthur E. and Thomas L. Flanagan, ""Considerations in the Selection of Cation Exchange resins for therapeutic use."" In Annals of the New York Academy of Sciences, 57:239-251 (1954).;;Harada, Susumu and Kunio Arai, ""The Cyclo-copolymerization of Diallyl Compounds and Sulfur Dioxide, II. Diallyldimethylammmonium Chloride and Sulfur Dioxide,"" Die Makromolekulare Chemie 107:64-77 (1967).",EXPIRED
79,US,B2,US 7638524 B2,145-264-433-841-014,2009-12-29,2009,US 2518401 A,2001-12-19,US 2518401 A;;US 31110399 A;;US 96453697 A,1997-11-05,Combination therapy for treating hypercholesterolemia,"The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.",GENZYME CORP,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GENZYME CORPORATION (2003-03-27),https://lens.org/145-264-433-841-014,Granted Patent,yes,93,9,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K9/14;;A01N43/40;;A01N43/64;;A61K9/00;;A61K31/41;;A61K31/435;;A61K31/785;;A61K31/795;;A61P3/06;;A61P7/02;;A61P9/10,514/277;;424/78.35;;424/78.14;;424/78.15;;424/400;;424/486;;514/359,38,24,014-643-407-527-54X;;104-688-531-120-765;;014-044-113-436-437;;001-845-021-830-136;;000-111-675-082-916;;003-000-209-760-799;;033-776-751-383-424;;155-318-150-693-959;;015-365-992-859-041;;066-089-402-703-998;;033-387-971-440-380;;063-878-329-583-207;;035-151-124-081-008;;102-493-675-137-571;;053-305-778-549-230;;037-615-967-244-405;;018-036-684-681-458;;078-019-009-387-02X;;006-632-877-272-12X;;095-940-201-265-555;;022-061-219-349-811;;053-094-133-518-878;;040-837-384-229-58X;;093-212-332-912-70X,8445955;;10.1002/med.2610130203;;13139319;;10.1111/j.1749-6632.1953.tb36398.x;;10.1002/macp.1967.021070106;;10.1002/pol.1967.150050812;;7193034;;10.1016/0021-9150(80)90139-2;;10.1021/jm00173a013;;2231596;;10.1016/s0957-4166(00)82337-x;;10.1016/0223-5234(90)90113-h;;971324;;10.1016/0006-291x(76)90751-8;;10.1002/jlcr.2580251116;;10.1016/s0040-4039(01)91076-7;;10.1021/jm00163a010;;2296036;;1656041;;10.1021/jm00114a004;;10.1021/jo00285a017;;10.7164/antibiotics.44.762;;1880066;;10.1016/0031-9422(89)80253-5;;10.1016/s0040-4039(00)74190-6;;10.1021/jm00041a013;;8057282;;10.1016/0021-9673(94)80473-7;;10.1021/jo00099a030;;10.1016/0925-4439(94)90088-4;;7986821;;8764882;;10.1002/ardp.19963290703;;10.1016/0223-5234(94)90029-9;;546421,"McCarthy, P.A., ""New Approaches to Atherosclerosis: An Overview,"" Medicinal Research Reviews, 13(2):139-159 (1993).;;Heming, A.E. and Flanagan, T.L., ""Considerations in the Selection of Cation Exchange Resins for Therapeutic Use,"" In Annals of the New York Academy of Sciences, 57:239-251 (1954).;;Harada, Susumu and Kunio Arai, ""The Cyclo-copolymerization of Diallyl Compounds and Sulfur Dioxide, II. Diallyldimethylammonium Chloride and Sulfur Dioxide,"" Die Makromolekulare Chemie 107:64-77 (1967).;;Negi, Youji et al., ""Cyclopolymerization of Diallylamine Derivatives in Dimethyl Sulfoxide,"" Journal of Polymer Science: Part A-1, 5:1951-1965 (1967).;;Kuron, G.W. et al., ""The Bile Acid Binding and Hypocholesterolemic Action of Two Water-soluable Polymers,"" Atherosclerosis 37:353-360 (1980).;;Hodgkin, J.H. et al., ""Use of 13C-NMR in the Study of Reactions on Crosslinked Resins,"" Journal of Polymer Science 19(5):1239-1249 (1981).;;U.S. Appl. No. 08/777,408, filed Dec. 30, 1996, ""Poly (diallylamine)-Based Bile Acid Sequestrant"" by Stephen Randall Holmes-Farley, Pradeep K. Dhal and John S. Petersen.;;Sit, S.Y., et al., ""Synthesis, Biological Profile, and Quantitative Structure-Activity Relationship of a Series of Novel 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors,"" J. Med. Chem., 33(11), 2982-99 (1990).;;Takano, S., et al., ""Enanticonvergent Synthesis of a Promising HMG Co-A Reductase Inhibitor NK-104 from Both Enantiomers of Epichlorohydrin,"" Tetrahedron:Assymetry, 4(2), 201-4 (1993).;;Sood, A., et al., ""Boron analogues of amino acids VI. Synthesis and characterization of di- and tripeptide analogues as antineoplastic, anti-flammatory and hypolipidemic agents,"" Eur. J. Med. Chem., 25(4), 301-8 (1990).;;Raulston, D.L., et al., ""Inhibition of Hepatic Sterol Synthesis and Reduction of Serum Cholesterol in Rats by 5alpha-Cholest-8(14)-En-3beta-O1-15-One,"" Biochem. Biophys. Res. Commun., 71(4), 984-9 (1976).;;Wint, L.T. and McCarthy,P.A., ""Synthesis of Tritium Labelled (3R*,5S*) -3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate,"" J. Labelled Compd. Radiopharm., 25(11), 1289-97 (1988).;;Falck, J.R. and Yang, Y-L., ""Total Synthesis of (+)-Dihydromevinolin,"" Tetrahedron Lett., 25(33), 3563-66 (1984).;;Beck, G., et al., ""Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 1.Lactones of Pyridine- and Pyrimidine- Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids,"" J. Med. Chem., 33(1), 52-60 (1990).;;Jendralla, H., et al., ""Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 3.1:2 Lactones of 6-Phenoxy-3,5-dihydroxyhexanoic Acids,"" J. Med. Chem., 34(10) 2962-83 (1991).;;Chiang, Y-C.P., et al., ""Total Synthesis of L-659,699, a Novel Inhibitor of Cholesterol Biosynthesis,"" J. Org. Chem., 54(24), 5708-12 (1989).;;Ogawa, H., et al., ""Pannorin, A New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Produced by Chrysosporium pannorum,"" J. Antibiot., 44(7), 762-7 (1991).;;Carte, B.K., et al., ""Rawsonol, An Inhibitor of HMG-CoA Reductase from the Tropical Green Alga Avrainvillea rawsoni,"" Phytochemistry, 28(11), 2917-19 (1989).;;Baumann, K.L., et al., ""The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase,"" Tetrahedron Lett., 33(17), 2283-4 (1992).;;Larsen, S.D., et al., ""Design and Synthesis of Seco-oxysterol Analogs as Potential Inhibitors of 3-Hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Reductase Gene Transcription,"" J. Med. Chem., 37(15), 2343-51 (1994).;;Kumar, N., et al., ""Separation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor drug substance diastereomers, and their analogues on beta-cyclodextrin stationary phase,"" J. Chromatrogr. A, 678(2), 259-63 (1994).;;Stokker, G.E., ""Synthesis of L-669,262, a Potent HMG-CoA Reductase Inhibitor,"" J. Org. Chem., 59(20), 5983-6 (1994).;;Kramer, W., et al., ""Bile Acid Derived HMG-CoA Reductase Inhibitors,"" Biochimica et Biophysica Acta, 1227(3), 137-54 (1994).;;Huang, Y. and Hall, I.H., ""Hypolipidemic Effects of alpha, beta, and gamma- Alkylaminophenone Analogs in Rodents,"" Eur. J. Med. Chem., 31(4), 281-90 (1996).;;Huang, Y. and Hall, I.H.,""Hypolipidemic Activity of 3-Amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl)propan-1-ones in Rodents,"" Arch. Pharm., Pharm. Med. Chem. 329(7), 339-346 (1996).;;Watanabe, S., et al., ""Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses,"" Eur. J. Med. Chem., 29(9), 675-86 (1994).;;Hermecz, I., et al., ""Synthesis of anti-atherosclerotic pyrido[1,2-a]pyrimidines,"" Arzneim-Forsch, 29(12), 1833-5 (1979).;;Ko, S.S., et al., ""Synthesis and HMG-CoA Reductase Suppression and LDL Receptor Induction Activities of DMP 565 and Related 15-Oxasterols,"" Abstr. #10 Papers Am. Chem. Soc. (207th National Meeting, Part 1, MEDI 10, 1994).;;Abstract for Accession No. 90-233170/199031 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 91-088314/199113 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 81-93634D/198151 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 71-08176S/197104 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 73-15504U/197311 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 73-21400U/197316 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 81-46770D/198126 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 96-205496/199621 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 95-167208/199522 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 3-109407/199125 from World Patent Index Database compiled by Derwent Information Limited.",EXPIRED
80,US,S,US D0987753 S,000-707-828-297-510,2023-05-30,2023,US 202129776617 F,2021-03-31,US 202129776617 F;;US 202029758034 F;;US 202029755891 F,2020-10-23,Golf club head,,TAYLOR MADE GOLF CO,GREENSMITH MATTHEW;;BEACH TODD P;;JOHNSON MATTHEW DAVID;;NUNEZ ROBERT;;FARLEY CHAD ALLEN,TAYLOR MADE GOLF COMPANY INC (2021-04-14),https://lens.org/000-707-828-297-510,Design Right,no,15,0,1,3,0,,,2102;;D21/752,7,0,,,"Golf wood google search; google.com; Jan. 6, 2023.;;Golf fairway wood google search; google.com; Jan. 6, 2023.;;Taylormadegolf.com; Jan. 6, 2023.;;“Nike SasQuatch Tour Driver Review,” TheSandTrap.com, retrieved from https://thesandtrap.com/b/clubs/nike_sasquatch_tour_driver_review (6 pages).;;“Cobra BiO Cell and BiO Cell+,” EighteenUnderPar.com, retrieved from http://www.eighteenunderpar.com/blog/2013/11/13/cobra-bio-cell/ (3 pages).;;“Nike SQ Sumo 4950 Driver 2007,” Golf Online, retrieved from https://www.golfonline.co.uk/nike-sq-sumo-4950-driver-2007-p-2209.html (2 pages)/.;;“Titleist 907D1 and 907D2 Driver Review,” TheSandTrap.com, retrieved from https://thesandtrap.com/b/clubs/titleist_907d1_and_907d2_driver_review (9 pages).",ACTIVE
81,BR,A,BR 9813961 A,010-742-610-006-318,2000-09-26,2000,BR 9813961 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,"Metodo para remover sais biliares de um paciente, polimero de polidialilamina e seus sais, e seu uso.","""MéTODO PARA REMOVER SAIS BILIARES DE UM PACIENTE, POLìMERO DE POLIDIALILAMINA E SEUS SAIS E SEU USO. "" Método para remover sais biliares de um paciente, que inclui administrar ao paciente uma quantidade terapeuticamente eficaz de polímeros de polidialilamina não absorvível.",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/010-742-610-006-318,Patent Application,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,DISCONTINUED
82,AU,A,AU 1999/039880 A,039-004-690-977-373,2000-12-05,2000,AU 1999/039880 A,1999-05-13,US 9910568 W,1999-05-13,Combination therapy for treating hypercholesterolemia,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/039-004-690-977-373,Patent Application,no,0,0,3,3,0,A61K45/06;;A61K31/785;;A61P9/10,A61K31/785;;A61K45/06;;A61P9/10,,0,0,,,,DISCONTINUED
83,WO,A1,WO 2000/069446 A1,093-168-833-942-67X,2000-11-23,2000,US 9910637 W,1999-05-13,US 9910637 W,1999-05-13,COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA,"The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/093-168-833-942-67X,Patent Application,yes,2,1,2,2,0,A61K45/06;;A61K31/785;;A61P9/10,A61K31/785;;A61K45/06;;A61P9/10,,0,0,,,,PENDING
84,US,A,US 6083497 A,198-905-502-698-515,2000-07-04,2000,US 96453697 A,1997-11-05,US 96453697 A,1997-11-05,Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers,A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GELTEX PHARMACEUTICALS INC (1998-02-03);;GENZYME CORPORATION (2003-03-27),https://lens.org/198-905-502-698-515,Granted Patent,yes,27,48,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,424/78.35;;514/824,7,5,014-643-407-527-54X;;104-688-531-120-765;;014-044-113-436-437;;001-845-021-830-136;;000-111-675-082-916,8445955;;10.1002/med.2610130203;;13139319;;10.1111/j.1749-6632.1953.tb36398.x;;10.1002/macp.1967.021070106;;10.1002/pol.1967.150050812;;7193034;;10.1016/0021-9150(80)90139-2,"McCarthy, Peter A., New Approaches to Atherosclerosis: An Overview. Medicinal Research Reviews , 13(2):139 159 (1993).;;Heming, Arthur E. and Thomas L. Flanagan, Considerations in the Selection of Cation Exchange Resins for Therapeutic Use. In Annals of the New York Academy of Sciences , 57:239 251 (1954).;;Harada, Susumu and Kunio Arai, The Cyclo copolymerization of Diallyl Compounds and Sulfur Dioxide, II. Diallyldimethylammonium Chloride and Sulfur Dioxide, Die Makromolekulare Chemie 107:64 77 (1967).;;Negi, Youji et al., Cyclopolymerization of Diallylamine Derivatives in Dimethyl Sulfoxide, Journal of Polymer Science: Part A 1 , 5:1951 1965 (1967).;;Kuron, G.W. et al., The Bile Acid Binding and Hypocholesterolemic Action of Two Water Soluble Polymers, Atherosclerosis 37:353 360 (1980).;;Hodgkin, J.H. et al., Use of 13 C NMR in the Study of Reactions on Crosslinked Resins, Journal of Polymer Science 19(5):1239 1249 (1981).;;United States Serial No. 08/777,408, filed on Dec. 30, 1996, Poly (diallylamine) Based Bile Acid Sequestrant by Stephen Randall Holmes Farley, Pradeep K. Dhal and John S. Petersen.",EXPIRED
85,AU,A,AU 1999/039903 A,041-683-635-627-177,2000-12-05,2000,AU 1999/039903 A,1999-05-13,US 9910637 W,1999-05-13,Combination therapy for treating hypercholesterolemia,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/041-683-635-627-177,Patent Application,no,0,0,2,2,0,A61K45/06;;A61K31/785;;A61P9/10,A61K31/785;;A61K45/06;;A61P9/10,,0,0,,,,DISCONTINUED
86,EP,A1,EP 2131820 A1,148-642-966-381-158,2009-12-16,2009,EP 08726435 A,2008-03-05,US 2008/0002900 W;;US 90559507 P,2007-03-08,SULFONE POLYMER COMPOSITIONS,,GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,,https://lens.org/148-642-966-381-158,Patent Application,yes,0,0,5,5,0,C08G65/24;;C08G73/0253;;A61P13/12;;A61P3/00;;A61P3/12;;C08G73/0253;;C08G65/24;;C08G75/20,A61K9/48,,0,0,,,,DISCONTINUED
87,NO,D0,NO 20002172 D0,161-057-805-421-300,2000-04-27,2000,NO 20002172 A,2000-04-27,US 96453697 A;;US 9822605 W,1997-11-05,FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN R;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/161-057-805-421-300,Patent Application,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,DISCONTINUED
88,WO,A1,WO 2008/103368 A1,034-961-798-342-962,2008-08-28,2008,US 2008/0002210 W,2008-02-20,US 90284807 P,2007-02-23,AMINE POLYMER COMPOSITIONS,"A pharmaceutical composition for treating hyperphosphatemia can include polymers derived from multi-amine monomers and multifunctional monomers, where the multifunctional monomer includes more than one electrophilic group.",GENZYME CORP;;POLOMOSCANIK STEVEN C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;HUVAL CHAD C,POLOMOSCANIK STEVEN C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;HUVAL CHAD C,,https://lens.org/034-961-798-342-962,Patent Application,yes,1,26,4,4,0,A61K31/785;;A61K31/795;;C08G73/0206;;A61P13/12;;A61P7/00;;A61K31/785;;C08G73/0206;;A61K31/795,A61K9/14;;A61K31/785;;A61K31/795,,0,0,,,,PENDING
89,US,A1,US 2002/0155091 A1,057-419-930-516-320,2002-10-24,2002,US 2518401 A,2001-12-19,US 2518401 A;;US 31110399 A;;US 96453697 A,1997-11-05,Combination therapy for treating hypercholesterolemia,"
   The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. 

   The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier. 
",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GENZYME CORPORATION (2003-03-27),https://lens.org/057-419-930-516-320,Patent Application,yes,56,10,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,424/78.29,0,0,,,,EXPIRED
90,AU,B2,AU 746876 B2,158-404-749-259-171,2002-05-02,2002,AU 1999/013646 A,1998-10-26,US 96453697 A;;US 9822605 W,1997-11-05,Method for treating hypercholesterolemia with unsubstituted polydiallylamine,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GENZYME CORPORATION (2003-07-10),https://lens.org/158-404-749-259-171,Granted Patent,no,3,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
91,WO,A3,WO 1999/022721 A3,155-216-231-717-214,1999-08-05,1999,US 9822605 W,1998-10-26,US 96453697 A,1997-11-05,UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA,A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/155-216-231-717-214,Search Report,yes,2,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,PATENTED
92,US,B1,US 6264938 B1,191-893-952-355-499,2001-07-24,2001,US 31140299 A,1999-05-13,US 31140299 A;;US 96453697 A,1997-11-05,Combination therapy for treating hypercholestrolemia,"The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GELTEX PHARMACEUTICALS INC (1999-06-28);;GENZYME CORPORATION (2003-03-27),https://lens.org/191-893-952-355-499,Granted Patent,yes,80,16,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,424/78.35;;514/824,37,24,014-643-407-527-54X;;104-688-531-120-765;;014-044-113-436-437;;001-845-021-830-136;;000-111-675-082-916;;003-000-209-760-799;;033-776-751-383-424;;155-318-150-693-959;;015-365-992-859-041;;066-089-402-703-998;;033-387-971-440-380;;063-878-329-583-207;;035-151-124-081-008;;102-493-675-137-571;;053-305-778-549-230;;037-615-967-244-405;;018-036-684-681-458;;078-019-009-387-02X;;006-632-877-272-12X;;095-940-201-265-555;;022-061-219-349-811;;053-094-133-518-878;;040-837-384-229-58X;;093-212-332-912-70X,8445955;;10.1002/med.2610130203;;13139319;;10.1111/j.1749-6632.1953.tb36398.x;;10.1002/macp.1967.021070106;;10.1002/pol.1967.150050812;;7193034;;10.1016/0021-9150(80)90139-2;;10.1021/jm00173a013;;2231596;;10.1016/s0957-4166(00)82337-x;;10.1016/0223-5234(90)90113-h;;971324;;10.1016/0006-291x(76)90751-8;;10.1002/jlcr.2580251116;;10.1016/s0040-4039(01)91076-7;;10.1021/jm00163a010;;2296036;;1656041;;10.1021/jm00114a004;;10.1021/jo00285a017;;10.7164/antibiotics.44.762;;1880066;;10.1016/0031-9422(89)80253-5;;10.1016/s0040-4039(00)74190-6;;10.1021/jm00041a013;;8057282;;10.1016/0021-9673(94)80473-7;;10.1021/jo00099a030;;10.1016/0925-4439(94)90088-4;;7986821;;8764882;;10.1002/ardp.19963290703;;10.1016/0223-5234(94)90029-9;;546421,"McCarthy, P.A., ""New Approaches to Atherosclerosis: An Overview,"" Medicinal Research Reviews, 13 (2) : 139-159 (1993).;;Heming, A. E. and Flanagan, T. L., ""Considerations in the Selection of Cation Exchange Resins for Therapeutic Use,"" In Annals of the New York Academy of Sciences, 57:239-251 (1954).;;Harada, Susuma and Kunio Arai, ""The Cyclo-copolymerization of Diallyl Compounds and Sulfur Dioxide, II. Diallyldimethylammonium Chloride and Sulfur Dioxide,"" Die Makromolekulare Chemie107 : 64-77 (1967).;;Negi, Youji et al., ""Cyclopolymerization of Diallylamine Derivatives in Dimethyl Sulfoxide,"" Journal of Polymer Science: Part A-1, 5 :1951-1965 (1967).;;Kuron, G.W. et al., ""The Bile Acid Binding and Hypocholesterolemic Action of Two Water-soluble Polymers,"" Atherosclerosis37 : 353-360 (1980).;;Hodgkin, J. H. et al., ""Use of 13C-NMR in the Study of Reactions on Crosslinked Resins,"" Journal of Polymer Science 19 (5) : 1239-1249 (1981).;;United States Serial No. 08/777,408, filed on Dec. 30, 1996, ""Poly (diallylamine) -Based Bile Acid Sequestrant"" by Stephen Randall Holmes-Farley, Pradeep K. Dhal and John S. Petersen.;;Sit, S.Y., et al., ""Synthesis, Biological Profile, and Quantitative Structure-Activity Relationship of a Series of Novel 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors,"" J. Med. Chem., 33(11), 2982-99 (1990).;;Takano, S., et al., ""Enanticonvergent Synthesis of a Promising HMG Co-A Reductase Inhibitor NK-104 from Both Enantiomers of Epichlorohydrin,"" Tetrahedron:Assymetry, 4(2), 201-4 (1993).;;Sood, A., et al., ""Boron analogues of amino acids VI. Synthesis and characterization of di- and tripeptide analogues as antineoplastic, anti-inflammatory and hypolipidemic agents,"" Eur. J. Med. Chem., 25(4), 301-8 (1990).;;Raulston, D.L., et al., ""Inhibition of Hepatic Sterol Synthesis and Reduction of Serum Cholesterol in Rats by 5alpha-Cholest-8(14)-En-3beta-01-15-One,"" Biochem. Biophys. Res. Commun., 71(4), 984-9 (1976).;;Wint, L.T. and McCarthy, P.A., ""Synthesis of Tritium Labelled (3R*, 5S*)-3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate,"" J. Labelled Compd. Radiopharm., 25(11), 1289-97 (1988).;;Falck, J.R. and Yang, Y-L., ""Total Synthesis of (+)-Dihydromevinolin,"" Tetrahedron Lett., 25(33), 3563-66 (1984).;;Beck, G., et al., ""Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 1.Lactones of Pyridine- and Pyrimidine-Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids,"" J. Med. Chem., 33(1), 52-60 (1990).;;Jendralla, H., et al., ""Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 3.1:2 Lactones of 6-Phenoxy-3, 5-dihydroxyhexanoic Acids,"" J. Med. Chem., 34(10) 2962-83 (1991).;;Chiang, Y-C.P., et al., ""Total Synthesis of L-659,699, a Novel Inhibitor of Cholesterol Biosynthesis,"" J. Org. Chem., 54(24), 5708-12 (1989).;;Ogawa, H., et al., ""Pannorin, A New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Produced by Chrysosporium pannorum,"" J. Antibiot., 44(7), 762-7 (1991).;;Carte, B.K., et al., ""Rawsonol, An Inhibitor of HMG-CoA Reductase from the Tropical Green Alga Avrainvillea Rawsoni,"" Phytochemistry, 28(11), 2917-19 (1989).;;Baumann, K.L., et al., ""The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase,"" Tetrahedron Lett., 33(17), 2283-4 (1992).;;Larsen, S.D., et al., ""Design and Synthesis of Seco-oxysterol Analogs as Potential Inhibitors of 3-Hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Reductase Gene Transcription,"" J. Med. Chem., 37(15), 2343-51 (1994).;;Kumar, N., et al., ""Separation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor drug substance diastereomers, and their analogues on beta-cyclodextrin stationary phase,"" J. Chromatrogr. A, 678(2), 259-63 (1994).;;Stokker, G.E., ""Synthesis of L-669,262, a Potent HMG-CoA Reductase Inhibitor,"" J. Org. Chem., 59(20), 5983-6 (1994).;;Kramer, W., et al., ""Bile Acid Derived HMG-CoA Reductase Inhibitors,"" Biochimica et Biophysica Acta, 1227(3), 137-54 (1994).;;Huang, Y. and Hall, I.H., ""Hypolipidemic Effects of alpha, beta, and gamma-Alkylaminophenone Analogs in Rodents,"" Eur. J. Med. Chem., 31(4), 281-90 (1996).;;Huang, Y. and Hall, I.H., ""Hypolipidemic Activity of 3-Amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl) propan-1-ones in Rodents,"" Arch. Pharm., Pharm. Med. Chem., 329(7), 339-346 (1996).;;Watanabe, S., et al., ""Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyoxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses,"" Eur. J. Med. Chem., 29(9), 675-86 (1994).;;Hermecz, I., et al., ""Synthesis of anti-atherosclerotic pyrido[1,2-a]pyrimidines,"" Arzneim-Forsch, 29(12), 1833-5 (1979).;;Ko, S.S., et al., ""Synthesis and HMG-CoA Reductase Suppression and LDL Receptor Induction Activities of DMP 565 and Related 15-Oxasterols,"" Abstr. #10 Papers Am. Chem. Soc. (207th National Meeting, Part 1, MEDI 10, 1994).;;Abstract for Accession No. 90-233170/199031 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 91-088314/199113 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 81-93634D/198151 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 71-08176S/197104 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 73-15504U/197311 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 73-21400U/197316 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 81-46770D/198126 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 96-205496/199621 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 95-167208/199522 from World Patent Index Database compiled by Derwent Information Limited.",EXPIRED
93,WO,A1,WO 2008/133954 A1,199-728-240-457-747,2008-11-06,2008,US 2008/0005308 W,2008-04-25,US 92404307 P,2007-04-27,AMIDO-AMINE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.",GENZYME CORP;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,,https://lens.org/199-728-240-457-747,Patent Application,yes,1,4,5,5,0,A61K31/131;;A61K31/74;;A61K31/785;;A61P13/12;;A61P3/12;;A61P3/14;;A61P5/18;;A61P7/08;;A61K31/131;;A61K31/74;;A61K31/785,A61K31/74,,0,0,,,,PENDING
94,EP,A1,EP 2114376 A1,044-279-361-734-93X,2009-11-11,2009,EP 08725806 A,2008-02-20,US 2008/0002210 W;;US 90284807 P,2007-02-23,AMINE POLYMER COMPOSITIONS,,GENZYME CORP,POLOMOSCANIK STEVEN C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;HUVAL CHAD C,,https://lens.org/044-279-361-734-93X,Patent Application,yes,0,0,4,4,0,A61K31/785;;A61K31/795;;C08G73/0206;;A61P13/12;;A61P7/00;;A61K31/785;;C08G73/0206;;A61K31/795,A61K9/14;;A61K31/785;;A61K31/795,,0,0,,,,DISCONTINUED
95,ZA,B,ZA 989673 B,088-499-098-633-787,1999-05-11,1999,ZA 989673 A,1998-10-23,US 96453697 A,1997-11-05,Method for treating hypercholesterolemia with unsubstituted polydiallylamine,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/088-499-098-633-787,Granted Patent,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
96,US,A1,US 2008/0014288 A1,125-960-234-306-135,2008-01-17,2008,US 82029707 A,2007-06-19,US 82029707 A;;US 2005/0047582 W;;US 64064304 P,2004-12-30,Zinc-containing treatments for hyperphosphatemia,"A method of treating hyperphosphatemia in a subject comprises the step of administering to the subject an effective amount of a pharmaceutically acceptable zinc salt. A pharmaceutical composition comprises a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and a phosphate sequestrant. In one embodiment, the phosphate sequestrant is selected from a pharmaceutically acceptable lanthanum, calcium, magnesium and iron salt. In another embodiment, the phosphate sequestrant is an amine polymer, wherein the molar ratio of a zinc ion of the zinc salt to amine nitrogen atoms in the amine polymer is 0.1-3.0. The invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and an agent selected from the group consisting of a phosphate transport inhibitor, an HMG-CoA reductase inhibitor and an alkaline phosphatase inhibitor.",HUVAL CHAD C;;HOLMES-FARLEY STEPHEN R;;DHAL PRADEEP K;;SYBERTZ EDMUND J,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN R;;DHAL PRADEEP K;;SYBERTZ EDMUND J,GENZYME CORPORATION (2007-08-30),https://lens.org/125-960-234-306-135,Patent Application,yes,64,7,4,4,0,A61K31/315;;A61K31/315;;A61K33/30;;A61K33/30;;A61K45/06;;A61K45/06;;A61P3/00;;A61P3/12;;A61P5/18;;A61P7/00;;A61P13/12;;A61P43/00,A61K33/30;;A61K31/315;;A61P7/00,424/641;;514/494,0,0,,,,DISCONTINUED
97,US,A1,US 2010/0196305 A1,149-111-124-925-730,2010-08-05,2010,US 44997408 A,2008-03-05,US 44997408 A;;US 90559507 P;;US 2008/0002900 W,2007-03-08,SULFONE POLYMER COMPOSITIONS,"Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi-amine monomer and a multifunctional sulfonyl-containing monomer comprising two or more amine-reactive groups.",DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,GENZYME CORPORATION (2009-10-28),https://lens.org/149-111-124-925-730,Patent Application,yes,101,0,5,5,0,C08G65/24;;C08G73/0253;;A61P13/12;;A61P3/00;;A61P3/12;;C08G73/0253;;C08G65/24;;C08G75/20,A61K31/795;;A61P3/00,424/78.08,2,2,034-091-939-029-106;;038-001-005-847-192,10.1021/ma000438j;;10.1016/j.progpolymsci.2003.12.002,"Yan, Deyue and Gao, Chao. ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)piperazine to Divinyl Sulfone"", Macromolecules, 33, 7693-7699. 2000.;;Yan[b]. Gao, C. and Yan, D. ""Hyperbranched polymers: from synthesis to applications"", Prog. Polym. Sci. 29, 183-275. 2004.",DISCONTINUED
98,US,A1,US 2010/0266526 A1,182-555-202-510-893,2010-10-21,2010,US 59051109 A,2009-11-09,US 59051109 A;;US 2518401 A;;US 31110399 A;;US 96453697 A,1997-11-05,Combination therapy for treating hypercholesterolemia,"The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.",GENZYME CORP,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GELTEX PHARMACEUTICALS INC (1999-06-28);;GENZYME CORPORATION (2003-04-01),https://lens.org/182-555-202-510-893,Patent Application,yes,8,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61K31/787;;A61P3/06;;A61P7/02;;A61P9/10,424/78.18;;424/78.35;;424/78.32,0,0,,,,DISCONTINUED
99,US,B1,US 6365186 B1,022-483-422-666-185,2002-04-02,2002,US 31110399 A,1999-05-13,US 31110399 A;;US 96453697 A,1997-11-05,Combination therapy for treating hypercholesterolemia,"
    The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. 

    The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier. 
",GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,GELTEX PHARMACEUTICALS INC (1999-06-28);;GENZYME CORPORATION (2003-03-27),https://lens.org/022-483-422-666-185,Granted Patent,yes,81,17,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,424/486;;514/824,36,23,014-643-407-527-54X;;104-688-531-120-765;;014-044-113-436-437;;001-845-021-830-136;;000-111-675-082-916;;033-776-751-383-424;;155-318-150-693-959;;015-365-992-859-041;;066-089-402-703-998;;033-387-971-440-380;;063-878-329-583-207;;035-151-124-081-008;;102-493-675-137-571;;053-305-778-549-230;;037-615-967-244-405;;018-036-684-681-458;;078-019-009-387-02X;;006-632-877-272-12X;;095-940-201-265-555;;022-061-219-349-811;;053-094-133-518-878;;040-837-384-229-58X;;093-212-332-912-70X,8445955;;10.1002/med.2610130203;;13139319;;10.1111/j.1749-6632.1953.tb36398.x;;10.1002/macp.1967.021070106;;10.1002/pol.1967.150050812;;7193034;;10.1016/0021-9150(80)90139-2;;10.1016/s0957-4166(00)82337-x;;10.1016/0223-5234(90)90113-h;;971324;;10.1016/0006-291x(76)90751-8;;10.1002/jlcr.2580251116;;10.1016/s0040-4039(01)91076-7;;10.1021/jm00163a010;;2296036;;1656041;;10.1021/jm00114a004;;10.1021/jo00285a017;;10.7164/antibiotics.44.762;;1880066;;10.1016/0031-9422(89)80253-5;;10.1016/s0040-4039(00)74190-6;;10.1021/jm00041a013;;8057282;;10.1016/0021-9673(94)80473-7;;10.1021/jo00099a030;;10.1016/0925-4439(94)90088-4;;7986821;;8764882;;10.1002/ardp.19963290703;;10.1016/0223-5234(94)90029-9;;546421,"McCarthy, P.A., ""New Approaches to Atherosclerosis: An Overview,"" Medicinal Research Reviews, 13(2):139-159 (1993).;;Heming, A.E. and Flanagan, T.L., ""Considerations in the Selection of Cation Exchange Resins for Therapeutic Use,"" In Annals of the New York Academy of Sciences, 57:239-251 (1954).;;Harada, Susumu and Kunio Arai, ""The Cyclo-copolymerization of Diallyl Compounds and Sulfur Dioxide, II. Diallyldimethylammonium Chloride and Sulfur Dioxide,"" Die Makromolekulare Chemie 107:64-77 (1967).;;Negi, Youji et al., ""Cyclopolymerization of Diallylamine Derivatives in Dimethyl Sulfoxide,"" Journal of Polymer Science: Part A-1, 5:1951-1965 (1967).;;Kuron, G.W. et al., ""The Bile Acid Binding and Hypocholesterolemic Action of Two Water-soluble Polymers,"" Atherosclerosis 37:353-360 (1980).;;Hodgkin, J.H. et al., ""Use of 13C-NMR in the Study of Reactions on Crosslinked Resins,"" Journal of Polymer Science 19(5):1239-1249 (1981).;;United States Serial No. 08/777,408, filed on Dec. 30, 1996, ""Poly(diallylamine)-Based Bile Acid Sequestrant"" by Stephen Randall Holmes-Farley, Pradeep K. Dhal and John S. Petersen.;;Takano, S., et al., ""Enantioconvergent Synthesis of a Promising HMG Co-A Reductase Inhibitor NK-104 from Both Enantiomers of Epichlorohydrin,"" Tetrahedron:Assymetry, 4(2), 201-4 (1993).;;Sood, A., et al., ""Boron analogues of amino acids VI. Synthesis and characterization of di- and tripeptide analgoues as antineoplastic, anti-inflammatory and hypolipidemic agents,"" Eur. J. Med. Chem., 25(4), 301-8 (1990).;;Raulston, D.L., et al., ""Inhibition of Hepatic Sterol Synthesis and Reduction of Serum Cholesterol in Rats by 5alpha-Cholest-8(14)-En-3beta-Ol-15-One,"" Biochem. Biophys. Res. Commun., 71(4), 984-9 (1976).;;Wint, L.T. and McCarthy, P.A., ""Synthesis of Tritium Labelled (3R*,5S*)-3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate,"" J. Labelled Compd. Radiopharm., 25(11), 1289-97 (1988).;;Falck, J.R. and Yang, Y-L., ""Total Synthesis of (+)-Dihydromevinolin,"" Tetrahedron Lett., 25(33), 3563-66 (1984).;;Beck, G., et al., ""Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 1.Lactones of Pyridine- and Pyrimidine-Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids,"" J. Med. Chem., 33(1), 52-60 (1990).;;Jendralla, H., et al., ""Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 3.1:2 Lactones of 6-Phenoxy-3,5-dihydroxyhexanoic Acids,"" J. Med. Chem., 34(10) 2962-83 (1991).;;Chiang, Y-C.P., et al., ""Total Synthesis of L-659,699, a Novel Inhibitor of Cholesterol Biosynthesis,"" J. Org. Chem., 54(24), 5708-12 (1989).;;Ogawa, H., et al., ""Pannorin, A New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Produced by Chrysosporium pannorum,"" J. Antibiot., 44(7), 762-7 (1991).;;Carte, B.K., et al., ""Rawsonol, An Inhibitor of HMG-CoA Reductase from the Tropical Green Alga Avrainvillea Rawsoni,"" Phytochemistry, 28(11), 2917-19 (1989).;;Baumann, K.L., et al., ""The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue selective Inhibitor of HMG-CoA Reductase,"" Tetrahedron Lett., 33(17), 2283-4 (1992).;;Larsen, S.D., et al., ""Design and Synthesis of Seco-oxysterol Analogs as Potential Inhibitors of 3-Hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) Reductase Gene Transcription,"" J. Med. Chem., 37(15), 2343-51 (1994).;;Kumar, N., et al., ""Separation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor drug substance diastereomers, and their analogues on beta-cyclodextrin stationary phase,"" J. Chromatrogr. A, 678(2): 259-63 (1994).;;Stokker, G.E., ""Synthesis of L-669,262, a Potent HMG-CoA Reductase Inhibitor,"" J. Org. Chem., 59(20), 5983-6 (1994).;;Kramer, W., et al., ""Bile Acid Derived HMG-CoA Reductase Inhibitors,"" Biochimica et Biophysica Acta, 1227(3), 137-54 (1994).;;Huang, Y. and Hall, I.H., ""Hypolipidemic Effects of alpha, beta, and gamma-Alkylaminophenone Analogs in Rodents,"" Eur. J. Med. Chem., 31(4), 281-90 (1996).;;Huang, Y. and Hall, I.H., ""Hypolipidemic Activity of 3-Amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl)propan-1-ones in Rodents,"" Arch. Pharm., Pharm. Med. Chem. 329(7), 339-346 (1996).;;Watanabe, S., et al., ""Synthesis of 4-[1-(substituted phenyl)-2-oxopyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses,"" Eur. J. Med. Chem.,29(9), 675-86 (1994).;;Hermecz, I., et al., ""Synthesis of anti-atherosclerotic pyrido[1,2-a]pyrimidines,"" Arzneim-Forsch, 29(12), 1833-5 (1979).;;Ko, S.S., et al., ""Synthesis and HMG-CoA Reductase Suppresison and LDL Receptor Induction Activities of DMP 565 and Related 15-Oxasterols,"" Abstr. #10 Papers Am. Chem. Soc. (207th National Meeting, Part 1, MEDI 10, 1994).;;Abstract for Accession No. 90-233170/199031 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 91-088314/199113 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 81-93634D/198151 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 71-08176S/197104 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 73-15504U/197311 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 73-21400U/197316 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 81-46770D/198126 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 96-205496/199621 from World Patent Index Database compiled by Derwent Information Limited.;;Abstract for Accession No. 95-167208/199522 from World Patent Index Database compiled by Derwent Information Limited.",EXPIRED
100,EP,A1,EP 2152277 A1,095-907-164-632-728,2010-02-17,2010,EP 08743263 A,2008-04-25,US 2008/0005308 W;;US 92404307 P,2007-04-27,AMIDO-AMINE DENDRIMER COMPOSITIONS,,GENZYME CORP,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,,https://lens.org/095-907-164-632-728,Patent Application,yes,0,0,5,5,0,A61K31/131;;A61K31/74;;A61K31/785;;A61P13/12;;A61P3/12;;A61P3/14;;A61P5/18;;A61P7/08;;A61K31/131;;A61K31/74;;A61K31/785,A61K31/74,,0,0,,,,DISCONTINUED
101,NO,L,NO 20002172 L,092-969-689-930-220,2000-07-04,2000,NO 20002172 A,2000-04-27,US 96453697 A;;US 9822605 W,1997-11-05,FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin,Fremgangsmåte for å fjerne gallesalter fra en pasient som innbefatter administrering av en terapeutisk effektiv mengde av en ikke-absorberbar polydiallylaminpolymer til pasienten.,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/092-969-689-930-220,Abstract,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,DISCONTINUED
102,EP,B1,EP 1028717 B1,006-281-324-948-730,2003-03-26,2003,EP 98957370 A,1998-10-26,US 9822605 W;;US 96453697 A,1997-11-05,UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA,,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,"*GENZYME CORP.ONE KENDALL SQUARE, CAMBRIDGE, MASSA (2003-03-26);;*GENZYME CORP. (2003-03-26);;GELTEX PHARMACEUTICALS, INC. (2003-01-08);;GENZYME CORPORATION (2003-11-03)",https://lens.org/006-281-324-948-730,Granted Patent,yes,2,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
103,EP,A1,EP 1830832 A1,171-864-760-183-612,2007-09-12,2007,EP 05856055 A,2005-12-29,US 2005/0047582 W;;US 64064304 P,2004-12-30,ZINC-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA,,GENZYME CORP,HUVAL CHAD C;;HOLMES-FARLEY STEPHEN RANDALL;;DHAL PRADEEP K;;SYBERTZ EDMUND J,,https://lens.org/171-864-760-183-612,Patent Application,yes,0,1,4,4,0,A61K31/315;;A61K31/315;;A61K33/30;;A61K33/30;;A61K45/06;;A61K45/06;;A61P3/00;;A61P3/12;;A61P5/18;;A61P7/00;;A61P13/12;;A61P43/00,A61K31/315;;A61P3/12,,1,0,,,See references of WO 2006072054A1,DISCONTINUED
104,WO,A2,WO 1999/022721 A2,115-031-050-327-389,1999-05-14,1999,US 9822605 W,1998-10-26,US 96453697 A,1997-11-05,METHOD FOR TREATING HYPERCHOLESTEROLEMIA WITH UNSUBSTITUTED POLYDIALLYLAMINE,A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.,GELTEX PHARMA INC,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/115-031-050-327-389,Patent Application,no,0,15,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,PATENTED
105,WO,A1,WO 2008/109095 A1,161-075-488-935-728,2008-09-12,2008,US 2008/0002900 W,2008-03-05,US 90559507 P,2007-03-08,SULFONE POLYMER COMPOSITIONS,"Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi- amine monomer and a multifunctional sulfonyl-containing monomer comprising two or more amine-reactive groups.",GENZYME CORP;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,,https://lens.org/161-075-488-935-728,Patent Application,yes,2,1,5,5,0,C08G65/24;;C08G73/0253;;A61P13/12;;A61P3/00;;A61P3/12;;C08G73/0253;;C08G65/24;;C08G75/20,A61K9/48,,0,0,,,,PENDING
106,US,A1,US 2010/0166696 A1,179-571-341-315-635,2010-07-01,2010,US 45106008 A,2008-04-25,US 45106008 A;;US 92404307 P;;US 2008/0005308 W,2007-04-27,AMIDO-AMINE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers and compositions, including amide compounds and amide polymers, may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.",DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,GENZYME CORPORATION (2009-11-04),https://lens.org/179-571-341-315-635,Patent Application,yes,100,12,5,5,0,A61K31/131;;A61K31/74;;A61K31/785;;A61P13/12;;A61P3/12;;A61P3/14;;A61P5/18;;A61P7/08;;A61K31/131;;A61K31/74;;A61K31/785,A61K31/765;;A61P13/12,424/78.37,5,4,129-619-170-721-01X;;023-566-681-585-910;;007-308-968-884-289;;055-944-809-531-054,10.1016/s0040-4039(97)00760-0;;12758154;;10.1016/s1570-9639(03)00117-1;;11738602;;10.1016/s0968-0896(01)00248-6;;11301287;;10.1016/s1359-6446(01)01757-3,"Lindhorst et al. (Tetrahedron Letters, Vol. 38, No. 22, Page 3885-3888, Published 1997);;Merriam-Webster Dictionary, http://www.merriam-webster.com/dictionary/residue, accessed January 30, 2013);;Klajnert et al. (Biochimica et Biophysica Acta, Proteins and Proteomics, Vol. 1648, Issue 1-2, Pages 115-126, Published 2003);;Roy et al. (Bioorganic and Medicinal Chemistry, Vol. 10, Pages 11-17, Published 2002);;Tomalia et al. (Drug Discovery Today, Issue 8, Vol. 6, Pages 427-436, Published 2001)",DISCONTINUED
107,ES,T3,ES 2196625 T3,067-782-338-975-906,2003-12-16,2003,ES 98957370 T,1998-10-26,US 96453697 A,1997-11-05,POLIDIALILAMINA NO SUSTITUIDA PARA TRATAR LA HIPERCOLESTEROLEMIA.,"Uso de un polímero para la fabricación de un medicamento para eliminar las sales biliares de un paciente, comprendiendo el polímero un polímero de polidialilamina y sus sales, estando dicho polímero sustancialmente libre de monómeros de amina alquilados.",GENZYME CORP,HUVAL CHAD CORI;;HOLMES-FARLEY STEPHEN RANDALL;;PETERSEN JOHN S;;DHAL PRADEEP K,,https://lens.org/067-782-338-975-906,Granted Patent,no,0,0,34,34,0,A61K31/785;;A61P1/16;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/02;;A61P9/10;;A61K31/785;;A61K31/785,A61K31/785;;A61P3/06;;A61P7/02;;A61P9/10,,0,0,,,,EXPIRED
108,US,A1,US 2010/0129309 A1,112-663-133-330-141,2010-05-27,2010,US 44972908 A,2008-02-20,US 44972908 A;;US 90284807 P;;US 2008/0002210 W,2007-02-23,AMINE POLYMER COMPOSITIONS,"A pharmaceutical composition for treating hyperphosphatemia can include polymers derived from multi-amine monomers and multifunctional monomers, where the multifunctional monomer includes more than one electrophilic group.",DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;POLOMOSCANIK STEVEN C,GENZYME CORPORATION (2009-09-01),https://lens.org/112-663-133-330-141,Patent Application,yes,99,11,4,4,0,A61K31/785;;A61K31/795;;C08G73/0206;;A61P13/12;;A61P7/00;;A61K31/785;;C08G73/0206;;A61K31/795,A61K31/785;;A61P13/12,424/78.12,1,1,010-409-808-387-102,10.3891/acta.chem.scand.50-0294,"Springborg et al (Acta Chemica Scandinavica, 1996, 50, p.294).",DISCONTINUED
109,HK,A1,HK 1065046 A1,138-050-315-904-62X,2005-02-08,2005,HK 04107699 A,2004-10-07,US 30208101 P;;US 35946702 P;;US 0220923 W,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA,,https://lens.org/138-050-315-904-62X,Patent Application,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;C07F/;;A61K/;;A61K31/74;;A61K31/785;;A61P/;;A61P3/04;;A61P3/06;;C07F5/02,,0,0,,,,DISCONTINUED
110,AU,A1,AU 2005/220192 A1,129-359-575-778-892,2005-12-01,2005,AU 2005/220192 A,2005-10-05,US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,DHAL PRADEEP K;;HUVAL CHAD CORI;;MANDEVILLE W HARRY;;LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/129-359-575-778-892,Patent Application,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,,0,0,,,,DISCONTINUED
111,PT,E,PT 1404685 E,008-932-706-156-658,2007-01-31,2007,PT 02746808 T,2002-07-01,US 30208101 P;;US 35946702 P,2001-06-29,ARYL BORONIC ACIDS FOR TREATING OBESITY,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HUVAL CHAD CORI;;DHAL PRADEEP K;;HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY;;LI XINHUA,,https://lens.org/008-932-706-156-658,Granted Patent,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/15;;C07F5/02;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06,,0,0,,,,EXPIRED
112,US,A1,US 2003/0064963 A1,093-240-834-003-600,2003-04-03,2003,US 18739702 A,2002-06-27,US 18739702 A;;US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"
    Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): 

   Ar is a substituted or unsubstituted aryl group. 

   Z and Z are independently O. NH or S. 

   X is an electron withdrawing group. 

    R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is H, an amine, NH(CH ₂ ) _{q} _{r} NH ₂ , halogen, CF ₃ , thiol ammonium, alcohol, COOH, SO ₃ H, OSO ₃ H or phosphonium group covalently bonded to the terminal position of R. Each NH in NH(CH ₂ ) _{q} _{r} NH ₂ is optionally N-alkylated or N,N-dialkylated and NH ₂ in NH(CH ₂ ) _{q} _{r} NH ₂ is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. 

   q is an integer from 2 to about 10 and r is an integer from 1 to about 5. 

    R ₁ and R ₁ are independently H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group N (R ¹ᵃ ). Each R ₁ is Structural Formula (I) is preferably H. 

    R ¹ᵃ is H, alkyl, substituted alkyl, phenyl or substituted phenyl. 

   Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent. 
",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA,GELTEX PHARMACEUTICALS INC (2002-09-26);;GENZYME CORPORATION (2003-03-27),https://lens.org/093-240-834-003-600,Patent Application,yes,13,4,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/74;;A61K31/69;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,514/64;;544/59;;544/106;;544/392;;544/157;;544/337;;546/22;;546/192,0,0,,,,EXPIRED
113,ES,T3,ES 2275888 T3,143-417-224-223-852,2007-06-16,2007,ES 02746808 T,2002-07-01,US 30208101 P;;US 35946702 P,2001-06-29,ACIDOS ARIL-BORONICOS PARA EL TRATAMIENTO DE LA OBESIDAD.,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA;;DHAL PRADEEP K,,https://lens.org/143-417-224-223-852,Granted Patent,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;C07F5/02;;A61K31/015;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06,,0,0,,,,EXPIRED
114,CA,A1,CA 2489681 A1,159-608-452-044-146,2003-01-09,2003,CA 2489681 A,2002-07-01,US 30208101 P;;US 35946702 P;;US 0220923 W,2001-06-29,ARYL BORONIC ACIDS FOR TREATING OBESITY,"Disclosed is a phenyl boronic acid compound represented by Structural Formul a (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-. -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linkin g groups and Y is -H, an amine, -[NH-(NH2)q]-NH2, halogen, -CF3, thiol, ammonium, alcohol, -COOH, -SO3H, -OSO3H or phosphonium group covalently bond ed to the terminal position of R. Each -NH- in -[NH-)CH2)q]r-NH2 is optionally N- alkylated or N,N-dialkylated and -NH2 in -[NH-(CH2)q]r-NH2 is optionally N- alkylated, N,N-dialkylated or N,N,N-triakylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R1 and R1' are independently - H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [- N+(R1a)-]. Each R1, is Structural Formula (I) is preferably -H. R1a is-H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carier or diluent.",GENZYME CORP,HUVAL CHAD CORI;;LI XINHUA;;HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;DHAL PRADEEP K,,https://lens.org/159-608-452-044-146,Patent Application,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,,0,0,,,,DISCONTINUED
115,EP,A1,EP 1404685 A1,023-075-344-489-198,2004-04-07,2004,EP 02746808 A,2002-07-01,US 0220923 W;;US 30208101 P;;US 35946702 P,2001-06-29,ARYL BORONIC ACIDS FOR TREATING OBESITY,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA;;DHAL PRADEEP K,GENZYME CORPORATION (2004-05-12),https://lens.org/023-075-344-489-198,Patent Application,yes,0,1,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,,0,0,,,,EXPIRED
116,US,B2,US 7049304 B2,091-498-714-780-793,2006-05-23,2006,US 2764304 A,2004-12-30,US 2764304 A;;US 18739702 A;;US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z′ are independently —O—. —NH— or —S—.X is an electron withdrawing group.R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH 2 ) q ] r —NH 2 , halogen, —CF 3 , thiol, ammonium, alcohol, —COOH, —SO 3 H, —OSO 3 H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated or N,N-dialkylated and —NH 2 in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated.q is an integer from 2 to about 10 and r is an integer from 1 to about 5.R 1 and R 1′ are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2–C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [—N + (R 1a )—]. Each R 1 is Structural Formula (I) is preferably —H.R 1a is —H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III W HARRY;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA,,https://lens.org/091-498-714-780-793,Granted Patent,yes,54,23,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,514/64;;558/44;;562/7,28,18,020-536-438-934-723;;036-448-812-422-623;;061-670-442-284-967;;061-670-442-284-967;;140-850-811-907-130;;005-316-633-999-516;;049-814-913-712-725;;018-889-723-036-887;;020-043-088-238-633;;043-211-954-038-529;;017-527-631-579-011;;019-065-876-769-496;;008-704-306-041-70X;;028-784-423-110-696;;151-661-812-954-496;;012-199-684-851-881;;147-306-745-100-368;;111-730-120-056-586,11234459;;10.1016/s0022-328x(00)00285-0;;10.1016/s0968-0896(99)00320-x;;10732973;;10.1016/s0968-0896(99)00320-x;;10732973;;10.1021/ol015560x;;11263915;;13428781;;10.1016/s0021-9258(18)64849-5;;11777432;;10.1021/jo0106501;;10.1002/(sici)1521-3773(19991018)38:20<3064::aid-anie3064>3.0.co;2-t;;10540423;;10.1002/(sici)1521-3757(19991018)111:20<3250::aid-ange3250>3.0.co;2-v;;10.1289/ehp.94102s721;;10.2307/3431958;;7889876;;pmc1566643;;10.1021/jo00128a024;;10.1021/jo00388a021;;10.1016/s0040-4039(98)01639-6;;10.1002/app.1973.070170818;;10.1021/ja00545a046;;7629792;;10.1021/jm00014a005;;11671907;;10.1021/jo9707848;;29711415;;10.1002/(sici)1521-3773(19981217)37:23<3279::aid-anie3279>3.0.co;2-m,"Medline, abstract No. 11234459, Obesity:preventing and managing the global epidemic. Report of a WHO consultation, World Health Orgainzation technical report series, (2000) 894 i-xii, 1-253.;;Barba, V., et al., ""Synthesis and molecular structures of dimeric boron compounds"", J. Organometallic Chem., 604:273-282 (2000).;;CA:119:139268 abs of EP 533266 Mar. 1993.;;CA:120:218155 abs JP 05301880 Nov. 1993.;;CA:126:144291 abs of WO 960681 Dec. 1996.;;CA:132:331255 abs of Biorganic & Medicinal Chem by DeSantis et al. 8(3) pp. 563-570 2000.;;CA:137:249492 abs of JP2002265472 Sep. 2002.;;CA:137:26190 abs of WO 2002044189 Jun. 2002.;;CA:140:59511 abs of WO 2003106384 Dec. 2003.;;CA:79:106049 abs of Journal of Applied Polymer Science by Leipins et al. 17 (8) pp. 2523-2532 (1973).;;Deantis, G., et al., ""Benzophenone boronic acid photoaffinity labeling of subtilisin CMMs to probe altered specificity,"" Bioorganic and Medicinal Chemistry, 8(3):563-570 (2000).;;Draffin, S.P., et al., ""Highly Fructose Selective Transport Promoted by Boronic Acids Based on a Pentaerythritol Core,"" American Chemical Society, Organic Letters, 3(6):917-920 (2001).;;English patent abstract of JP 2002-265472.;;English patent abstract of JP 3257029B2.;;Folch, J., et al., ""A Simple Method For The Isolation and Purification of Total Lipides From Animal Tissues"", J. Biol. Chem., 226:497 (1957).;;Gravel, M., et al., ""Universal Solid-Phase Approach for the Immobilization, Derivatization, and Resin-to-Resin Transfer reactions of Boronic Acids,"" J. Org. Chem., 67:3-15 (2002).;;Hall, D.G., et al., ""N, N-Diethanolaminomethyl Polystyrene: An Efficient Solid Support to Immobilze Boronic Acids,"" Angew. Chem. Int. Ed., 38(20):3064-3067 (1998).;;Hall, D.G., et al., ""N,N-Diethanolaminomethylpolystyrol: ein effizienter fester Träger für die Immobilisierung van Boronsäuren,"" Angew. Chem. Int., 111:3250-3253 (1999).;;Hall, I., et al., ""Hypolipidemic, Anti-obesity, Anti-inflammatory, Anti-osteoporotic, and Anti-neoplastic Properties of Amine Carboxyboranes,"" Environ. Health Perspect. Suppl. 102(S3):21-30 (1994).;;Hansch, C., et al., ""Hammett Sigmas,"" Exploring QSAR Hydrophobic, Electronic and Steric Constants, American Chemical Society, 217-232 (1995).;;Ishiyama, T., et al., ""Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters"", J. Org. Chem., 60(23):7508-7510 (1995).;;Kinder, D. H., et al., ""Synthesis of 2-Amino-3-Boronopropionic Acid: A Boron-Containing Analogue of Aspartic Acid,"" J. Org. Chem., 52(12):2452-2454 (1987).;;Kobayashi, Y., et al., ""Preparation of Functionalized Zinc Borates an their Coupling Reaction with Allylic Acetates,"" Tetrahedron Lett., 39:7537-7540 (1998).;;Leipins, R. et al., ""Organoboron compounds as durable flame retardants for cotton fabric,"" Journal of Applied Polymer Science, 17(8):2523-32 (1973).;;Matteson, D. S., et al., ""Directed Chiral Synthesis with Pinanediol Boronic Esters"", J. Am. Chem. Soc., 102(25):7590-7591 (1980).;;Reuman, M., et al., ""Synthesis and Antibacterial Activity of Some Novel 1-Substituted 1, 4-Dihydro-4-Oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent Antistaphylococcal Agents."" J. Med. Chem., 38(14):2531-2540 (1995).;;Saito, S., et al., ""Synthesis of Biaryls via a Nickel(0)-Catalyzed Cross-Coupling Reaction of Chloroarenes with Arylboronic Acids"", J. Org. Chem. 62:8024-8030 (1997).;;Sakai, M., et al., ""Rhodium-Catalyzed Addition of Organoboronic Acids to Aldehydes"", Angew. Chem. Int. Ed. 37(23):3279-3281 (1998).",EXPIRED
117,US,B2,US 7456156 B2,179-521-374-247-071,2008-11-25,2008,US 34359806 A,2006-01-31,US 34359806 A;;US 2764304 A;;US 18739702 A;;US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group.Z and Z′ are independently —O—, —NH— or —S—.X is an electron withdrawing group.R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH 2 ) q ] r —NH 2 , halogen, —CF 3 , thiol, ammonium, alcohol, —COOH, —SO 3 H, —OSO 3 H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated or N,N-dialkylated and —NH 2 in —[NH—CH 2 ) q ] r —NH 2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated.q is an integer from 2 to about 10 and r is an integer from 1 to about 5.R 1 and R 1′ are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [—N + (R 1a )—]. Each R 1 is Structural Formula (I) is preferably —H.R 1a is —H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III HARRY W;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA,,https://lens.org/179-521-374-247-071,Granted Patent,yes,56,2,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,514/64;;562/7,29,19,028-784-423-110-696;;036-448-812-422-623;;061-670-442-284-967;;061-670-442-284-967;;140-850-811-907-130;;005-316-633-999-516;;049-814-913-712-725;;018-889-723-036-887;;020-043-088-238-633;;043-211-954-038-529;;017-527-631-579-011;;019-065-876-769-496;;008-704-306-041-70X;;028-784-423-110-696;;151-661-812-954-496;;012-199-684-851-881;;147-306-745-100-368;;111-730-120-056-586;;020-536-438-934-723,10.1002/app.1973.070170818;;10.1016/s0022-328x(00)00285-0;;10.1016/s0968-0896(99)00320-x;;10732973;;10.1016/s0968-0896(99)00320-x;;10732973;;10.1021/ol015560x;;11263915;;13428781;;10.1016/s0021-9258(18)64849-5;;11777432;;10.1021/jo0106501;;10.1002/(sici)1521-3773(19991018)38:20<3064::aid-anie3064>3.0.co;2-t;;10540423;;10.1002/(sici)1521-3757(19991018)111:20<3250::aid-ange3250>3.0.co;2-v;;10.1289/ehp.94102s721;;10.2307/3431958;;7889876;;pmc1566643;;10.1021/jo00128a024;;10.1021/jo00388a021;;10.1016/s0040-4039(98)01639-6;;10.1002/app.1973.070170818;;10.1021/ja00545a046;;7629792;;10.1021/jm00014a005;;11671907;;10.1021/jo9707848;;29711415;;10.1002/(sici)1521-3773(19981217)37:23<3279::aid-anie3279>3.0.co;2-m;;11234459,"Liepins et al., Journal of Applied Polymer Science, vol. 17, pp. 2523-2532 (1973).;;Barba, V., et al., ""Synthesis and molecular structures of dimeric boron compounds"", J. Organometallic Chem., 604:273-282 (2000).;;CA:119:139268 abs of EP 533266 Mar. 1993.;;CA:120:218155 abs JP 05301880 Nov. 1993.;;CA:126:144291 abs of WO 960681 Dec. 1996.;;CA:132:331255 abs of Biorganic & Medicinal Chem by DeSantis et al. 8(3) pp. 563-570 2000.;;CA:137:249492 abs of JP20022654 Sep. 2002.;;CA:137:26190 abs of WO 2002044189 Jun. 2002.;;CA:140:59511 abs of WO 2003106384 Dec. 2003.;;CA:79:106049 abs of Journal of Applied Polymer Science by Leipins et al. 17 (8) pp. 2523-2532 (1973).;;Deantis, G., et al., ""Benzophenone boronic acid photoaffinity labeling of subtilisin CMMs to probe altered specificity,"" Bioorganic and Medicinal Chemistry, 8(3):563-570 (2000).;;Draffin, S.P., et al., ""Highly Fructose Selective Transport Promoted by Boronic Acids Based on a Pentaerythritol Core,"" American Chemical Society, Organic Letters, 3(6):917-920 (2001).;;English patent abstract of JP 2002-265472, Aug. 6, 2004.;;English patent abstract of JP 3257029B2, Aug. 9, 2004.;;Folch, J., et al., ""A Simple Method For The Isolation and Purification of Total Lipides From Animal Tissues"", J. Biol. Chem., 226:497 (1957).;;Gravel, M., et al., ""Universal Solid-Phase Approach for the Immobilization, Derivatization, and Resin-to-Resin Transfer reactions to Boronic Acids,"" J. Org. Chem., 67:3-15 (2002).;;Hall, D.G., et al., ""N, N-Diethanolaminomethyl Polystyrene: An Efficient Solid Support to Immobilze Boronic Acids,"" Angew. Chem. Int. Ed., 38(20):3064-3067 (1998).;;Hall, D.G., et al., ""N,N-Diethanolaminomethylpolystyrol: ein effizienter fester Träger für die Immobilisierung von Boronsäuren,"" Angew. Chem. Int., 111:3250-3253 (1999).;;Hall, I., et al., ""Hypolipidemic, Anti-obesity, Anti-inflammatory, Anti-osteoporotic, and Anti-neoplastic Properties of Amine Carboxyboranes,"" Environ. Health Perspect. Suppl. 102(S3):21-30 (1994).;;Hansch, C., et al., ""Hammett Sigmas,"" Exploring QSAR Hydrophobic, Electronic and Steric Constants, American Chemical Society, 217-232 (1995).;;Ishiyama, T., et al., ""Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters"", J. Org. Chem., 60(23):7508-7510 (1995).;;Kinder, D. H., et al., ""Synthesis of 2-Amino-3-Boronopropionic Acid: A Boron-Containing Analogue of Aspartic Acid,"" J. Org. Chem., 52(12):2452-2454 (1987).;;Kobayashi, Y., et al., ""Preparation of Functionalized Zinc Borates an their Coupling Reaction with Allylic Acetates,"" Tetrahedron Lett., 39:7537-7540 (1998).;;Leipins, R. et al., ""Organoboron compounds as durable flame retardants for cotton fabric,"" Journal of Applied Polymer Science, 17(8):2523-32 (1973).;;Matteson, D. S., et al., ""Directed Chiral Synthesis with Pinanediol Boronic Esters"", J. Am. Chem. Soc., 102(25):7590-7591 (1980).;;Reuman, M., et al., ""Synthesis and Antibacterial Activity of Some Novel 1-Substituted 1,4-Dihydro-4-Oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent Antistaphylococcal Agents."" J. Med. Chem., 38(14):2531-2540 (1995).;;Saito, S., et al., ""Synthesis of Biaryls via a Nickel(0)-Catalyzed Cross-Coupling Reaction of Chloroarenes with Arylboronic Acids"", J. Org. Chem. 62:8024-8030 (1997).;;Sakai, M., et al., ""Rhodium-Catalyzed Addition of Organoboronic Acids to Aldehydes"", Angew. Chem. Int. Ed. 37(23):3279-3281 (1998).;;Medilne, abstract No. 11234459, ""Obesity: preventing and managing the global epidemic"", Report of a WHO consultation, World Health Organization technical report series, (2000) 894 i-xii, 1-253.",EXPIRED
118,US,A1,US 2006/0128664 A1,086-154-254-289-599,2006-06-15,2006,US 34359806 A,2006-01-31,US 34359806 A;;US 2764304 A;;US 18739702 A;;US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z′ are independently —O—. —NH— or —S—. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH 2 ) q ] r —NH 2 , halogen, —CF 3 , thiol, ammonium, alcohol, —COOH, —SO 3 H, —OSO 3 H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated or N,N-dialkylated and —NH 2 in —[NH—CH 2 ) q ] r —NH 2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R 1 and R 1 ′ are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [—N + (R 1a )—]. Each R 1 is Structural Formula (I) is preferably —H. R 1a is —H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN R;;MANDEVILLE W H III;;DHAL PRADEEP K;;HUVAL CHAD C;;LI XINHUA,,https://lens.org/086-154-254-289-599,Patent Application,yes,17,5,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,514/64;;562/7,0,0,,,,EXPIRED
119,AU,B2,AU 2002/316499 B2,120-118-830-106-467,2005-08-04,2005,AU 2002/316499 A,2002-07-01,US 30208101 P;;US 35946702 P;;US 0220923 W,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA;;DHAL PRADEEP K,,https://lens.org/120-118-830-106-467,Granted Patent,no,1,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,,2,0,,,"Angew. Chem., vol.11 (1999) pp.3250-3253;;J. Org. Chem. vol.67, no.1 (2001) pp.3-15",EXPIRED
120,US,B2,US 6858592 B2,126-714-005-372-975,2005-02-22,2005,US 18739702 A,2002-06-27,US 18739702 A;;US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group.Z and Z′ are independently —O—. —NH— or —S—.X is an electron withdrawing group.R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH 2 ) q ] r —NH 2 , halogen, —CF 3 , thiol ammonium, alcohol, —COOH, —SO 3 H, —OSO 3 H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated or N,N-dialkylated and —NH 2 in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated.q is an integer from 2 to about 10 and r is an integer from 1 to about 5.R 1 and R 1′ are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [—N + (R 1a )—]. Each R 1 is Structural Formula (I) is preferably —H.R 1a is —H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III W HARRY;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA,GELTEX PHARMACEUTICALS INC (2002-09-26);;GENZYME CORPORATION (2003-03-27),https://lens.org/126-714-005-372-975,Granted Patent,yes,53,7,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/74;;A61K31/785;;A61K31/69;;A61P3/04;;A61P3/06;;C07F5/02,514/64;;558/44;;562/7,28,17,061-670-442-284-967;;043-211-954-038-529;;018-889-723-036-887;;028-784-423-110-696;;061-670-442-284-967;;049-814-913-712-725;;140-850-811-907-130;;043-211-954-038-529;;005-316-633-999-516;;012-199-684-851-881;;111-730-120-056-586;;036-448-812-422-623;;147-306-745-100-368;;008-704-306-041-70X;;019-065-876-769-496;;151-661-812-954-496;;017-527-631-579-011,10.1016/s0968-0896(99)00320-x;;10732973;;10.1289/ehp.94102s721;;10.2307/3431958;;7889876;;pmc1566643;;10.1002/(sici)1521-3773(19991018)38:20<3064::aid-anie3064>3.0.co;2-t;;10540423;;10.1002/app.1973.070170818;;10.1016/s0968-0896(99)00320-x;;10732973;;11777432;;10.1021/jo0106501;;10.1021/ol015560x;;11263915;;10.1289/ehp.94102s721;;10.2307/3431958;;7889876;;pmc1566643;;13428781;;10.1016/s0021-9258(18)64849-5;;7629792;;10.1021/jm00014a005;;29711415;;10.1002/(sici)1521-3773(19981217)37:23<3279::aid-anie3279>3.0.co;2-m;;10.1016/s0022-328x(00)00285-0;;11671907;;10.1021/jo9707848;;10.1016/s0040-4039(98)01639-6;;10.1021/jo00388a021;;10.1021/ja00545a046;;10.1021/jo00128a024,"CA:119:139268 abs of EP 533266 Mar. 1993.*;;CA:79:106049 abs of Journal of Applied Polymer Science by Leipins et al 17 (8) pp 2523-2532 1973.*;;CA:137:26190 ab of WO 2002044189 Jun. 2002.*;;CA:132:331255 abs of Biorganic & Medicinal Chem by DeSantis et al 8(3) pp 563-570 2000.*;;CA:120:218155 abs JP05301880 Nov. 1993.*;;CA:140:59511 abs of WO2003106384 Dec. 2003.*;;CA:137:249492 abs of JP2002265472 Sep. 2002.*;;CA:126:144291 abs of WO960681 Dec. 1996.*;;Hall, Iris et al., ""Hypolipidemic, Anti-obesity, Anti-inflammatory, Anti-osteoporotic, and Anti-neoplastic Properties of Amine Carboxyboranes,"" Environ. Health Perspect. Suppl. 102 (S3):21-30 (1994).;;Hall, Dennis G. et al., ""N, N-Diethanolaminomethyl Polystyrene: An Efficient Solid Support to Immobilze Boronic Acids,"" Angew. Chem. Int. Ed. 38(20):3064-3067 (1998).;;Leipins, R. et al., Organoboron compounds as durable flame retardants for cotton fabric, Journal of Applied Polymer Science (1973), 17(8), 2523-32.;;Deantis, G. et al., Benzophenone boronic acid photoaffinity labeling of subtilisin CMMs to probe altered specificity, Bioorganic and Medicinal Chemistry (2000), 8 (3), 563-570.;;English patent abstract of JP 3257029B2.;;English patent abstract of JP 2002-265472.;;Gravel, Michel et al. ""Universal Solid-Phase Approach for the Immobilization, Derivatization, and Resin-to-Resin Transfer reactions of Boronic Acids,"" J. Org. Chem. 67 :3-15 (2002).;;Draffin, S.P. et al., ""Highly Fructose Selective Transport Promoted by Boronic Acids Based on a Pentaerythritol Core,"" American Chemical Society, Organic Letters, 3(6):917-920 (2001).;;Hall, Iris H., et al., ""Hypolipidemic, anti-obesity, anti-inflammatory, anti-osteoporotic, and anti-neoplastic properties of amine carboxyboranes,"" Environ. Health Perspect. Suppl. 102(7):21-30 (1994).;;Hall, Dennis G., et al. Angew. Chem. Int. 111:3250-3253 (1999).;;Folch, J. et al., ""A Simple Method For The Isolation and Purification of Total Lipides From Animal Tissues"", J. Biol. Chem., 226: 497 (1957).;;Reuman, M. et al., ""Synthesis and Antibacterial Activity of Some Novel 1-Substituted 1, 4-Dihydro-4-Oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent Antistaphylococcal Agents."" J. Med. Chem., 38(14):2531-2540 (1995).;;Sakai, M. et al., ""Rhodium-Catalyzed Addition of Organoboronic Acids to Aldehydes"", Angew. Chem. Int. Ed. 37(23): 3279-3281 (1998).;;Barba, V. et al., ""Synthesis and molecular structures of dimeric boron compounds"", J. Organometallic Chem., 604: 273-282 (2000).;;Saito, S. et al., ""Synthesis of Biaryls via a Nickel(0)-Catalyzed Cross-Coupling Reaction of Chloroarenes with Arylboronic Acids"", J. Org. Chem. 62: 8024-8030 (1997).;;Kobayashi, Y. et al., ""Preparation of Functionalized Zinc Borates an their Coupling Reaction with Allylic Acetates"", Tetrahedron Lett. 39: 7537-7540 (1998).;;Hansch C. et al. ""Hammett Sigmas"" in Exploring QSAR Hydrophobic, Electronic and Steric Constants, American Chemical Society: 217-232 (1995).;;Kinder, D. H. et al., ""Synthesis of 2-Amino-3-Boronopropionic Acid: A Boron-Containing Analogue of Aspartic Acid"" J. Org. Chem.., 52(12):2452-2454 (1987).;;Matteson, D. S., et al., ""Directed Chiral Synthesis with Pinanediol Boronic Esters"", J. Am. Chem. Soc., 102(25): 7590-7591 (1980).;;Ishiyama, T., et al., ""Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters"", J. Org. Chem., 60(23): 7508-7510 (1995).",EXPIRED
121,DK,T3,DK 1404685 T3,075-509-656-535-474,2007-01-22,2007,DK 02746808 T,2002-07-01,US 30208101 P;;US 35946702 P,2001-06-29,Arylboronsyrer til behandling af fedme,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;DHAL PRADEEP K;;LI XINHUA,,https://lens.org/075-509-656-535-474,Granted Patent,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;C07F5/02;;A61K31/015;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06,,0,0,,,,EXPIRED
122,WO,A1,WO 2003/002570 A1,198-821-882-481-781,2003-01-09,2003,US 0220923 W,2002-07-01,US 30208101 P;;US 35946702 P,2001-06-29,ARYL BORONIC ACIDS FOR TREATING OBESITY,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-. -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(NH2)q]-NH2, halogen, -CF3, thiol, ammonium, alcohol, -COOH, -SO3H, -OSO3H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-)CH2)q]r-NH2 is optionally N-alkylated or N,N-dialkylated and -NH2 in -[NH-(CH2)q]r-NH2 is optionally N-alkylated, N,N-dialkylated or N,N,N-triakylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R1 and R1' are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N+(R1a)-]. Each R¿1?, is Structural Formula (I) is preferably -H. R?1a¿ is-H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carier or diluent.",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA;;DHAL PRADEEP K,,https://lens.org/198-821-882-481-781,Patent Application,yes,1,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/74;;A61K31/69;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,,4,3,049-814-913-712-725;;140-850-811-907-130;;043-211-954-038-529,11777432;;10.1021/jo0106501;;10.1021/ol015560x;;11263915;;10.1289/ehp.94102s721;;10.2307/3431958;;7889876;;pmc1566643,"GRAVEL M. ET AL.: ""Universal Solid-Phase Approach for the Immobilization, Derivatization, and Resin-to Resin Transfer Reactions of Boronic Acids"", J. ORG. CHEM., vol. 67, no. 1, 29 November 2001 (2001-11-29), pages 3- - 15, XP002211041;;DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002211043, Database accession no. BRN8490515;;DRAFFIN, SCOTT P. ET AL: ""Highly Fructose Selective Transport Promoted by Boronic Acids Based on a Pentaerythritol Core"", ORGANIC LETTERS (2001), 3(6), 917-920, XP002211042;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HALL, IRIS H. ET AL: ""Hypolipidemic, anti- obesity, anti-inflammatory, anti-osteoporotic, and anti-neoplastic properties of amine carboxyboranes"", XP002211044, retrieved from STN Database accession no. 122:230161",PATENTED
123,EP,B1,EP 1404685 B1,089-055-224-693-908,2006-09-13,2006,EP 02746808 A,2002-07-01,US 0220923 W;;US 30208101 P;;US 35946702 P,2001-06-29,ARYL BORONIC ACIDS FOR TREATING OBESITY,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA;;DHAL PRADEEP K,GENZYME CORPORATION (2004-05-12),https://lens.org/089-055-224-693-908,Granted Patent,yes,1,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;C07F5/02;;A61K31/015;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06,,4,0,,,"GRAVEL M. ET AL.: ""Universal Solid-Phase Approach for the Immobilization, Derivatization, and Resin-to Resin Transfer Reactions of Boronic Acids"" J. ORG. CHEM., vol. 67, no. 1, 29 November 2001 (2001-11-29), pages 3--15, XP002211041;;DATABASE CROSSFIRE BEILSTEIN [Online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. BRN8490515 XP002211043 & HALL, D. ET AL.: ANGEW. CHEM, vol. 11, 1999, pages 3250-3253,;;DRAFFIN, SCOTT P. ET AL: ""Highly Fructose Selective Transport Promoted by Boronic Acids Based on a Pentaerythritol Core"" ORGANIC LETTERS (2001), 3(6), 917-920 , XP002211042;;DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HALL, IRIS H. ET AL: ""Hypolipidemic, anti- obesity, anti-inflammatory, anti-osteoporotic, and anti-neoplastic properties of amine carboxyboranes"" retrieved from STN Database accession no. 122:230161 XP002211044 & ENVIRON. HEALTH PERSPECT. SUPPL. (1994), 102(SUPPL. 7), 21-30 ,",EXPIRED
124,AT,T1,AT E339426 T1,057-930-041-379-029,2006-10-15,2006,AT 02746808 T,2002-07-01,US 30208101 P;;US 35946702 P,2001-06-29,ARYLBORSÄUREN FÜR DIE BEHANDLUNG VON FETTSUCHT,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-, -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2</SUB>, halogen, -CF<SUB>3</SUB>, thiol, ammonium, alcohol, -COOH, -SO<SUB>3</SUB>H, -OSO<SUB>3</SUB>H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-(CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated or N,N-dialkylated and -NH<SUB>2 </SUB>in -[NH-CH<SUB>2</SUB>)<SUB>q</SUB>]<SUB>r</SUB>-NH<SUB>2 </SUB>is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R<SUB>1 </SUB>and R<SUB>1'</SUB> are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N<SUP>+</SUP>(R<SUP>1a</SUP>)-]. Each R<SUB>1 </SUB>is Structural Formula (I) is preferably -H. R<SUP>1a </SUP>is -H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY III;;HUVAL CHAD CORI;;LI XINHUA;;DHAL PRADEEP K,,https://lens.org/057-930-041-379-029,Granted Patent,no,0,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/69;;A61K31/74;;A61K31/785;;A61P3/04;;A61P3/06;;C07F5/02,,0,0,,,,EXPIRED
125,US,A1,US 2005/0107336 A1,155-496-186-011-966,2005-05-19,2005,US 2764304 A,2004-12-30,US 2764304 A;;US 18739702 A;;US 30208101 P;;US 35946702 P,2001-06-29,Aryl boronic acids for treating obesity,"Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z′ are independently —O—. —NH— or —S—. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is —H, an amine, —[NH—(CH 2 ) q ] r —NH 2 , halogen, —CF 3 , thiol, ammonium, alcohol, —COOH, —SO 3 H, —OSO 3 H or phosphonium group covalently bonded to the terminal position of R. Each —NH— in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated or N,N-dialkylated and —NH 2 in —[NH—(CH 2 ) q ] r —NH 2 is optionally N-alkylated, N,N-dialkylated or N,N,N-trialkylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R 1 and R 1′ are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [—N + (R 1a )—]. Each R 1 is Structural Formula (I) is preferably —H. R 1a is —H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.",HOLMES-FARLEY STEPHEN R.;;MANDEVILLE W. H.III;;DHAL PRADEEP K.;;HUVAL CHAD C.;;LI XINHUA,HOLMES-FARLEY STEPHEN R;;MANDEVILLE W H III;;DHAL PRADEEP K;;HUVAL CHAD C;;LI XINHUA,,https://lens.org/155-496-186-011-966,Patent Application,yes,16,0,20,39,0,A61K31/74;;A61K31/785;;C07F5/025;;A61P3/04;;A61P3/06;;C07F5/025;;A61K31/785;;A61K31/74,A61K31/74;;A61K31/785;;A61K31/69;;A61P3/04;;A61P3/06;;C07F5/02,514/64;;562/7,0,0,,,,EXPIRED
126,US,B2,US 9066972 B2,023-799-917-829-801,2015-06-30,2015,US 201414260917 A,2014-04-24,US 201414260917 A;;US 201313848968 A;;US 31136209 A;;US 2007/0020852 W;;US 84790506 P,2006-09-29,Amide dendrimer compositions,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/023-799-917-829-801,Granted Patent,yes,99,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K8/72;;A61K31/785;;C07C237/10;;C08G83/00;;C08L101/00,,46,37,014-421-542-498-637;;090-264-176-174-068;;073-074-746-492-276;;089-551-918-367-384;;016-205-437-942-376;;055-585-701-440-853;;019-501-367-052-495;;148-264-692-351-393;;036-961-131-011-471;;159-263-834-456-866;;042-991-943-849-821;;034-091-939-029-106;;137-110-048-545-719;;081-358-209-315-340;;029-651-022-420-201;;081-472-928-361-748;;000-719-232-475-767;;006-836-959-903-102;;031-846-521-635-380;;071-216-935-223-604;;150-928-460-596-448;;015-930-525-310-569;;084-167-477-082-034;;061-217-689-441-682;;116-635-444-889-388;;045-357-296-258-363;;036-910-309-684-180;;099-738-580-867-973;;000-261-303-928-531;;110-841-784-249-474;;016-727-749-993-963;;037-984-672-901-82X;;053-660-488-479-381;;023-702-197-545-187;;095-708-959-753-29X;;128-292-318-129-648;;039-890-476-525-420,10.1016/j.tet.2006.07.094;;10.1021/ma060950q;;10.1021/cm048821g;;10.1021/jo0481304;;15760182;;10.1002/1521-3935(20011001)202:15<3035::aid-macp3035>3.0.co;2-l;;10.1002/1521-3935(20010801)202:12<2623::aid-macp2623>3.0.co;2-i;;10.1007/bf02879540;;10.1016/s0032-3861(01)00256-7;;10.1016/s0032-3861(00)00757-6;;10.1039/b006048h;;10.1021/ma001090v;;10.1021/ma000438j;;10.1016/s0032-3861(98)00268-7;;10.1093/ndt/12.5.961;;9175050;;10.1021/ma00035a017;;14533165;;10.1002/anie.200351500;;10.1016/s0021-9673(00)88914-1;;10.1021/ma00089a012;;10.1021/ja00120a032;;10.1002/ange.19931050916;;16297497;;10.1016/j.addr.2005.09.019;;10.1016/j.eurpolymj.2003.11.012;;10.1021/jo025625p;;12027725;;15588909;;10.1016/j.jconrel.2004.08.024;;10.1016/j.memsci.2004.03.034;;16787091;;10.1021/ja060875z;;10.1021/ie048837g;;15848007;;10.1016/j.ijpharm.2005.01.026;;10.1007/s00396-001-0625-4;;10.1159/000072822;;12915774;;10.1177/039139880502800806;;16211530;;10.3109/03639049109043813;;10.1016/0378-5173(92)90302-i;;10.1016/0378-5173(90)90404-r;;10.1016/0378-5173(93)90263-f;;10.1016/0378-5173(96)04489-4;;12210050;;10.1002/jps.10197,"International Search Report dated Oct. 1, 2008 for PCT/US2007/020852.;;Jayamurugan, Govindasamy, et al, ""Synthesis of Large Generatoin Poly(Propul Ether Imine) (PETIM) Dendrimers"" Tetrahedron, 82, (2006), 9582-9588.;;Xiuru Li, et al., Synthesis and Charactenzation of Hyperbranched Poly(Ester Amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines Macromolecules, 39 (2006) 7889-7899.;;Perignon, Nelly et al., ""Formation and Stabilization in Water of Metal Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers"" Chem Mater., 16 (2004)4856-4858.;;Koc, Fikret, et al, ""Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence"" J. Org. Chem , 70 (2005) 2021-2025.;;Gao, Chao, ""Hyperbranched Copolymers Made from A2, B2 and BB'2 Type Monomers, 3a: Comparison of Copoly(Sulfone-Amine)s Containing Piperazine and 4,4'-Trimethyienedipiperidine Untis"" Macromolecular Chemistry and Physics, (2001), 202(15), 3035-3042.;;Gao, Chao, Hyperbranched Polymers made from A2- and BB2'-type Monomers: 3. Polyaddition of N-Methyl 1,3-Propanediamine to Divinyl Sulfone: Macromolecular Chemistry and Physics, (2001), 202(12), 2623-2629.;;Gao, Chao, ""Hyperbranched Copolymers Made from A2, B2 and BB'2 Type Monomers (iv), Copolymerization of Divinyl Sulfone with 4,4'-trimethylenodipiperidine and N-Ethylethylenediamine"" Science in China. Series B: Chemistry, (2001), 44(2), 207-215;;Gao, C., ""Preparation of Water Soluble Hyperbranched Poly(Sulfone-Amine)s by Polyaddition of N-Ethylethylenediamine to Divinyl Sulfone"" Polymer, (2001), 42(18), 7603-7810.;;Gao, C, ""Hyperbranched Polymers Made from A2, B2 and BB'2 Type Monomers, 2. Preparation of Hyperbranched Copoly(Sulfone-Amine)s by Polyaddition of N-ethylethylenediamine and Piperazine to Divinylsulfone"" Polymer, (2001). 42(8), 3437-3443.;;Gao, Chao, ""Synthesis of Hyperbranched Polymers from Commercially Available A2 and BB'2 Type Monomers"" Chemical Communications (Cambridge): 1, (2001), 107-108.;;Geo, Chao, ""Polyaddition of B2 and BB'2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(Sulfon-Amine)s"" Macromolecules, (2001), 34(2), 156-161.;;Yan, Deyue, ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers, 1. Polyaddition of 1-(2-Aminoethyl)Piperazine to Divinyl Sulfone,"" Macromolecules, (2000), 33(21), 7693-7699.;;Hobson, Lois J., et al., ""Poly(Amidoamine) Hyperbranched Systems: Synthesis, Structure and Characterization"" Polymer. 40, (1999), 1279-129.;;Rosenbaum, Holmes-Farley: Mandevillie, Pitruzzello, Goldberg, ""Effect of RenaGelm, a Non-Absorbable, Cross-Linked; Polymeric Phosphate Binder, on Urinary Phosphorus Excretion in Rats"" Nephrology Dialysis Transplantation, vol. 12. (1997), 961-964.;;Mourey, T.H., et al., ""Unique Behavior of Dendrilic Molecules Intrinsic Viscosity of Polyether Dendrimers"" Macromolecules, 25, (1992), 2401-2406.;;Janssen, H.M., et al., ""The Synthesis and Characterization of Dendritic Molecules"" Eindhoven University of Technology, (No Date Available).;;Klapper, Marcus, et al., ""Poly(Methylene Amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone"" Angew. Chem. Int. Ed., 42, (2003), 4687-4690 (XP002456407).;;Kuga, Shigenori, ""Pore Size Distribution Analysis of Gel Substances by Size Exclusion Chromatography"", J. Chromatography, 206, (1961), 449-461.;;Kremer, Michael, et al., ""Pore-Size Distributions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and Crosslnker/Monomer Ratio"" Macromolecules, 27, (1994), 2065-2973.;;Jansen. Johan F.G.A., et al., ""The Dendritic Box: Shape-Selective Liberation of Encapsulated Guests"" J. Am. Chem, Soc., 117, (1995),4417-4418.;;de Brabancter-van den Berg, Ellen M. M., et al., ""Poly(Propylenimin)-Dendrimere Synthese in groBerem MaBstab durch heterogen katalysierte Hydrierungan"" Angew. Chem., (1993), 1370-1372. (In Geman Only).;;Duncan, Ruth, et al., ""Dendrimer Biocompatibility and Toxicity"" Advanced Drug Delivery Reviews, 57 (2005), 2215-223).;;Huval, Chad C., et al., ""Syntheses of Hydrophobically Modified Cationic Hydrogels by Copolymerization of Alkyl Substituted Dratlylamine Monomers and Their Use as Bile Acid Sequestrants"" European Polymer Journal, 40, (2004), 693-701.;;Newkome, George R., et al., ""Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction"" J. Org. Chem., 67. (2002), 3957-3960.;;Schatzlein Andreas G. et al., ""Preferential Liver Gene Expression With Polypropylenimine Dendrimers"" Journal of Controlled Release, 101, (2005), 247-258.;;Shea, Lu, et al., ""Transport Properties of Cross-Linked Polyimide Membranes Induced by Different Generations of Diaminobutane (DAB) Dendrimers"" Journal of Membrane Science. 238, (2004), 153-163.;;Stasko, Nathan A., et al., ""Dendrimers as a Scaffold for Nitric Oxide Release"" J. Am. Chem. Soc., 128, (2006), 8265-8271;;Xiao, Youchang, et al., ""Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Filmes"" Ind. Eng. Chem. Res., 44, (2005), 3059-3067.;;Bhadra, D., et al., ""Giycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting"" International Journal of Pharmaceutics, 295, (Mar. 2005), 221-233.;;Pavlov, G. M., et al., ""Molecular Characteristics of Poly(Propylene Imine)Deridrimers as Studied With Translational Diffusion and Viscometry"" Colloid. Polym. Sci., 280, (2002), 416-423.;;Chertow: Glenn M., et al., ""The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients"", Am. J. Nephrol., 235, (2003), 307-314.;;Katopodis, K. P., et al., ""Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphosphatemia in Dialysis Patients"" The international Journal of Artificiai Organs. 28:8, (2005), 803-807.;;Selmeczi, B., et al., ""Investigations of the influence of some Novel Auxiliary Agents on the Physical Properties of Tablets"" Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary), (No date available).;;Mattsson. S., et al., ""Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties"" S.T.P Pharma Sciences, 11:3. (2001), 211-220.;;Soltero, Richard, et al., ""The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Gluconate Sustained Release Dosage Forms"" Drug Development and Industrial Pharmacy, 17:1. (1991), 113-140.;;Hammouda. Y., et al., ""The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets"" Pharm. Ind., 37:5, (1976), 361-363.;;Caramella, Carla, et al., ""Experimental Evidence of Disintegration Mechanisms"". Acta Pharma. Technol. 35:1, (1989), 30-33.;;Tirkkonen, Sirpa, et al., ""Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall"", International Journal of Pharmaceutics, 86, (1992), 39-51.;;Mitchell, Karen, et al., ""The Influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydoxypropylmethylcalluiose Gels and Matrix Tablets"" International Journal of Pharmaceutics. 66, (1990) 233-242.;;Tirkkonen, Sirpa, et al., ""Release of Indomethacin from Tabletted Ethylcellulose Microcapsules"" International Journal of Pharmaceutics, 92, (1993), 55-62.;;Ferrari, F., et al., ""Investigation on Bonding and Disintegration Properties of Pharmaceutical Materials"" International Journal of Pharmaceutics, 136. (1996), 71-79.;;Lin, Shan-Yang, et al., ""Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets"" Journal of Pharmaceutical Sciences, 91:9, (Sep. 2002), 2040-2046.;;Schutz, W., ""Brief Evaluation: Sevelamer Hydrochloride"" Drug, Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3. (2001), 621-626.;;Maroni, Bradley J., et al., ""Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial"" ERA-EDTA: Abstract #1551794, (2006).;;""Renvela: sevelamer carbonate"" Prescribing Information: Genzyme Corporation, Nov. 2007.",INACTIVE
127,US,A1,US 2017/0152347 A1,147-138-961-050-545,2017-06-01,2017,US 201615346995 A,2016-11-09,US 201615346995 A;;US 201514718244 A;;US 201414260917 A;;US 201313848968 A;;US 31136209 A;;US 2007/0020852 W;;US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,,https://lens.org/147-138-961-050-545,Patent Application,yes,0,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,C08G69/40,,2,2,039-991-479-693-369;;115-741-866-157-198,10.1080/00914030490429915;;10.1002/pol.1977.170150108,"Mathakiya et al. “NOVEL BIODEGRADABLE POLYAMIDES BASEDON TARTARIC ACID: PREPARATION AND PROPERTIES”, 2004, International Journal of Polymeric Materials, Vol. 53, pages 405–418;;Ueda et al., “Synthesis of Polyamides by Ring-Opening Polyaddition of 4,4’-Disubstituted Bis(3-buten-4-olide) with Aliphatic Diamines”, 1977, JOURNAL OF POLYMER SCIENCE: Polymer Chemistry Edition, VOL. 15, pages 73-79",DISCONTINUED
128,US,A1,US 2015/0321996 A1,050-006-194-831-161,2015-11-12,2015,US 201514718244 A,2015-05-21,US 201514718244 A;;US 201414260917 A;;US 201313848968 A;;US 31136209 A;;US 2007/0020852 W;;US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/050-006-194-831-161,Patent Application,yes,0,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,C07C235/08;;C08G83/00,,1,1,033-845-003-634-386,10.1016/s0032-3861(03)00651-7,"D. Esquivel et al. ""Synthesis, characterization and degradability of polyamides derived from tartaric acid and diaminoethersâ, Polymer 44 (2003) 6169â6177",DISCONTINUED
129,NZ,A,NZ 728111 A,092-439-284-851-120,2022-07-29,2022,NZ 72811115 A,2015-06-09,US 2015/0034951 W;;US 201562172291 P;;US 201462013731 P;;US 201562172281 P;;US 201562172287 P;;US 201462009778 P;;US 201462016501 P;;US 201562145840 P;;US 2014/0072246 W,2014-06-09,Controlled system and methods for storage fire protection,"A fire protection system and method for ceiling-only high-piled storage protection is disclosed which can determine the location of a fire within a storage facility and activate the fluid distribution devices above and about the fire. The system comprises a plurality of fluid distribution devices disposed beneath the ceiling and above a high-piled storage facility in the storage occupancy having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft., the storage commodity including any one of Class I, II, III or IV, Group A, Group B, or Group C plastics, elastomers, rubber, and exposed expanded plastic commodities. The plurality of fluid distribution devices includes a fluid distribution device with a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet. The sealing assembly has a sealing button or a plug. The system further includes a fluid distribution system including a network of pipes interconnecting the plurality of fluid distribution devices to a water supply, a plurality of detectors to monitor the storage occupancy for a fire, and a controller coupled to the plurality of detectors to detect and locate the fire. The controller is also coupled to the plurality of fluid distribution devices. The controller receives an input signal from each of the plurality of detectors, determines whether the input signal from one or more detectors of the plurality of detectors meets or exceeds a pre-alarm threshold using the input signal from each of the plurality of detectors, assigns a fluid distribution device of the plurality of fluid distribution devices associated with the one or more detectors of the plurality of detectors for which the input signal meets or exceeds the pre-alarm threshold to a device queue, and generates an output signal for operation of each assigned fluid distribution device of the plurality of fluid distribution devices responsive to the input signal meeting or exceeding an alarm threshold greater than the pre-alarm threshold. Wherein, the device queue has met a minimum threshold number of assigned fluid distribution devices of the plurality of fluid distribution devices within the device queue to allow for operation of each assigned fluid distribution device of the plurality of fluid distribution devices. to identify and control operation of a select number of fluid distribution devices of the plurality of fluid distribution devices defining a discharge array above and about the fire.",TYCO FIRE & SECURITY GMBH;;TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY;;FARLEY DANIEL;;DESROSIER JOHN;;BRIGHENTI DONALD;;GOYETTE CHAD;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/092-439-284-851-120,Patent Application,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,PENDING
130,WO,A3,WO 2008/042222 A3,067-045-209-680-52X,2008-12-18,2008,US 2007/0020852 W,2007-09-26,US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP;;DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,,https://lens.org/067-045-209-680-52X,Search Report,yes,1,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K8/72,,0,0,,,,PENDING
131,US,B2,US 8900560 B2,144-937-387-042-613,2014-12-02,2014,US 201313848968 A,2013-03-22,US 201313848968 A;;US 31136209 A;;US 2007/0020852 W;;US 84790506 P,2006-09-29,Amide dendrimer compositions,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",SANOFI SA;;GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/144-937-387-042-613,Granted Patent,yes,99,2,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K8/72;;A61K31/785,424/70.11;;414/78.08;;414/78.17,46,37,014-421-542-498-637;;090-264-176-174-068;;073-074-746-492-276;;089-551-918-367-384;;016-205-437-942-376;;055-585-701-440-853;;019-501-367-052-495;;148-264-692-351-393;;036-961-131-011-471;;159-263-834-456-866;;042-991-943-849-821;;034-091-939-029-106;;137-110-048-545-719;;081-358-209-315-340;;029-651-022-420-201;;081-472-928-361-748;;000-719-232-475-767;;006-836-959-903-102;;000-261-303-928-531;;110-841-784-249-474;;016-727-749-993-963;;037-984-672-901-82X;;053-660-488-479-381;;023-702-197-545-187;;031-846-521-635-380;;071-216-935-223-604;;150-928-460-596-448;;015-930-525-310-569;;084-167-477-082-034;;061-217-689-441-682;;116-635-444-889-388;;045-357-296-258-363;;036-910-309-684-180;;099-738-580-867-973;;095-708-959-753-29X;;128-292-318-129-648;;039-890-476-525-420,10.1016/j.tet.2006.07.094;;10.1021/ma060950q;;10.1021/cm048821g;;10.1021/jo0481304;;15760182;;10.1002/1521-3935(20011001)202:15<3035::aid-macp3035>3.0.co;2-l;;10.1002/1521-3935(20010801)202:12<2623::aid-macp2623>3.0.co;2-i;;10.1007/bf02879540;;10.1016/s0032-3861(01)00256-7;;10.1016/s0032-3861(00)00757-6;;10.1039/b006048h;;10.1021/ma001090v;;10.1021/ma000438j;;10.1016/s0032-3861(98)00268-7;;10.1093/ndt/12.5.961;;9175050;;10.1021/ma00035a017;;14533165;;10.1002/anie.200351500;;10.1016/s0021-9673(00)88914-1;;10.1021/ma00089a012;;10.1007/s00396-001-0625-4;;10.1159/000072822;;12915774;;10.1177/039139880502800806;;16211530;;10.3109/03639049109043813;;10.1016/0378-5173(92)90302-i;;10.1016/0378-5173(90)90404-r;;10.1021/ja00120a032;;10.1002/ange.19931050916;;16297497;;10.1016/j.addr.2005.09.019;;10.1016/j.eurpolymj.2003.11.012;;10.1021/jo025625p;;12027725;;15588909;;10.1016/j.jconrel.2004.08.024;;10.1016/j.memsci.2004.03.034;;16787091;;10.1021/ja060875z;;10.1021/ie048837g;;15848007;;10.1016/j.ijpharm.2005.01.026;;10.1016/0378-5173(93)90263-f;;10.1016/0378-5173(96)04489-4;;12210050;;10.1002/jps.10197,"Internationat Search Report dated Oct. 1, 2006 for PCT/US2007/020652.;;Jayamuruga, Govindasamy, et al. ""Synthesis of Large Generation Poly(Propul Ether Imine) (PETIM) Dendrimers"" Tetrahedron, 62, (2006), 9582-9588.;;Xiuru Li, et al., Synthesis and Characterization of Hyperbranched Poly(Ester Amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines Macromolecules, 39 (2006) 7880-7889.;;Perignon, Neliy et al., ""Formation and Stabilization in Water of Metai Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers"" Chem Mater., 16 (2004) 4856-4858.;;Koc, Fikret, et al. ""Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence"" J. Org. Chem., 70 (2005) 2021-2025.;;Gao, Chao, ""Hyperbranched Copolymers Made from A2, B2 and BB'2 Type Monomers, 3a; Comparison of Copoly(Sulfone-Amine)s Containing Piperazine and 4,4'-Trimethylenedipiperidine Units"" Macromolecular Chemistry and Physics. (2001), 202(15), 3035-3042.;;Gao, Chao, Hyperbranched Polymers made from A2- and BB2'-type Monomers: 3. Polyaddition of N-Methyl 1,3-Propanediamine to Divinyl Sulfone: Macromolecular Chemistry and Physics, (2001), 202(12), 2623-2629.;;Gao, Chao, ""Hyperbranched Copolymers Made from A2, B2 and BB'2 Type Monomers (iv). Copolymerization of Divinyl Sulfone with 4.4'-trimethylenedipiperidine and N-Ethylethylenediamine"" Science in China, Series B: Chemistry, (2001), 44(2), 207-215.;;Gao, C., ""Preparation of Water Soluble Hyperbranched Poly(Sulfone-Amine)s by Polyaddition of N-Ethylethylenediamine to Divinyl Sulfone"" Polymer, (2001), 42(18), 7603-7610.;;Gao, C., ""Hyperbranched Polymers Made from A2, 62 and BB'2 Type Monomers. 2. Preparation of Hyperbranched Copoly(Sulfone-Amine)s by Polyaddition of N-ethylethylenediamine and Piperazine to Divinylsulfone"" Polymer, (2001), 42(8), 3437-3443.;;Geo, Chao, ""Synthesis of Hyperbranched Polymers from Commercially Available A2 and BB'2 Type Monomers"" Chemical Communications (Cambridge), 1, (2001), 107-108.;;Gao, Chao, ""Polyaddition of B2 and BB'2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(Sulfon-Amine)s"" Macromolecules, (2001), 34(2), 156-161.;;Yan, Deyue, ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)Piperazine to Divinyl Sulfone"" Macromolecules, (2000), 33(21), 7663-7699.;;Hobson, Lois J., et al., ""Poly(Amidoamine) Hyperbranched Systems: Synthesis, Structure and Characterization"" Polymer, 40, (1999), 1279-1297.;;Rosenbaum, Holmes-Farley Mandeville, Pitruzzello Goldberg, ""Effect of RenaGelm, a Non-Absorbable, Cross-Linked, Polymeric Phosphate Binder, on Urinary Phosphorus Excretion in Rats"" Nephrology Dialysis Transplantation. vol. 12, (1997), 961-964.;;Mourey, T.H., et al., ""Unique Behavior of Dendritic, Molecules: Intrinsic Viscosity of Polyether Dedrimers"" Macromolecules, 25, (1992): 2401-2406.;;Janssen, H.M. et al., ""The Synthesis and Charactertzation of Dendritic Molecules"" Eindhoven University of Technology, (No Date Available).;;Klapper, Marcus, et al., ""Poly(Methylene Amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone"" Angew. Chem. Int. Ed., 42, (2003), 4687-4690 (XP002456407).;;Kuga, Shigenori, ""Pore Size Distribution Analysis of Gel Substances by Size Exclusion Chromatography"", J. Chromatography, 206, (1981) 449-461.;;Kremer, Michael, et al., ""Pore-size Distubutions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and Crossinker/Monomer Ratio"" Macromolecules, 27, (1994), 2065-2973.;;Pavlov, G. M., et al., ""Molecular Characteristics of Poly(Propylene Imine) Dendrimers as Studied With Translational Diffusion and Viscometry"" Colloid. Polym. Sci., 280, (2002), 416-423.;;Cherlow, Glenn M., et al., ""The Effects of Sevelamer and Calcium Acetate on Proxies a Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients"", Am. J. Nephrol., 23.5, (2003), 307-314.;;Katopodis, K. P., et al., ""Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphosphatemia in Dialysis Patients"" The International Journal of Artificial Organs, 28:8, (2005), 803-807.;;Selmeczi. B., et al., ""Investigations of the Influence of some Novel Auxiliary Agents on the Physical Properties of Tabtets"" Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary), (No date available).;;Matisson, S., et al., ""Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties"" S.T.P Pharma Sciences, 11:3, (2001), 211-220.;;Sollero, Richard, et al., ""The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Glucoconate Sustained Release Dosage Forms"" Drug Development and Industrial Pharmacy, 17:1; (1991), 113-140.;;Hammouda, Y., et al., ""The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets"" Pharm. Ind., 37:5, (1975), 361-363.;;Caramella, Cada, et al., ""Experimental Evidence of Disintegration Mechanisms"" Acta Pharma. Technol., 36:1, (1989), 30-33.;;Tirkkonen, Sirpa, et at., ""Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall"", International Journal of Pharmaceutics, 88, (1992), 39-51.;;Mitchell Karen, et al., ""The influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydroxypropylmethylcellulose Gels and Matrix Tablets"" International Journal of Pharmaceutics, 66, (1990) 233-242.;;Jansen, Johan F.G A., et al., ""The Dendritic Box: Shape-Seleclive Liberation of Encapsulated Guests"" J. Am. Chem. Soc., 117, (1995), 4417-4418.;;de Brabander-van den Berg, Ellen M. M., et al., ""Poly(Propylenimin)-Dendrimere: Synthese in groBerem MaBstab durch heterogen katalysierte Hydrierungen"" Angew. Chem., (1993), 1370-1372 (In Geman only).;;Duncan, Ruth, et al., ""Dendrimer Biocompatibility and Toxicity"" Advanced Drug Delivery Reviews, 57 (2005), 2215-2237.;;Huval Chad C., et al., ""Syntheses of Hydrophobically Modified Cationic Hydrogels by Copolymerization of Alkyl Substituted Diallylamine Monomers and Their Use an Bile Acid Sequestrants"" European Polymer Journal, 40, (2004), 693-701.;;Newkome, George R., et al., ""Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction"" J. Org. Chem., 67, (2002), 3957-3960.;;Schatziein, Andreas G., et al., ""Preferential Liver Gene Expression With Polypropylenimine Dendrimers"" Journal of Controlled Release, 101, (2005), 247-258.;;Shao, Lu, et al., ""Transport Properties of Cross-Linked Polyimide Membranes Induced by Different Generations of Diaminobutane (DAB) Dendrimers"" Journal of Membrane Science, 238, (2004), 153-163.;;Stasko, Nathan A., et al., ""Dendrimers as a Scaffold for Nitric Oxide Release"" J. Am. Chem. Soc., 128, (2006), 8265-8271.;;Xiao, Youchang, et al., ""Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Fumes"" Ind. Eng. Chem. Res., 44, (2005), 3059-3067.;;Bhadra, D., et al., ""Glycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting"" International Journal of Pharmaceutics, 295, (Mar. 2005), 221-233.;;Tirkkonen, Sirpa, et al., ""Release of Indomethacin from Tabletted Ethylcellulose Microcapsules"" International Journal of Pharmaceutics, 92, (1993), 55-62.;;Ferrari, F., et al., ""Investigation on Bonding and Disintegration Properties of Pharmaceutical Materials "" International Journal of Pharmaceutics, 136, (1996), 71-79.;;Lin, Shan-Yang, et al., ""Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets"" Journal of Pharmaceutical Sciences, 91:9, (Sep. 2002), 2040-2046.;;Schulz, W., ""Brief Evaluation: Sevelamer Hydrochloride"" Drug. Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3, (2001), 621-626.;;Maroni, Bradley J., et al., ""Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial"" ERA-EDTA: Abstract #551794, (2006).;;""Renvela: sevelamer carbonate"" Prescribing Information, Genzyme Corporaton, Nov. 2007.",INACTIVE
132,WO,A2,WO 2008/042222 A2,116-605-507-418-157,2008-04-10,2008,US 2007/0020852 W,2007-09-26,US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP;;DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,,https://lens.org/116-605-507-418-157,Patent Application,yes,0,1,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K31/785,,0,0,,,,PENDING
133,BR,A2,BR PI0717545 A2,044-484-249-488-452,2013-10-22,2013,BR PI0717545 A,2007-09-26,US 84790506 P;;US 2007/0020852 W,2006-09-29,"COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAR UMA DOENÇA, POLÍMERO DE AMIDA, REDE DE POLÍMERO, E, MÉTODO PARA PREPARAR UM POLÍMERO DE AMIDA",,GEZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,,https://lens.org/044-484-249-488-452,Patent Application,no,0,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K8/72,,0,0,,,,DISCONTINUED
134,EP,A2,EP 2066293 A2,117-133-627-084-036,2009-06-10,2009,EP 07838935 A,2007-09-26,US 2007/0020852 W;;US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,,GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,,https://lens.org/117-133-627-084-036,Patent Application,yes,0,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K8/72,,0,0,,,,DISCONTINUED
135,US,B2,US 8425887 B2,027-298-460-651-176,2013-04-23,2013,US 31136207 A,2007-09-26,US 31136207 A;;US 84790506 P;;US 2007/0020852 W,2006-09-29,Amide dendrimer compositions,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE;;GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/027-298-460-651-176,Granted Patent,yes,100,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K8/72,424/70.11;;424/78.08;;424/78.17;;977/754,46,37,014-421-542-498-637;;090-264-176-174-068;;073-074-746-492-276;;089-551-918-367-384;;016-205-437-942-376;;055-585-701-440-853;;019-501-367-052-495;;148-264-692-351-393;;036-961-131-011-471;;159-263-834-456-866;;042-991-943-849-821;;034-091-939-029-106;;137-110-048-545-719;;081-358-209-315-340;;029-651-022-420-201;;081-472-928-361-748;;000-719-232-475-767;;006-836-959-903-102;;031-846-521-635-380;;071-216-935-223-604;;150-928-460-596-448;;015-930-525-310-569;;084-167-477-082-034;;061-217-689-441-682;;116-635-444-889-388;;045-357-296-258-363;;036-910-309-684-180;;099-738-580-867-973;;000-261-303-928-531;;110-841-784-249-474;;016-727-749-993-963;;037-984-672-901-82X;;053-660-488-479-381;;023-702-197-545-187;;095-708-959-753-29X;;128-292-318-129-648;;039-890-476-525-420,10.1016/j.tet.2006.07.094;;10.1021/ma060950q;;10.1021/cm048821g;;10.1021/jo0481304;;15760182;;10.1002/1521-3935(20011001)202:15<3035::aid-macp3035>3.0.co;2-l;;10.1002/1521-3935(20010801)202:12<2623::aid-macp2623>3.0.co;2-i;;10.1007/bf02879540;;10.1016/s0032-3861(01)00256-7;;10.1016/s0032-3861(00)00757-6;;10.1039/b006048h;;10.1021/ma001090v;;10.1021/ma000438j;;10.1016/s0032-3861(98)00268-7;;10.1093/ndt/12.5.961;;9175050;;10.1021/ma00035a017;;14533165;;10.1002/anie.200351500;;10.1016/s0021-9673(00)88914-1;;10.1021/ma00089a012;;10.1021/ja00120a032;;10.1002/ange.19931050916;;16297497;;10.1016/j.addr.2005.09.019;;10.1016/j.eurpolymj.2003.11.012;;10.1021/jo025625p;;12027725;;15588909;;10.1016/j.jconrel.2004.08.024;;10.1016/j.memsci.2004.03.034;;16787091;;10.1021/ja060875z;;10.1021/ie048837g;;15848007;;10.1016/j.ijpharm.2005.01.026;;10.1007/s00396-001-0625-4;;10.1159/000072822;;12915774;;10.1177/039139880502800806;;16211530;;10.3109/03639049109043813;;10.1016/0378-5173(92)90302-i;;10.1016/0378-5173(90)90404-r;;10.1016/0378-5173(93)90263-f;;10.1016/0378-5173(96)04489-4;;12210050;;10.1002/jps.10197,"Jayamurugan, Govindasamy, et al., ""Synthesis of Large Generation poly(propul ether imine) (PETIM) Dendrimers"" Tetrahedron, 62 (2006) 9582-9588.;;Xiuru Li, et al., ""Synthesis and Characterization of Hyperbranched Poly(ester amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines"" Macromolecules, 39 (2006) 7889-7899.;;Pérignon, Nelly et al., ""Formation and Stabilization in Water of Metal Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers"" Chem Mater., 16 (2004) 4856-4858.;;Koç, Fikret, et al. ""Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence"" J. Org. Chem., 70 (2005) 2021-2025.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers, 3a: comparison of copoly(sulfone-amine)s containing piperazine and 4,4'-trimethylenedipiperidine units"" Macromolecular Chemistry and Physics (2001), 202(15), 3035-3042.;;Gao, Chao, ""Hyperbranched polymers made from A2- and BB2'-type monomers; 3. Polyaddition of N-methyl 1,3-propanediamine to divinyl sulfone"" Macromolecular Chemistry and Physics (2001), 202(12), 2623-2629.;;Gao, Chao, ""Hyperbranched copolymers made from A2, B2 and BB'2 type monomers (iv). Copolymerization of divinyl sulfone with 4,4'-trimethylenedipiperidine and N-ethylethylenediamine"" Science in China, Series B: Chemistry (2001), 44(2), 207-215.;;Gao, C., ""Preparation of Water Soluble hyperbranched poly(sulfone-amine)s by polyaddition of N-ethylethylenediamine to divinyl sulfone"" Polymer (2001), 42(18), 7603-7610.;;Gao, C., ""Hyperbranched polymers made from A2, B2 and BB'2 type monomers, 2. Preparation of hyperbranched copoly(sulfone-amine)s by polyaddition of N-ethylethylenediamine and piperazine to divinylsulfone"" Polymer (2001), 42(8), 3437-3443.;;Gao, Chao, ""Synthesis of hyperbranched polymers from commercially available A2 and BB'2 type monomers"" Chemical Communications (Cambridge), 1 (2001) 107-108.;;Gao, Chao, ""Polyaddition of B2 and BB'2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(sulfon-amine)s"" Macromolecules (2001), 34(2), 156-161.;;Yan, Deyue, ""Hyperbranched Polymers Made from A2 and BB'2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)piperazine to Divinyl Sulfone"" Macromolecules (2000), 33(21), 7693-7699.;;Hobson, Lois J., et al. ""Poly(amidoamine) Hyperbranched Systems:Synthesis, Structure and Characterization"" Polymer, 40 (1999) 1279-1297.;;Rosenbaum, Holmes-Farley, Mandeville, Pitruzzello, Goldberg, ""Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats"" Nephrology Dialysis Transplantation, vol. 12 (1997) 961-964.;;Mourey, T. H., et al., ""Unique Behavior of Dendritic Molecules: Intrinsic Viscosity of Polyether Dendrimers"" Macromolecules, 25 (1992) 2401-2406.;;Janssen, H.M. et al, ""The Synthesis and Characterization of Dendritic Molecules"" Eindhoven University of Technology [No date available].;;Klapper, Marcus et al., ""Poly(methylene amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone"" Angew. Chem. Int. Ed., 42 (2003) 4687-4690 (XP002456407).;;Kuga, Shigenori, ""Pore Size Ditribution Analysis of Gel Substances by Size Exclusion Chromatography"" J. Chromatography, 206 (1981) 449-461.;;Kremer, Michael, et al., ""Pore-Size Distributions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and CrossInker/Monomer Ratio"" Macromolecules, 27 (1994) 2065-2973.;;Jansen, Johan F.G.A. et al. ""The Dendritic Box: Shape-Selective Liberation of Encapsulated Guests"" J. Am. Chem. Soc., 117 (1995) 4417-4418.;;de Brabander-van den Berg, Ellen M. M. et al., ""Poly(propylenimin)-Dendrimere: Synthese in gröbetaerem Mabetastab durch heterogen katalysierte Hydrierungen"" Angew. Chem. (1993) 1370-1372. [in German only].;;Duncan, Ruth et al., ""Dendrimer biocompatibility and toxicity"" Advanced Drug Delivery Reviews, 57 (2005) 2215-2237.;;Huval, Chad C. et al., ""Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants"" European Polymer Journal, 40 (2004) 693-701.;;Newkome, George R. et al., ""Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction"" J. Org. Chem., 67 (2002) 3957-3960.;;Schatzlein, Andreas G. et al., ""Preferential liver gene expression with polypropylenimine dendrimers"" Journal of Controlled Release, 101 (2005) 247-258.;;Shao, Lu et al., ""Transport properties of cross-linked polyimide membranes induced by different generations of diaminobutane (DAB) dendrimers"" Journal of Membrane Science, 238 (2004) 153-163.;;Stasko, Nathan A. et al., ""Dendrimers as a Scaffold for Nitric Oxide Release"" J. Am. Chem. Soc., 128 (2006) 8265-8271.;;Xiao, Youchang et al., ""Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Films"" Ind. Eng. Chem. Res., 44 (2005) 3059-3067.;;Bhadra, D. et al., ""Glycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting"" International Journal of Pharmaceutics, 295 (Mar. 2005) 221-233.;;Pavlov, G. M. et al. ""Molecular Characteristics of Poly(propylene imine) Dendrimers as Studied with Translational Diffusion and Viscometry"" Colloid. Polym. Sci., 280 (2002) 416-423.;;Chertow, Glenn M. et al. ""The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients"" Am. J. Nephrol. 23:5 (2003) 307-314.;;Katopodis, K. P. et al. ""Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphospharemia in Dialysis Patients"" The International Journal of Artificial Organs, 28:8 (2005) 803-807.;;Selmeczi, B. et al. ""Investigations of the Influence of Some Novel Auxiliary Agents on the Physical Properties of Tablets"" Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary ), [No date available].;;Mattsson, S. et al. ""Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties"" S.T.P. Pharma Sciences, 11:3 (2001) 211-220.;;Soltero, Richard et al. ""The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Gluconate Sustained Release Dosage Forms"" Drug Development and Industrial Pharmacy, 17:1 (1991) 113-140.;;Hammouda, Y. et al. ""The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets"" Pharm. Ind., 37:5 (1975) 361-363.;;Caramella, Carla et al. ""Experimental Evidence of Disintegration Mechanisms"" Acta Pharm. Technol., 35:1 (1989) 30-33.;;Tirkkonen, Sirpa et al. ""Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall"" International Journal of Pharmaceutics, 88 (1992) 39-51.;;Mitchell, Karen et al. ""The Influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydroxypropylmethylcellulose Gels and Matrix Tablets"" International Journal of Pharmaceutics, 66 (1990) 233-242.;;Tirkkonen, Sirpa et al. ""Release of Indomethacin from Tabletted Ethylcellulose Microcapsules"" International Journal of Pharmaceutics, 92 (1993) 55-62.;;Ferrari, F. et al. ""Investigation on Bonding and Distintegration Properties of Pharmaceutical Materials"" International Journal of Pharmaceutics, 136 (1996) 71-79.;;Lin, Shan-Yang et al. ""Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets"" Journal of Pharmaceutical Sciences, 91:9 (Sep. 2002) 2040-2046.;;Schulz, W. ""Brief Evaluation: Sevelamer Hydrochloride"" Drug, Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3 (2001) 621-626.;;Maroni, Bradley J. et al. ""Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial"" ERA-EDTA: Abstract #551794 (2006).;;""Renvela: sevelamer carbonate"" Prescribing Information, Genzyme Corporation, Nov. 2007.;;International Search Report dated Oct. 1, 2008 for PCT/US2007/0208852.",INACTIVE
136,US,A1,US 2010/0069500 A1,011-472-085-674-770,2010-03-18,2010,US 31136207 A,2007-09-26,US 31136207 A;;US 84790506 P;;US 2007/0020852 W,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/011-472-085-674-770,Patent Application,yes,1,13,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K31/16;;A61P13/12,514/626;;977/754,0,0,,,,INACTIVE
137,US,A1,US 2013/0251667 A1,019-564-256-329-744,2013-09-26,2013,US 201313848968 A,2013-03-22,US 201313848968 A;;US 31136209 A;;US 2007/0020852 W;;US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",SANOFI SA,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/019-564-256-329-744,Patent Application,yes,0,11,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,A61K31/785,424/78.37,0,0,,,,INACTIVE
138,US,A1,US 2014/0235724 A1,084-925-857-582-508,2014-08-21,2014,US 201414260917 A,2014-04-24,US 201414260917 A;;US 201313848968 A;;US 31136209 A;;US 2007/0020852 W;;US 84790506 P,2006-09-29,AMIDE DENDRIMER COMPOSITIONS,"Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.",GENZYME CORP,DHAL PRADEEP K;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;NIVOROZHKIN VITALY;;SHUTTS BRUCE,GENZYME CORPORATION (2009-05-11),https://lens.org/084-925-857-582-508,Patent Application,yes,0,0,13,13,0,C08G83/003;;A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/02;;A61P27/02;;A61P3/12;;A61P3/14;;A61P43/00;;A61P5/18;;A61P9/00;;C08G83/003;;A61K8/72;;C08L101/00;;C07C235/08;;A61K31/785;;C07C237/10;;C08G69/40,C07C237/10,514/616,0,0,,,,INACTIVE
139,US,A1,US 2003/0059399 A1,034-242-640-321-837,2003-03-27,2003,US 18731602 A,2002-06-27,US 18731602 A;;US 30222101 P;;US 35947302 P,2001-06-29,Aryl boronate functionalized polymers for treating obesity,"
    Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: 

   Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is O, NH or S and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. 

   Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention. 
",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE W HARRY;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA;;POLOMOSCANIK STEVEN CRAIG,GELTEX PHARMACEUTICALS INC (2002-09-16);;GENZYME CORPORATION (2003-03-27),https://lens.org/034-242-640-321-837,Patent Application,yes,33,23,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/74;;A61K31/785;;A61K31/80;;A61P3/04;;C08F30/06;;C08G79/08,424/78.08;;528/394,0,0,,,,EXPIRED
140,WO,A1,WO 2015/191619 A1,114-471-252-068-947,2015-12-17,2015,US 2015/0034951 W,2015-06-09,US 201462013731 P;;US 201562172281 P;;US 201562172287 P;;US 201462009778 P;;US 201562172291 P;;US 201462016501 P;;US 201562145840 P;;US 2014/0072246 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL;;HOLLENBECK GREGG WILLIAM;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD,,https://lens.org/114-471-252-068-947,Patent Application,yes,13,26,4,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;A62C37/04;;A62C37/40;;G08B17/00;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,PENDING
141,SA,B1,SA 516380463 B1,141-784-596-894-093,2021-01-30,2021,SA 516380463 A,2016-12-08,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2014/0072246 W;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet. FIG 7",TYCO FIRE & SECURITY GMBH;;TYCO FIRE PRODUCTS LP,ABELS BERNHARD;;BRIGHENTI DONALD;;DUBE JAKE;;GOYETTE CHAD;;BONNEAU RICHARD P;;DESROSIER JOHN;;FARLEY DANIEL G;;MAGNONE ZACHARY,,https://lens.org/141-784-596-894-093,Granted Patent,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,,,0,0,,,,ACTIVE
142,US,A1,US 2006/0128663 A1,014-635-278-861-68X,2006-06-15,2006,US 34212906 A,2006-01-27,US 34212906 A;;US 18731602 A;;US 30222101 P;;US 35947302 P,2001-06-29,Aryl boronate functionalized polymers for treating obesity,"Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.",GENZYME CORP,HOLMES-FARLEY STEPHEN R;;MANDEVILLE W H III;;DHAL PRADEEP K;;HUVAL CHAD C;;LI XINHUA;;POLOMOSCANIK STEVEN C,,https://lens.org/014-635-278-861-68X,Patent Application,yes,67,1,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/69;;A01N55/08;;A61K31/80;;A61K31/74;;A61K31/785;;A61P3/04;;C08F30/06;;C08G79/08,514/64;;528/4;;528/7;;528/8,0,0,,,,DISCONTINUED
143,WO,A1,WO 2003/002571 A1,145-697-864-933-715,2003-01-09,2003,US 0220947 W,2002-07-01,US 30222101 P;;US 35947302 P,2001-06-29,ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY,"Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is O-, NH-or -S- and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The arly boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.",GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE HARRY W III;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA;;POLOMOSCANIK STEVEN C,,https://lens.org/145-697-864-933-715,Patent Application,yes,1,0,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/74;;A61K31/80;;A61K31/785;;A61P3/04;;C08F30/06;;C08G79/08,,2,2,050-664-157-268-466;;084-655-011-612-219,8924421;;10.1163/156856295x00463;;8373418;;10.1006/bbrc.1993.2120,"AOKI T ET AL: ""Endothelial cell differentiation into capillary structures by copolymer surfaces with phenylboronic acid groups"", JOURNAL OF BIOMATERIALS SCIENCE. POLYMER EDITION, VSP, UTRECHT, NL, vol. 7, no. 7, 1995, pages 539 - 550, XP002097651, ISSN: 0920-5063;;MIYAZAKI H ET AL: ""BORONATE-CONTAINING POLYMER AS NOVEL MITOGEN FOR LYMPHOCYTES"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 195, no. 2, 1993, pages 829 - 836, XP000887259, ISSN: 0006-291X",PATENTED
144,CA,A1,CA 2487857 A1,052-022-893-402-369,2003-01-09,2003,CA 2487857 A,2002-07-01,US 30222101 P;;US 35947302 P;;US 0220947 W,2001-06-29,ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY,"Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronami de and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted o r unsubstituted; and each Z is O-, NH-or -S- and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The arly boronate ester, boronamide or boronate thioester can be cleaved to release t he corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.",GENZYME CORP,LI XINHUA;;HUVAL CHAD CORI;;POLOMOSCANIK STEVEN C;;DHAL PRADEEP K;;MANDEVILLE HARRY W III;;HOLMES-FARLEY STEPHEN RANDALL,,https://lens.org/052-022-893-402-369,Patent Application,no,0,0,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/80;;A61K31/74;;A61K31/785;;A61P3/04;;C08F30/06;;C08G79/08,,0,0,,,,DISCONTINUED
145,AU,B2,AU 2002/318470 B2,103-712-110-999-522,2005-09-08,2005,AU 2002/318470 A,2002-07-01,US 30222101 P;;US 35947302 P;;US 0220947 W,2001-06-29,Aryl boronate functionalized polymers for treating obesity,,GENZYME CORP,LI XINHUA;;POLOMOSCANIK STEVEN C;;HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE HARRY W III;;DHAL PRADEEP K;;HUVAL CHAD CORI,,https://lens.org/103-712-110-999-522,Granted Patent,no,0,0,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/80;;A61K31/74;;A61K31/785;;A61P3/04;;C08F30/06;;C08G79/08,,0,0,,,,EXPIRED
146,US,B2,US 7041280 B2,133-452-975-927-149,2006-05-09,2006,US 18731602 A,2002-06-27,US 18731602 A;;US 30222101 P;;US 35947302 P,2001-06-29,Aryl boronate functionalized polymers for treating obesity,"Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.",GENZYME CORP,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III W HARRY;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA;;POLOMOSCANIK STEVEN CRAIG,GELTEX PHARMACEUTICALS INC (2002-09-16);;GENZYME CORPORATION (2003-03-27),https://lens.org/133-452-975-927-149,Granted Patent,yes,67,1,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/80;;A61K31/74;;A61K31/785;;A61P3/04;;C08F30/06;;C08G79/08,424/78.17;;424/78.18;;424/78.26;;525/337;;528/4;;528/8;;528/394,16,15,019-065-876-769-496;;151-661-812-954-496;;017-527-631-579-011;;005-316-633-999-516;;043-211-954-038-529;;018-889-723-036-887;;049-814-913-712-725;;140-850-811-907-130;;012-199-684-851-881;;111-730-120-056-586;;036-448-812-422-623;;147-306-745-100-368;;008-704-306-041-70X;;050-664-157-268-466;;084-655-011-612-219,10.1021/jo00388a021;;10.1021/ja00545a046;;10.1021/jo00128a024;;13428781;;10.1016/s0021-9258(18)64849-5;;10.1289/ehp.94102s721;;10.2307/3431958;;7889876;;pmc1566643;;10.1002/(sici)1521-3773(19991018)38:20<3064::aid-anie3064>3.0.co;2-t;;10540423;;11777432;;10.1021/jo0106501;;10.1021/ol015560x;;11263915;;7629792;;10.1021/jm00014a005;;29711415;;10.1002/(sici)1521-3773(19981217)37:23<3279::aid-anie3279>3.0.co;2-m;;10.1016/s0022-328x(00)00285-0;;11671907;;10.1021/jo9707848;;10.1016/s0040-4039(98)01639-6;;8924421;;10.1163/156856295x00463;;8373418;;10.1006/bbrc.1993.2120,"Hansch C. et al. ""Hammett Sigmas"" in Exploring QSAR Hydrophobic, Electronic and Steric Constants, American Chemical Society: Washington, D.C. pp. 219-304 (1995).;;Kinder, D. H. et al., ""Synthesis of 2-Amino-3-Boronopropionic Acid: A Boron-Containing Analog of Aspartic Acid"" J. Org. Chem., 52(12): 2452-2454 (1987).;;Matteson, D. S., et al., ""Directed Chiral Synthesis with Pinanediol Boronic Esters"", J. Am. Chem. Soc., 102(25): 7590-7591 (1980).;;Ishiyama, T., et al., ""Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters"", J. Org. Chem., 60(23): 7508-7510 (1995).;;Folch, J. et al., ""A Simple Method For The Isolation and Purification of Total Lipides From Animal Tissues"", J. Biol. Chem., 226: 497-509 (1957).;;Hall, I. H. et al., ""Hypolipidemic, Anti-Obesity, Anti-inflammatory, Anti-osteoporotic, and Anti-neoplastic Properties of Amine Carboxyboranes"", Environ. Health Perspect. 102(S3): 21-30 (1994).;;Hall, D.G., et al., ""N, N-Diethanolaminomethyl Polystyrene: An Efficient Solid Suport to Immobilze Boronic Acids"", Angew. Chem. Int. Ed., 38(20): 3064-3067 (1999).;;Gravel, M. et al,. ""Universal Solid-Phase Approach for the Immobilization, Derivatization, and Resin-to-Resin Transfer Reactions of Boronic Acids"", J. Org. Chem., 67: 3-15 (2002).;;Draffin, S.P., et al., ""Highly Fructose Selective Transport Promoted by Boronic Acids Based on a Pentaerythritol Core,"" Organic Letters, 3(6): 917-920 (2001).;;Reuman, M. et al., ""Synthesis and Antibacterial Activity of Some Novel 1-Substituted 1, 4-Dihydro-4-Oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent Antistaphylococcal Agents."" J. Med. Chem., 38(14): 2531-2540 (1995).;;Sakai, M. et al., ""Rhodium-Catalyzed Addition of Organoboronic Acids to Aldehydes"", Angew. Chem. Int. Ed. 37(23): 3279-3281 (1998).;;Barba, V. et al., ""Synthesis and Molecular Structures of Dimeric Boron Compounds"", J. Organometallic Chem., 604: 273-282 (2000).;;Saito, S. et al., ""Synthesis of Biaryls via a Nickel(0)-Catalyzed Cross-Coupling Reaction of Chloroarenes with Arylboronic Acids"", J. Org. Chem. 62: 8024-8030 (1997).;;Kobayashi, Y. et al., ""Preparation of Functionalized Zinc Borates and their Coupling Reaction with Allylic Acetates"", Tetrahedron Lett. 39: 7537-7540 (1998).;;Aoki, T., et al., ""Endothelial cell differentiation into capillary structures by copolymer surfaces with phenylboronic acid groups,"" J Biomater Sci: Polymer Edn., 7(7) :539-550, (1995).;;Miyazaki, H., et al., ""Boronate-Containing Polymer as Novel Mitogen for Lymphocytes,"" Biochemical and Biophysical Research Communications, 195(2) ;829-836, (1993).",EXPIRED
147,EP,A1,EP 1404686 A1,099-310-798-803-393,2004-04-07,2004,EP 02748036 A,2002-07-01,US 0220947 W;;US 30222101 P;;US 35947302 P,2001-06-29,ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY,,GELTEX PHARMA INC,HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE HARRY W III;;DHAL PRADEEP K;;HUVAL CHAD CORI;;LI XINHUA;;POLOMOSCANIK STEVEN C,GENZYME CORPORATION (2004-06-16),https://lens.org/099-310-798-803-393,Patent Application,yes,0,0,8,39,0,A61K31/74;;A61K31/785;;C08F8/42;;C08F8/44;;C08G65/331;;C08G73/0206;;C08G79/08;;A61K47/58;;A61P3/04;;C08F8/42;;A61K31/74;;C08G65/331;;C08F8/44;;C08G73/0206;;A61K31/785;;C08G79/08;;A61K47/58,A61K31/80;;C07F5/02;;A61K31/74;;A61K31/785;;A61P3/04;;C08F30/06;;C08G79/08,,0,0,,,,DISCONTINUED
148,WO,A2,WO 2008/027551 A2,009-402-972-122-045,2008-03-06,2008,US 2007/0019201 W,2007-08-31,US 84156606 P;;US 84943406 P;;US 85344006 P,2006-09-01,DENDRIMER COMPOSITIONS,"Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",GENZYME CORP;;COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,,https://lens.org/009-402-972-122-045,Patent Application,yes,0,20,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,A61K31/785,,0,0,,,,PENDING
149,EP,A1,EP 3763420 A1,019-269-881-473-184,2021-01-13,2021,EP 20176523 A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;EP 15730628 A;;US 2014/0072246 W;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.
",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIERS JOHN;;BRIGHENTI DONALD;;ABELS BERNHARD;;BONNEAU RICHARD P;;DUBE JAKE,,https://lens.org/019-269-881-473-184,Patent Application,yes,18,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,1,0,,,"""TFP312: Model ESFR-25 Early Suppression, Fast Response Pendent Sprinklers 25.2 K-factor"", November 2012, TYCO FIRE PRODUCTS, LP",PENDING
150,US,A1,US 2015/0094379 A1,142-423-550-874-102,2015-04-02,2015,US 201414551913 A,2014-11-24,US 201414551913 A;;US 31051410 A;;US 2007/0019201 W;;US 84156606 P;;US 84943406 P;;US 85344006 P,2006-09-01,Dendrimer Compositions,"Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",GENZYME CORP,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD R,,https://lens.org/142-423-550-874-102,Patent Application,yes,0,0,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,C07C217/08,514/668,0,0,,,,DISCONTINUED
151,EP,A2,EP 2068819 A2,102-040-860-308-668,2009-06-17,2009,EP 07837624 A,2007-08-31,US 2007/0019201 W;;US 84156606 P;;US 84943406 P;;US 85344006 P,2006-09-01,DENDRIMER COMPOSITIONS,,GENZYME CORP,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,,https://lens.org/102-040-860-308-668,Patent Application,yes,0,0,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,A61K8/72;;A61K31/785;;A61P3/12,,0,0,,,,DISCONTINUED
152,EP,A4,EP 2068819 A4,158-045-950-519-578,2011-04-20,2011,EP 07837624 A,2007-08-31,US 2007/0019201 W;;US 84156606 P;;US 84943406 P;;US 85344006 P,2006-09-01,DENDRIMER COMPOSITIONS,,GENZYME CORP,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,,https://lens.org/158-045-950-519-578,Search Report,no,1,0,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,A61K8/72;;A61K31/785;;A61P3/12,,2,2,084-167-477-082-034;;033-188-338-468-634,10.1021/jo025625p;;12027725;;10.1016/s1381-1169(01)00173-x,"NEWKOME G R ET AL: ""Improved synthesis of an ethereal tetraamine core for dendrimer construction"", JOURNAL OF ORGANIC CHEMISTRY 20020531 US LNKD- DOI:10.1021/JO025625P, vol. 67, no. 11, 31 May 2002 (2002-05-31), pages 3957 - 3960, XP002626851, ISSN: 0022-3263;;HUKKAMAKI, J. AND PAKKANEN, T. T.: ""Study on catalytic hydrogenation in synthesis of four-directional amine-terminated dendritic molecules"", JOURNAL OF MOLECULAR CATALYSIS A: CHEMICAL, vol. 174, no. 1-2, 2001, pages 205 - 211, XP002626852",DISCONTINUED
153,BR,A2,BR PI0716066 A2,031-502-034-652-707,2013-09-17,2013,BR PI0716066 A,2007-08-31,US 84156606 P;;US 84943406 P;;US 85344006 P;;US 2007/0019201 W,2006-09-01,"composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina","COMPOSIÇçO FARMACÊUTICA, MÉTODO PARA TRATAR DOENÇAS, POLÍMERO DE AMINA, REDE POLÍMERICA, MÉTODO PARA PREPARAR UM POLÍMERO DE AMINA, E, COMPOSTO DE AMINA. Compostos de amina, polímeros de amina, polímeros de amina reticulados e composições farmacêuticas compreendendo os mesmos podem incluir núcleos contendo poliidróxi que podem se substituídos por grupos amina e podem ser usados para tratar hiperfosfatemia ou para remover íons do trato gastrintestinal de animais, incluindo humanos.",GENZYME CORP,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,,https://lens.org/031-502-034-652-707,Patent Application,no,0,0,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,A61K8/72,,0,0,,,,DISCONTINUED
154,WO,A3,WO 2008/027551 A3,054-925-784-746-656,2008-11-06,2008,US 2007/0019201 W,2007-08-31,US 84156606 P;;US 84943406 P;;US 85344006 P,2006-09-01,DENDRIMER COMPOSITIONS,"Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",GENZYME CORP;;COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,,https://lens.org/054-925-784-746-656,Search Report,yes,1,0,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,A61K8/72,,0,0,,,,PENDING
155,US,A1,US 2010/0234309 A1,093-156-972-694-954,2010-09-16,2010,US 31051407 A,2007-08-31,US 31051407 A;;US 84156606 P;;US 84943406 P;;US 85344006 P;;US 2007/0019201 W,2006-09-01,Dendrimer Compositions,"Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.",GENZYME CORP,COOPER CHRISTOPHER;;DHAL PRADEEP K;;GIMI RAYOMAND H;;HARRIS DAVID J;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD C;;LEE EDWARD,GENZYME CORPORATION (2009-03-11),https://lens.org/093-156-972-694-954,Patent Application,yes,0,12,8,8,0,A61K31/785;;A61P11/00;;A61P13/12;;A61P19/02;;A61P21/00;;A61P27/02;;A61P3/12;;A61P35/00;;A61P39/00;;A61P5/16;;A61P7/00;;A61P9/00;;A61K31/785;;C07C217/08,A61K31/7004;;A61K31/13;;A61P7/00;;A61P39/00,514/23;;514/668,0,0,,,,DISCONTINUED
156,AU,B2,AU 2015/274770 B2,053-209-794-022-631,2020-12-17,2020,AU 2015/274770 A,2015-06-09,US 201562172291 P;;US 201462016501 P;;US 201562172287 P;;US 201462009778 P;;US 201562145840 P;;US 2014/0072246 W;;US 201562172281 P;;US 201462013731 P;;US 2015/0034951 W,2014-06-09,Controlled system and methods for storage fire protection,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,TYCO FIRE PRODUCTS LP (2019-03-28),https://lens.org/053-209-794-022-631,Granted Patent,no,3,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,ACTIVE
157,CA,C,CA 2951703 C,118-768-807-135-617,2023-07-11,2023,CA 2951703 A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/118-768-807-135-617,Granted Patent,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,PENDING
158,US,B1,US 6299868 B1,163-180-318-817-566,2001-10-09,2001,US 35332999 A,1999-07-14,US 35332999 A,1999-07-14,Fat-binding polymers,"The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.",GELTEX PHARMA INC,JOZEFIAK THOMAS;;HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III W HARRY;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,GELTEX PHARMACEUTICALS INC (1999-09-22);;GENZYME CORPORATION (2003-03-27),https://lens.org/163-180-318-817-566,Granted Patent,yes,43,16,2,39,0,A61K31/785;;A61K45/06;;A61K45/06;;A61K31/785,A61K31/785;;A61K45/06,424/78.35;;424/78.31;;424/78.38,15,15,018-131-239-199-212;;057-292-767-349-853;;011-488-303-075-503;;090-302-628-385-777;;020-533-691-848-42X;;025-282-768-506-603;;055-220-569-293-101;;016-362-040-736-32X;;057-110-500-429-82X;;008-047-538-157-245;;035-396-764-753-808;;056-559-651-251-030;;088-104-047-449-972;;033-086-322-527-639;;018-345-769-242-592,10.1016/s0140-6736(97)11509-4;;9683204;;2804064;;10.1016/0005-2760(89)90335-4;;10.1016/s0005-2760(97)81102-2;;9022752;;9031529;;10.1515/znc-1996-11-1222;;10.1016/0005-2760(82)90051-0;;7104374;;6777199;;10.1016/0014-5793(80)80315-2;;8982269;;10.1016/s0005-2760(96)00123-3;;10.1271/bbb.61.102;;9028038;;10.1016/0005-2760(77)90170-9;;588583;;7190135;;8280765;;10.1016/0005-2760(94)90116-3;;10.1016/0005-2760(95)00145-3;;7492616;;10.1039/p19950002927;;10.1038/sj.ijo.0800806;;10078853;;10.1002/j.1550-8528.1995.tb00218.x;;8697049,"Sjöström, L. et al., ""Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients,"" The Lancet, GB, Lancet Limited, 352(9123) :167-172 (1998).;;Gargouri, Y., et al., ""Ajoene prevents fat digestion by human gastric lipase in vitro,"" Biochemica et Biophysica Acta. 1006:137-139 (1989).;;Gargouri, Y., et al., ""Covalent inhibition of digestive lipases: an in vitro study,"" Biochimica et Biophysica Acta. 1344:6-37 (1997).;;Karamać, M. and Amarowicz, R., ""Inhibition of Pancreatic Lipase by Phenolic Acids, Examination in vitro,"" Verlag der Zeitschrift für Naturforschung:903-905 (1996).;;Vainio, P., et al., ""Inhibition of Lippoprotein Lipase by Benzene Boronic Acid Effect of Apolipoprotein C-II,"" Biochimica et Biophysica Acta. 711:386-390 (1982).;;Bagree, A., et al., ""Modification of ∈-Amino Group of Lysine in Proteins by Acylation with Pyromellitic Dianhydride and 0-Sulphobenzoic Anhydride,"" FEBS Letters 120(2):275-277 (1980).;;Stadler, P., et al., ""Inhibition of microbial lipases with stereoisomeric triradylglycerol analog phosphonates,"" Biochimica et Biophysica Acta. 1304:229-244 (1996).;;Kawaguchi, K., et al. ""Hesperidin as an Inhibitor of Lipases from Procine Pancreas and Pseudomonas,"" Biosci. Biotech. Biochem. 61(1):102-104 (1997).;;Bochenek, W.J. and Rodgers, J.B., ""Effect of Polyol Detergents on Cholesterol and Triglyceride Absorption,"" Biochimica et Biophysica Acta 489:503-506 (1977).;;Comai, K. and Sullivan, A.C., ""Antiobesity activity of pluronic L-101,"" International Journal of Obesity 4:33-42 (1980).;;Marguet, F., et al., ""Digestive lipases: inactivation by phosphonates,"" Biochimica et Biophysica Acta. 1210:157-166 (1994).;;Mannesse, M.L.M., et al., ""Phosphonate analogues of triacylglycerols are potent inhibitor of lipase,"" Biochimica et Biophysica Acta. 1259:56-64 (1995).;;Martichonok, V. and Jones, J.B., ""(Z)-Heptadec-8-enylboronic acid: a potential lipase inhibitor,"" J. Chem. Soc. Perkin Trans. I:2927-2929 (1995).;;Han, L-K, et al., ""Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet,"" International Journal of Obesity 23:174-179 (1999).;;Atkinson, et al., ""Combined drug treatment of obesity,"" Obesity Research, vol. 3, No. S4:497S-500S (1995).",EXPIRED
159,ZA,B,ZA 201700146 B,081-921-316-027-918,2020-05-27,2020,ZA 201700146 A,2017-01-06,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,,TYCO FIRE PRODUCTS LP A LP ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE;;TYCO FIRE & SECURITY GMBH A COMPAY INCORPORATED IN SWITZERLAND,ZACHARY L MAGNONE;;DANIEL G FARLEY;;CHAD ALBERT GOYETTE;;JOHN DESROSIER;;DONALD D BRIGHENTI;;BERNHARD ABELS;;JAKE DUBE;;RICHARD P BONNEAU,,https://lens.org/081-921-316-027-918,Granted Patent,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,,,0,0,,,,ACTIVE
160,EP,B1,EP 3151928 B1,014-058-091-129-301,2020-05-27,2020,EP 15730628 A,2015-06-09,US 201462013731 P;;US 201562172281 P;;US 201562172287 P;;US 201462009778 P;;US 201562172291 P;;US 201462016501 P;;US 2014/0072246 W;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,,TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;BONNEAU RICHARD P;;DUBE JAKE,TYCO FIRE PRODUCTS LP (2018-12-05),https://lens.org/014-058-091-129-301,Granted Patent,yes,4,0,4,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;A62C37/04;;A62C37/40;;G08B17/00;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,ACTIVE
161,CN,A,CN 106714911 A,052-553-683-318-751,2017-05-24,2017,CN 201580042353 A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172287 P;;US 201562172291 P;;US 201562172281 P;;US 2015/0034951 W,2014-06-09,Controlled system and methods for storage fire protection,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE & SECURITY GMBH;;TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/052-553-683-318-751,Patent Application,no,10,2,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,ACTIVE
162,US,B1,US 6726906 B1,092-117-020-275-527,2004-04-27,2004,US 72131000 A,2000-11-22,US 72131000 A;;US 35332999 A,1999-07-14,Fat-binding polymers,"
    The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin. 
",GENZYME CORP,JOZEFIAK THOMAS;;HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III W HARRY;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,GENZYME CORPORATION (2003-03-27),https://lens.org/092-117-020-275-527,Granted Patent,yes,44,7,2,39,0,A61K31/785;;A61K45/06;;A61K45/06;;A61K31/785,A61K31/785;;A61K45/06,424/78.35;;424/78.31;;424/78.02;;424/78.32;;424/78.34;;526/122;;526/121;;526/120,16,15,018-131-239-199-212;;057-292-767-349-853;;011-488-303-075-503;;090-302-628-385-777;;035-396-764-753-808;;056-559-651-251-030;;088-104-047-449-972;;020-533-691-848-42X;;025-282-768-506-603;;055-220-569-293-101;;016-362-040-736-32X;;057-110-500-429-82X;;008-047-538-157-245;;033-086-322-527-639;;018-345-769-242-592,10.1016/s0140-6736(97)11509-4;;9683204;;2804064;;10.1016/0005-2760(89)90335-4;;10.1016/s0005-2760(97)81102-2;;9022752;;9031529;;10.1515/znc-1996-11-1222;;8280765;;10.1016/0005-2760(94)90116-3;;10.1016/0005-2760(95)00145-3;;7492616;;10.1039/p19950002927;;10.1016/0005-2760(82)90051-0;;7104374;;6777199;;10.1016/0014-5793(80)80315-2;;8982269;;10.1016/s0005-2760(96)00123-3;;10.1271/bbb.61.102;;9028038;;10.1016/0005-2760(77)90170-9;;588583;;7190135;;10.1038/sj.ijo.0800806;;10078853;;10.1002/j.1550-8528.1995.tb00218.x;;8697049,"CA Abstract Registry 147867-87-6.;;Sjöström, et al., ""Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients,"" The Lancet, 352:167-172 (1998).;;Gargouri, Y., et al., ""Ajoene prevents fat digestion by human gastric lipase in vitro,"" Biochimica et Biophysica Acta. 1006:137-139 (1989).;;Gargouri, Y., et al., ""Covalent inhibition of digestive lipases: an in vitro study,"" Biochimica et Biophysica Acta. 1344:6-37 (1997).;;Karamac, M. and Amarowicz, R., ""Inhibition of Pancreatic Lipase by Phenolic Acids, Examination in vitro,"" Verlag der Zeitschrift für Naturforschung:903-905 (1996).;;Marguet, F., et al., ""Digestive lipases: inactivation by phosphonates,"" Biochimica et Biophysica Acta. 1210:157-166 (1994).;;Mannesse, M.L.M., et al., ""Phosphonate analogues of triacylglycerols are potent inhibitors of lipase,"" Biochimica et Biophysica Acta. 1259:56-64 (1995).;;Martichonok, V. and Jones, J.B., ""(Z) -Heptadec-8-enylboronic acid: a potential lipase inhibitor,"" J. Chem. Soc. Perkin Trans. I:2927-2929 (1995).;;Vainio, P., et al., ""Inhibition of Lipoprotein Lipase by Benzene Boronic Acid Effect of Apolipoprotein C-II,"" Biochimica et Biophysica Acta. 711:386-390 (1982).;;Bagree, A., et al., ""Modification of epsilon-Amino Group of Lysine in Proteins by Acylation with Pyromellitic Dianhydride and o-Sulphobenzoic Anhydride,"" FEBS Letters 120 (2) :275-277 (1980).;;Stadler, P., et al., ""Inhibition of microbial lipases with steroisomeric triradylglycerol analog phosphonates,"" Biochimica et Biophysica Acta. 1304:229-244 (1996).;;Kawaguchi, K., et al.""Hesperidin as an Inhibitor of Lipases from Procine Pancreas and Pseudomonas,"" Biosci. Biotech. Biochem. 61(1):102-104 (1997).;;Bochenek, W.J. and Rodgers, J.B., ""Effect of Polyol Detergents on Cholesterol and Triglyceride Absorption,"" Biochimica et Biophysica Acta 489:503-506 (1977).;;Comai, K. and Sullivan, A.C., ""Antiobesity activity of pluronic L-101,"" International Journal of Obesity 4:33-42 (1980).;;Han, L-K, et al., ""Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet,"" International Journal of Obesity 23:174-179 (1999).;;Atkinson, et al., ""Combined drug treatment of obesity,"" Obesity Research, vol. 3, No. S4:497S-500S (1995).",EXPIRED
163,US,B1,US 7048917 B1,107-533-241-095-939,2006-05-23,2006,US 72129100 A,2000-11-22,US 72129100 A;;US 35332999 A;;US 16645398 A;;US 496398 A,1998-01-09,Fat-binding polymers,"The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.",GENZYME CORP,JOZEFIAK THOMAS;;HOLMES-FARLEY STEPHEN RANDALL;;MANDEVILLE III W HARRY;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,GENZYME CORPORATION (2003-03-27),https://lens.org/107-533-241-095-939,Granted Patent,yes,45,2,1,39,0,A61K31/74;;A61K31/785;;A61K31/795;;A61K31/74;;A61K31/795;;A61K31/785,A61K31/795;;A61K31/74;;A61K31/785,424/78.35;;424/78.01;;424/78.36;;424/78.31;;514/449;;514/909,17,15,057-292-767-349-853;;011-488-303-075-503;;090-302-628-385-777;;035-396-764-753-808;;056-559-651-251-030;;088-104-047-449-972;;020-533-691-848-42X;;025-282-768-506-603;;055-220-569-293-101;;016-362-040-736-32X;;057-110-500-429-82X;;008-047-538-157-245;;033-086-322-527-639;;018-345-769-242-592;;018-131-239-199-212,2804064;;10.1016/0005-2760(89)90335-4;;10.1016/s0005-2760(97)81102-2;;9022752;;9031529;;10.1515/znc-1996-11-1222;;8280765;;10.1016/0005-2760(94)90116-3;;10.1016/0005-2760(95)00145-3;;7492616;;10.1039/p19950002927;;10.1016/0005-2760(82)90051-0;;7104374;;6777199;;10.1016/0014-5793(80)80315-2;;8982269;;10.1016/s0005-2760(96)00123-3;;10.1271/bbb.61.102;;9028038;;10.1016/0005-2760(77)90170-9;;588583;;7190135;;10.1038/sj.ijo.0800806;;10078853;;10.1002/j.1550-8528.1995.tb00218.x;;8697049;;10.1016/s0140-6736(97)11509-4;;9683204,"CAPLUS Abstract, AN 1993:256861, JP 04333694, 1992, Niike et al.;;CAS registry 147867-87-6.;;Gargouri, Y., et al., ""Ajoene prevents fat digestion by human gastric lipase in vitro,"" Biochimica et Biophysica Acta. 1006:137-139 (1989).;;Gargouri, Y., et al., ""Covalent inhibition of digestive lipases: an in vitro study,"" Biochimica et Biophysica Acta. 1344:6-37 (1997).;;Karamac, M. and Amarowicz, R., ""Inhibition of Pancreatic Lipase by Phenolic Acids, Examination in vitro,"" Verlag der Zeitschrift für Naturforschung:903-905 (1996).;;Marguet, F., et al., ""Digestive lipases: inactivation by phosphonates,"" Biochimica et Biophysica Acta. 1210:157-166 (1994).;;Mannesse, M.L.M., et al., ""Phosphonate analogues of triacylglycerols are potent inhibitors of lipase,"" Biochimica et Biophysica Acta. 1259:56-64 (1995).;;Martichonok, V. and Jones, J.B., ""(Z)-Heptadec-8-enylboronic acid: a potential lipase inhibitor,"" J. Chem. Soc. Perkin Trans. I:2927-2929 (1995).;;Vainio, P., et al., ""Inhibition of Lipoprotein Lipase by Benzene Boronic Acid Effect of Apolipoprotein C-II,"" Biochimica et Biophysica Acta. 711:386-390 (1982).;;Bagree, A., et al., ""Modification of epsilon-Amino Group of Lysine in Proteins by Acylation with Pyromellitic Dianhydride and o-Sulphobenzoic Anhydride,"" FEBS Letters 120 (2):275-277 (1980).;;Stadler, P., et al., ""Inhibition of microbial lipases with stereoisomeric triradylglycerol analog phosphonates,"" Biochimica et Biophysica Acta. 1304:229-244 (1996).;;Kawaguchi, K., et al. Hesperidin as an Inhibitor of Lipases from Procine Pancreas and Pseudomonas, Biosci. Biotech. Biochem. 61(1):102-104 (1997).;;Bochenek, W.J. and Rodgers, J.B., ""Effect of Polyol Detergents on Cholesterol and Triglyceride Absorption,"" Biochimica et Biophysica Acta 489:503-506 (1977).;;Comai, K. and Sullivan, A.C., ""Antiobesity activity of pluronic L-101,"" International Journal of Obesity 4:33-42 (1980).;;Han, L-K, et al., ""Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet,"" International Journal of Obesity 23:174-179 (1999).;;Atkinson, et al., ""Combined drug treatment of obesity,"" Obesity Research, vol. 3, No. S4:497S-500S (1995).;;Sjöström, et al., ""Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients,"" The Lancet, 352:167-172 (1998).",EXPIRED
164,BR,A2,BR 112016028873 A2,090-305-367-076-274,2017-08-22,2017,BR 112016028873 A,2015-06-09,US 2015/0034951 W;;US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P,2014-06-09,sistema controlado e métodos para proteção contra fogo de armazenamen,"a presente invenção refere-se a sistemas e métodos de proteção contra fogo para proteção armazenamento de pilha alta. os sistemas incluem uma pluralidade de dispositivos de distribuição de fluido dispostos sobre um teto e acima de uma mercadoria de armazenamento em pilha alta que tem uma altura de armazenamento nominal que varia de 6,0 m (20 pés) nominais para uma altura de armazenamento nominal máxima de 16,5 m (55 pés) e um meio para apagar um fogo na mercadoria de armazenamento. a mercadoria armazenada a ser protegida pode inclui plástico expandido exposto. os dispositivos de distribuição de fluido incluem um corpo de estrutura que tem uma entrada, uma saída, um conjunto de vedação, e um mecanismo de liberação eletronicamente operado que suporta o conjunto de vedação na saída.",TYCO FIRE & SECURITY GMBH;;TYCO FIRE PRODUCTS LP,BERNHARD ABELS;;CHAD ALBERT GOYETTE;;DANIEL G FARLEY;;DONALD D BRIGHENTI;;JAKE DUBE;;JOHN DESROSIER;;RICHARD P BONNEAU;;ZACHARY L MAGNONE,,https://lens.org/090-305-367-076-274,Patent Application,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,PENDING
165,CL,A1,CL 2016003176 A1,016-884-004-296-193,2017-10-20,2017,CL 2016003176 A,2016-12-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2014/0072246 W,2014-06-09,Sistema controlado y métodos para protección contra incendios de mercancías.,"<p>SISTEMAS Y MÉTODOS DE PROTECCIÓN CONTRA INCENDIOS SOLO PARA TECHOS, PARA LA PROTECCIÓN DE BODEGAS CON ALTOS APILADOS. LOS SISTEMAS INCLUYEN, UNA PLURALIDAD DE DISPOSITIVOS DE DISTRIBUCIÓN DE FLUIDO DISPUESTOS BAJO UN TECHO Y POR ENCIMA DE UNA MERCANCÍA DE ALMACENAMIENTO DE GRAN ALTURA, QUE TIENE UNA ALTURA DE ALMACENAMIENTO NOMINAL QUE VARÍA DESDE UNA ALTURA NOMINAL DE ALMACENAMIENTO DE 6 [m] A UNA ALTURA MÁXIMA DE ALMACENAMIENTO DE 16,7 [m] Y MEDIOS PARA EXTINGUIR UN INCENDIO EN LA BODEGA DE ALMACENAMIENTO. EL PRODUCTO ALMACENADO A PROTEGER PUEDE INCLUIR PLÁSTICOS EXPANDIDOS EXPUESTOS. LOS DISPOSITIVOS DE DISTRIBUCIÓN DE FLUIDO INCLUYEN, UN CUERPO DE BASTIDOR QUE TIENE UNA ENTRADA, UNA SALIDA, UN CONJUNTO DE SELLADO Y UN MECANISMO DE LIBERACIÓN OPERADO ELECTRÓNICAMENTE, QUE APOYA EL CONJUNTO DE SELLADO EN LA SALIDA.</p>",TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/016-884-004-296-193,Patent Application,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/40,,0,0,,,,PENDING
166,US,A1,US 2017/0120090 A1,075-133-911-527-664,2017-05-04,2017,US 201515317524 A,2015-06-09,US 201515317524 A;;US 2014/0707224 W;;US 201562172291 P;;US 201562172287 P;;US 201562172281 P;;US 201562145840 P;;US 201462016501 P;;US 201462013731 P;;US 201462009778 P;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,TYCO FIRE & SECURITY GMBH (2017-01-03);;TYCO FIRE PRODUCTS LP (2016-09-08),https://lens.org/075-133-911-527-664,Patent Application,yes,6,31,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,ACTIVE
167,BR,A8,BR 112016028873 A8,198-932-033-184-32X,2021-04-20,2021,BR 112016028873 A,2015-06-09,US 2015/0034951 W;;US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P,2014-06-09,sistema controlado e métodos para proteção contra fogo de armazenamento,"sistema controlado e métodos para proteção contra fogo de armazenamento. a presente invenção refere-se a sistemas e métodos de proteção contra fogo para proteção armazenamento de pilha alta. os sistemas incluem uma pluralidade de dispositivos de distribuição de fluido dispostos sobre um teto e acima de uma mercadoria de armazenamento em pilha alta que tem uma altura de armazenamento nominal que varia de 6,0 m (20 pés) nominais para uma altura de armazenamento nominal máxima de 16,5 m (55 pés) e um meio para apagar um fogo na mercadoria de armazenamento. a mercadoria armazenada a ser protegida pode inclui plástico expandido exposto. os dispositivos de distribuição de fluido incluem um corpo de estrutura que tem uma entrada, uma saída, um conjunto de vedação, e um mecanismo de liberação eletronicamente operado que suporta o conjunto de vedação na saída.",TYCO FIRE & SECURITY GMBH;;TYCO FIRE PRODUCTS LP,BERNHARD ABELS;;CHAD ALBERT GOYETTE;;DANIEL G FARLEY;;DONALD D BRIGHENTI;;JAKE DUBE;;JOHN DESROSIER;;RICHARD P BONNEAU;;ZACHARY L MAGNONE,,https://lens.org/198-932-033-184-32X,Patent Application,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,PENDING
168,EP,A1,EP 3151928 A1,001-420-791-016-604,2017-04-12,2017,EP 15730628 A,2015-06-09,US 201462013731 P;;US 201562172281 P;;US 201562172287 P;;US 201462009778 P;;US 201562172291 P;;US 201462016501 P;;US 2014/0072246 W;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,,TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;BONNEAU RICHARD P;;DUBE JAKE,TYCO FIRE PRODUCTS LP (2018-12-05),https://lens.org/001-420-791-016-604,Patent Application,yes,0,0,4,65,0,A62C3/002;;A62C3/002;;A62C37/40;;A62C3/002;;A62C35/60;;A62C35/60;;A62C37/04;;A62C37/10;;A62C37/10;;A62C37/10;;A62C37/40;;A62C37/40;;A62C37/40;;A62C37/46;;A62C37/46;;A62C37/46;;A62C99/0072;;A62C99/0072;;G08B17/00;;H01B7/0045,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,1,0,,,See references of WO 2015191619A1,ACTIVE
169,ES,T3,ES 2813826 T3,068-841-232-049-844,2021-03-25,2021,ES 15730628 T,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 201562145840 P;;US 2014/0072246 W;;US 2015/0034951 W,2014-06-09,Sistema y métodos controlados para la protección contra incendios de almacenes,"Sistema de protección contra incendios de tipo solo en el techo para un lugar de almacenamiento que tiene un techo que define una altura de techo nominal de 9,14 m (treinta pies) o mayor, comprendiendo el sistema: múltiples dispositivos (110) de distribución de fluido dispuestos debajo del techo y encima de un producto almacenado en pilas altas en el lugar de almacenamiento que tiene una altura de almacenamiento nominal que varía desde una altura de almacenamiento nominal de 6,10 m (20 pies) hasta una altura de almacenamiento nominal máxima de 16,76 m (55 pies), incluyendo el producto almacenado uno cualquiera de plásticos de Clase I, II, III o IV, Grupo A, Grupo B o Grupo C, elastómeros, caucho y productos de plástico expandido expuesto, incluyendo los múltiples dispositivos de distribución de fluido un dispositivo de distribución de fluido con un cuerpo (322) de bastidor que tiene una entrada (330), una salida (332), un conjunto (324) de sellado y un mecanismo (328) de liberación operado electrónicamente que mantiene el conjunto de sellado en la salida; y medios (100a,b,c) para apagar un incendio en el producto almacenado, el mecanismo de liberación operado eléctricamente es un conjunto de poste y palanca con una región de fractura diseñada que incluye: un miembro (344) de gancho que tiene un primer extremo y un segundo extremo; un miembro (342) de poste que tiene un primer extremo y un segundo extremo, estando el primer extremo del miembro de poste en contacto con el miembro de gancho entre los extremos primero y segundo del miembro de gancho para definir un fulcro (358); un miembro (353) de carga que actúa sobre el miembro de gancho en un primer lado del fulcro para definir un primer momento de fuerza; un eslabón (346) que se extiende entre los miembros de gancho y de poste que tiene una región (376) de fractura para mantener el miembro de gancho en una posición estática con respecto al miembro de poste para definir el estado no activado del conjunto, estando el eslabón acoplado con el miembro de gancho en un segundo lado del fulcro opuesto al primer lado del fulcro con respecto al miembro de carga para definir un segundo momento de fuerza; y un actuador (314) acoplado a uno de los elementos de gancho y de poste para aplicar una fuerza entre los miembros de gancho y de poste que rompe la región de fractura del eslabón de manera que el elemento de gancho pivote alrededor del fulcro para definir el estado activado del conjunto disparador.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;BONNEAU RICHARD P;;DUBE JAKE,,https://lens.org/068-841-232-049-844,Granted Patent,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,ACTIVE
170,NZ,A,NZ 516554 A,106-997-220-702-76X,2003-08-29,2003,NZ 51655499 A,1999-07-14,NZ 51655499 A;;US 9915958 W,1999-07-14,"Fat-binding polymers, optionally combined with lipase inhibitors","Use of a polymer, salt or copolymer which is characterized by a combination of repeat units having the formula (IV) where R1, R2 and R3 is H or CH3, R4 is a hydrophobic group, and m is 0-4. Formula (IV) is combined with at least one lipase inhibitor. Use of a polymer, salt or copolymer characterised by a combination of repeat units having the formula (V) where R1 is H or CH3, R4 is a hydrophobic group, R5 is an alkyl chain from C1 to C22, and m is 0-4. Formula (IV) and (V) are used for the treatment of steatorrhea, hypertriglyceridemia and reducing absorption of dietary fat.",GENZYME CORP,JOZEFIAK THOMAS HENRY;;MANDEVILLE W HARRY;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,,https://lens.org/106-997-220-702-76X,Patent Application,no,0,0,1,1,0,,A61K31/785;;A61P3/04;;A61P3/06,,0,0,,,,PENDING
171,CA,A1,CA 2951703 A1,146-338-444-804-062,2015-12-17,2015,CA 2951703 A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/146-338-444-804-062,Patent Application,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,PENDING
172,WO,A8,WO 2015/191619 A8,016-555-638-854-735,2016-02-25,2016,US 2015/0034951 W,2015-06-09,US 201462013731 P;;US 201562172281 P;;US 201562172287 P;;US 201462009778 P;;US 201562172291 P;;US 201462016501 P;;US 201562145840 P;;US 2014/0072246 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/016-555-638-854-735,Amended Application,yes,0,0,4,65,0,A62C3/002;;A62C3/002;;A62C37/40;;A62C3/002;;A62C35/60;;A62C35/60;;A62C37/04;;A62C37/10;;A62C37/10;;A62C37/10;;A62C37/40;;A62C37/40;;A62C37/40;;A62C37/46;;A62C37/46;;A62C37/46;;A62C99/0072;;A62C99/0072;;G08B17/00;;H01B7/0045,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,PENDING
173,AU,A1,AU 2015/274770 A1,019-831-510-415-773,2017-02-02,2017,AU 2015/274770 A,2015-06-09,US 201562172291 P;;US 201462016501 P;;US 201562172287 P;;US 201462009778 P;;US 201562145840 P;;US 2014/0072246 W;;US 201562172281 P;;US 201462013731 P;;US 2015/0034951 W,2014-06-09,Controlled system and methods for storage fire protection,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE & SECURITY GMBH;;TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,TYCO FIRE PRODUCTS LP (2019-03-28),https://lens.org/019-831-510-415-773,Patent Application,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,ACTIVE
174,SG,A,SG 11201610370Y A,110-574-910-918-189,2017-01-27,2017,SG 11201610370Y A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,,TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/110-574-910-918-189,Unknown,no,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/40;;A62C37/10;;A62C37/46,,0,0,,,,PENDING
175,CN,A,CN 113633906 A,076-047-909-099-336,2021-11-12,2021,CN 202110787295 A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;CN 201580042353 A,2014-06-09,Controlled system and methods for storage fire protection,"The invention discloses fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOJETT CHAD ALBERT;;DESROSIERS JOHN;;BONNEAU DONALD D;;EJBELZ BERNKHARD;;JAKE DUBE;;BONNEAU RICHARD P,,https://lens.org/076-047-909-099-336,Patent Application,no,5,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C31/05;;A62C31/28;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,PENDING
176,KR,A,KR 20170016475 A,079-866-606-220-942,2017-02-13,2017,KR 20177000629 A,2015-06-09,US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 2014/0072246 W;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P;;US 2015/0034951 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"천장-유일(ceiling-only)의 높게 적재되는 저장소 보호를 위한 방화 시스템 및 방법. 시스템은 천장 아래에 그리고 공칭적인 20 피트 내지 55피트의 최대 공칭 저장 높이의 범위의 공칭 저장 높이를 가지는 높게 적재된 저장 상품 위에 배치되는 복수의 유체 분배 장치, 및 저장 상품 내의 화재를 진화하기 위한 수단을 포함한다. 보호하고자 하는 저장된 상품이 노출된 발포 플라스틱을 포함할 수 있다. 유체 분배 장치는, 유입구, 배출구, 밀봉 조립체, 및 배출구 내에서 밀봉 조립체를 지지하는 전자적으로 동작되는 해제(releasing) 메커니즘을 가지는 프레임 본체를 포함한다.",TYCO FIRE PRODUCTS LP;;TYCO FIRE&SECURITY GMBH,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JAKE;;BONNEAU RICHARD P,,https://lens.org/079-866-606-220-942,Patent Application,no,3,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C37/40;;A62C3/00;;A62C37/10;;A62C37/46,,0,0,,,,ACTIVE
177,JP,A,JP 2020179179 A,083-045-207-981-345,2020-11-05,2020,JP 2020102131 A,2020-06-12,US 201462013731 P;;US 201562172281 P;;US 201562172287 P;;US 201462009778 P;;US 201562172291 P;;US 201462016501 P;;US 201562145840 P;;US 2014/0072246 W,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"To provide fire protection systems and methods for ceiling-only high-piled storage protection.SOLUTION: A system includes a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body 322 having an inlet 330, an outlet 332, a sealing assembly 324, and an electronically operated releasing mechanism 328 supporting the sealing assembly 324 in the outlet 332.SELECTED DRAWING: Figure 7",TYCO FIRE PRODUCTS LP;;TYCO FIRE & SECURITY GMBH,ZACHARY L MAGNONE;;DANIEL G FARLEY;;CHAD ALBERT GOYETTE;;JOHN DESROSIER;;DONALD D BRIGHENTI;;BERNHARD ABELS;;JAKE DUBE;;RICHARD P BONNEAU,,https://lens.org/083-045-207-981-345,Patent Application,no,7,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C37/40;;G08B17/00,,0,0,,,,ACTIVE
178,AU,A,AU 1999/049957 A,192-516-593-292-782,2001-02-05,2001,AU 1999/049957 A,1999-07-14,US 9915958 W,1999-07-14,"Fat-binding polymers, optionally combined with cipase inhibitors",,GELTEX PHARMA INC,JOZEFIAK THOMAS HENRY;;MANDEVILLE W HARRY;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,GENZYME CORPORATION (2003-07-10),https://lens.org/192-516-593-292-782,Patent Application,no,0,0,9,9,0,A61K31/785;;A61P3/00,A61K31/785;;A61P3/00,,0,0,,,,EXPIRED
179,EP,A1,EP 1196181 A1,098-565-108-620-572,2002-04-17,2002,EP 99934037 A,1999-07-14,US 9915958 W,1999-07-14,"FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH LIPASE INHIBITORS",,GELTEX PHARMA INC,JOZEFIAK THOMAS HENRY;;MANDEVILLE W HARRY III;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,GENZYME CORPORATION (2003-08-27),https://lens.org/098-565-108-620-572,Patent Application,yes,5,1,9,9,0,A61K31/785;;A61P3/00,A61K31/785;;A61P3/00,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1996, no. 04 30 April 1996 (1996-04-30);;See also references of WO 0105408A1",DISCONTINUED
180,CA,A1,CA 2379308 A1,123-765-022-919-881,2001-01-25,2001,CA 2379308 A,1999-07-14,US 9915958 W,1999-07-14,"FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH LIPASE INHIBITORS","The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step o f orally administering to a mammal, such as a human, a therapeutically effecti ve amount of one or more fat-binding polymers. The administration of the fat- binding polymer of the invention facilitates the removal of fat from the bod y prior to digestion, with minimal side effects and low toxicity. In a preferr ed embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.",GELTEX PHARMA INC,HUVAL CHAD CORI;;MANDEVILLE W HARRY III;;GARIGAPATI VENKATA R;;JOZEFIAK THOMAS HENRY;;SHACKETT KEITH K;;HOLMES-FARLEY STEPHEN RANDALL;;CONCAGH DANNY,,https://lens.org/123-765-022-919-881,Patent Application,no,0,0,9,9,0,A61K31/785;;A61P3/00,A61K31/785;;A61P3/00,,0,0,,,,DISCONTINUED
181,US,A1,US 2024/0042253 A1,159-278-101-340-630,2024-02-08,2024,US 202318380973 A,2023-10-17,US 202318380973 A;;US 202017097385 A;;US 201615317524 A;;US 2015/0034951 W;;US 2014/0072246 W;;US 201462009778 P;;US 201462013731 P;;US 201462016501 P;;US 201562145840 P;;US 201562172281 P;;US 201562172287 P;;US 201562172291 P,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include ex posed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JACOB JOSEPH;;BONNEAU RICHARD P,TYCO FIRE & SECURITY GMBH (2017-01-03);;TYCO FIRE PRODUCTS LP (2016-09-08),https://lens.org/159-278-101-340-630,Patent Application,yes,0,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,PENDING
182,AU,B2,AU 774636 B2,025-022-044-227-464,2004-07-01,2004,AU 1999/049957 A,1999-07-14,US 9915958 W,1999-07-14,"Fat-binding polymers, optionally combined with lipase inhibitors",,GENZYME CORP,JOZEFIAK THOMAS HENRY;;MANDEVILLE W HARRY III;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,GENZYME CORPORATION (2003-07-10),https://lens.org/025-022-044-227-464,Granted Patent,no,3,0,9,9,0,A61K31/785;;A61P3/00,A61K31/785;;A61P3/00,,0,0,,,,EXPIRED
183,WO,A8,WO 2001/005408 A8,045-103-322-569-828,2001-07-19,2001,US 9915958 W,1999-07-14,US 9915958 W,1999-07-14,"FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH LIPASE INHIBITORS","The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.",GELTEX PHARMA INC,JOZEFIAK THOMAS HENRY;;MANDEVILLE W HARRY III;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,,https://lens.org/045-103-322-569-828,Patent Application,no,0,0,9,9,0,A61K31/785;;A61P3/00,A61K31/785;;A61P3/00,,0,0,,,,PATENTED
184,US,A1,US 2021/0077841 A1,093-703-363-748-486,2021-03-18,2021,US 202017097385 A,2020-11-13,US 202017097385 A;;US 2015/0034951 W;;US 201615317524 A;;US 201562172291 P;;US 2014/0072246 W;;US 201562172287 P;;US 201562172281 P;;US 201562145840 P;;US 201462016501 P;;US 201462013731 P;;US 201462009778 P,2014-06-09,CONTROLLED SYSTEM AND METHODS FOR STORAGE FIRE PROTECTION,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JACOB JOSEPH;;BONNEAU RICHARD P,TYCO FIRE & SECURITY GMBH (2017-01-03);;TYCO FIRE PRODUCTS LP (2016-09-08),https://lens.org/093-703-363-748-486,Patent Application,yes,3,2,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46,,0,0,,,,ACTIVE
185,US,B2,US 10870024 B2,141-318-344-530-519,2020-12-22,2020,US 201515317524 A,2015-06-09,US 201515317524 A;;US 2014/0707224 W;;US 201562172291 P;;US 201562172287 P;;US 201562172281 P;;US 201562145840 P;;US 201462016501 P;;US 201462013731 P;;US 201462009778 P;;US 2015/0034951 W,2014-06-09,Controlled system and methods for storage fire protection,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JACOB JOSEPH;;BONNEAU RICHARD P,TYCO FIRE & SECURITY GMBH (2017-01-03);;TYCO FIRE PRODUCTS LP (2016-09-08),https://lens.org/141-318-344-530-519,Granted Patent,yes,19,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/00,,3,0,,,"English translation of CN1134276C (Year: 2004).;;International Search Report and Written Opinion for International Application No. PCT/US2014/072246, dated Apr. 30, 2015, 8 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2015/034951, dated Nov. 6, 2015, 17 pages.",ACTIVE
186,US,B2,US 11844971 B2,124-148-575-487-890,2023-12-19,2023,US 202017097385 A,2020-11-13,US 202017097385 A;;US 2015/0034951 W;;US 201615317524 A;;US 201562172291 P;;US 2014/0072246 W;;US 201562172287 P;;US 201562172281 P;;US 201562145840 P;;US 201462016501 P;;US 201462013731 P;;US 201462009778 P,2014-06-09,Controlled system and methods for storage fire protection,"Fire protection systems and methods for ceiling-only high-piled storage protection. The systems include a plurality of fluid distribution devices disposed beneath a ceiling and above a high-piled storage commodity having a nominal storage height ranging from a nominal 20 ft. to a maximum nominal storage height of 55 ft. and means for quenching a fire in the storage commodity. The stored commodity to be protected may include exposed expanded plastics. The fluid distribution devices include a frame body having an inlet, an outlet, a sealing assembly, and an electronically operated releasing mechanism supporting the sealing assembly in the outlet.",TYCO FIRE PRODUCTS LP,MAGNONE ZACHARY L;;FARLEY DANIEL G;;GOYETTE CHAD ALBERT;;DESROSIER JOHN;;BRIGHENTI DONALD D;;ABELS BERNHARD;;DUBE JACOB JOSEPH;;BONNEAU RICHARD P,TYCO FIRE & SECURITY GMBH (2017-01-03);;TYCO FIRE PRODUCTS LP (2016-09-08),https://lens.org/124-148-575-487-890,Granted Patent,yes,33,0,33,65,0,A62C37/10;;A62C37/40;;A62C37/46;;A62C3/002;;A62C35/60;;A62C99/0072;;A62C3/002;;A62C37/46;;A62C37/40;;A62C37/10;;A62C3/002;;A62C37/10;;A62C37/40;;A62C37/46;;G08B17/00;;A62C37/04;;A62C37/40;;H01B7/0045;;A62C3/002;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/0072,A62C3/00;;A62C35/60;;A62C37/10;;A62C37/40;;A62C37/46;;A62C99/00,,2,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2015/034951, dated Nov. 6, 2015, 17 pages.;;International Search Report and Written Opinion on PCT/US2014/072246, dated Apr. 30, 2015, 9 pages.",ACTIVE
187,WO,A1,WO 2001/005408 A1,015-155-846-807-299,2001-01-25,2001,US 9915958 W,1999-07-14,US 9915958 W,1999-07-14,"FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH CIPASE INHIBITORS","The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.",GELTEX PHARMA INC,JOZEFIAK THOMAS HENRY;;MANDEVILLE W HARRY III;;HOLMES-FARLEY STEPHEN RANDALL;;HUVAL CHAD CORI;;GARIGAPATI VENKATA R;;SHACKETT KEITH K;;CONCAGH DANNY,,https://lens.org/015-155-846-807-299,Patent Application,yes,9,10,9,9,0,A61K31/785;;A61P3/00,A61K31/785;;A61P3/00,,2,1,018-131-239-199-212,10.1016/s0140-6736(97)11509-4;;9683204,"SJÖSTRÖM L ET AL: ""Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients"", LANCET THE,GB,LANCET LIMITED. LONDON, vol. 352, no. 9123, 18 July 1998 (1998-07-18), pages 167 - 172-172, XP002123840, ISSN: 0140-6736;;See also references of EP 1196181A1",PATENTED
188,HK,A1,HK 1046092 A1,129-716-034-203-001,2002-12-27,2002,HK 02107346 A,2002-10-08,US 9915958 W,1999-07-14,"FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH LIPASE INHIBITORS",,GENZYME CORP,THOMAS HENRY JOZEFIAK;;W HARRY MANDEVILLE III;;STEPHEN RANDALL HOLMES-FARLEY;;CHAD CORI HUVAL;;VENKATA R GARIGAPATI;;KEITH K SHACKETT;;DANNY CONCAGH,,https://lens.org/129-716-034-203-001,Patent Application,no,0,0,9,9,0,A61K31/785;;A61P3/00,A61K/;;A61K31/785;;A61P/;;A61P3/00,,0,0,,,,PENDING
